WO2005086667A2 - High efficiency peptide production in plant cells - Google Patents

High efficiency peptide production in plant cells Download PDF

Info

Publication number
WO2005086667A2
WO2005086667A2 PCT/US2005/006342 US2005006342W WO2005086667A2 WO 2005086667 A2 WO2005086667 A2 WO 2005086667A2 US 2005006342 W US2005006342 W US 2005006342W WO 2005086667 A2 WO2005086667 A2 WO 2005086667A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
plant cell
virus
nucleic acid
plant
Prior art date
Application number
PCT/US2005/006342
Other languages
French (fr)
Other versions
WO2005086667A3 (en
Inventor
Lada Rasochova
Philip P. Dao
Original Assignee
The Dow Chemical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Dow Chemical Company filed Critical The Dow Chemical Company
Priority to AU2005220734A priority Critical patent/AU2005220734A1/en
Priority to EP05756363A priority patent/EP1720990A4/en
Priority to EP18173991.3A priority patent/EP3388521A1/en
Priority to JP2007500784A priority patent/JP2007528727A/en
Priority to CA002557668A priority patent/CA2557668A1/en
Publication of WO2005086667A2 publication Critical patent/WO2005086667A2/en
Publication of WO2005086667A3 publication Critical patent/WO2005086667A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]

Definitions

  • the present invention provides an improved process for the production of recombinant peptides.
  • the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures.
  • the invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.
  • Bacterial, yeast, plant, insect, and mammalian cell expression systems are currently used to produce recombinant peptides, with varying degrees of success.
  • One goal in creating expression systems for the production of heterologous peptides is to provide broad based, flexible, efficient, economic, and practical platforms and processes that can be utilized in commercial, therapeutic, and vaccine applications.
  • bacteria are the most widely used expression system for the production of recombinant peptides because of their potential to produce abundant quantities of recombinant peptides.
  • Bacteria generally do not glycosylate, acetylate, acylate, phosphorylate, or gam a- carboxylate eukaryotic proteins, and, therefore, are limited in their capacities to produce, in vivo, certain types of heterologous eukaryotic peptides that require post-translational modifications. Additional steps modifying the bacterially produced eukaryotic peptides are likely to increase the time and reduce the overall yield of peptide production, diluting many of the advantages of the bacterial host expression system. Therefore, alternative non-bacterial expression systems have been utilized to overcome the inherent limitations of bacterial expression systems.
  • One particular host expression systems analyzed for their ability to produce heterologous peptides has been whole plants and plant cell suspension cultures.
  • Viruses and Virus Like Particles One approach for improving peptide production in host cell expression systems is to make use of the properties of infectious recombinant viruses to produce recombinant peptides of interest.
  • infectious viruses in plant host systems is particularly well known. See, for example, Porta & Lomonossoff, (2002) "Viruses as vectors for the expression of foreign sequences in plants," Biotechnology and Genetic Enginering Reviews 19: 245-291.
  • Recent strategies have focused on the production of heterologous peptides in virus like particle (NLP) structures.
  • encapsidated viruses include a protein coat or "capsid" that is assembled to contain the viral nucleic acid.
  • capsids that can be "self- assembled” from the individually expressed capsids, both within the cell the capsid is expressed in (“in vivo assembly"), and outside of the cell after isolation and purification ("in vitro assembly”).
  • capsids are modified to contain a target recombinant peptide, generating a recombinant viral capsid-peptide fusion.
  • the fusion peptide can then be expressed in a cell, and, ideally, assembled in vivo to form recombinant viral or virus-like particles.
  • the production of heterologous proteins via virus capsid fusion proteins assembled into VLPs in plants has been met with varying success. See, for example, C Marusic et al, J Virol.
  • US Patent No. 5,874,087 to Lomonossoff & Johnson describes production of infectious plant viruses, in plant cells or whole plants, wherein the viral capsids are engineered to contain a biologically active peptide, such as a hormone, growth factor, or antigenic peptide.
  • a virus selected from the genera Comovirus, Tombusvirus, Sobemovirus, and Nepovirus is engineered to contain the exogenous peptide encoding sequence and the entire engineered genome of the virus is expressed to produce the recombinant virus.
  • the specification stresses that multiplication of the modified virus is a central part of the invention. .
  • Rod- shaped viruses also classified as helical viruses, such as potato virus X (PVX) have recombinant peptides of interest inserted into the genome of the virus to create recombinant viral capsid- peptide fusions.
  • PVX potato virus X
  • the recombinant, infective virus is then used to infect a plant cell of a whole plant, wherein, the virus actively replicates in the plant cell and further infects other cells, ultimately infecting the entire host plant.
  • the recombinant viral capsid-peptide fusion is purified from the plant. Chapman et al.
  • fusion capsid proteins comprising a plant virus capsid protein fused to an antigenic polypeptide.
  • the resultant particles are produced in whole plants.
  • the utilization of infectious recombinant viruses to produce heterologous proteins in capsid fusion proteins is not, however, without its drawbacks.
  • One particularly froubling aspect is the ability of these viruses to mutate in vivo, resulting in capsid proteins that are essentially wild type revertants without the fused heterologous protein of interest, or mutated, non-desirable recombination capsid fusion protein products.
  • the present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture.
  • the viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles.
  • the present invention does not require the utilization of an infective viral agent; rather, non-infectious nucleic acid encoding a capsid- heterologous peptide fusion product is stably inserted into the genome of a plant cell, which can be cultured in a fermentation process to produce the peptide of interest. Such a process results in a less variable, and more stable host system for the expression of capsid fusion proteins containing heterologous peptides.
  • infectious viruses containing capsid-heterologous peptide fusion proteins utilized to express heterologous peptides of interest in whole plants exhibit genetic instability in the whole plant that results in mutations in the recombinant capsid protein nucleic acid, and the expressed mutant capsid either cannot assemble into virus particles or contains a mutated target peptide.
  • the present invention provides increased stability of the resultant heterologous peptide, with the additional benefits of precise control over growth conditions, batch to batch consistency, a high level of containment, and the ability to produce recombinant proteins in compliance with good manufacturing practices.
  • the capsid-fusion protein products can form virus like particles within the cell.
  • the virus like particle may result in the improved efficiency of achieving a high purity of the recovered peptide.
  • the virus like particles produced in the cell typically are not capable of infecting the plant cell.
  • the viral capsid sequence can be derived from both trophic and non-trophic viruses, wherein trophism is determined by the specific plant cell utilized as the expression host.
  • the viral capsid protein is derived from a virus that exhibits a native or natural trophism towards the plant cell utilized to express the fusion product.
  • the viral capsid protein is derived from a virus that does not exhibit a native or natural trophism towards the plant cell utilized to express the fusion product.
  • the cell does not include artificially introduced viral proteins other than the desired capsid protein sequences utilized to produce the fusion product.
  • the cell includes artificially introduced viral proteins or nucleic acids other than the desired capsid protein sequences utilized to produce the fusion product, wherein the additional viral proteins or nucleic acids do not confer infectivity to the nucleic acid sequences.
  • the viral capsid is derived from a virus with a tropism to a different family of organisms than the plant cell expression host.
  • the viral capsid is derived from a virus with a tropism to a different genus of organisms than the plant cell expression host.
  • the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell utilized to express the fusion product.
  • the capsid is derived from a rod shaped plant virus.
  • the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus and Potato Virus X (PVX).
  • the capsid protein is derived from an icosahedral virus.
  • the capsid is derived from a plant icosahedral virus.
  • the icosahedral capsid is derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
  • the present invention also provides plant cells that include a non-infectious nucleic acid construct containing an expression cassette encoding for a fusion protein of a virus capsid and a recombinant peptide.
  • the fusion peptide of the virus capsid and recombinant peptide is operably linked to a promoter and terminator that functions in plant cells.
  • the nucleic acid is genomically integrated in the plant cell, wherein the integration results in the stable inheritance and expression of the nucleic acid encoding the capsid fusion protein from generation to generation.
  • the capsid protein is derived from an icosahedral virus.
  • the cell produces virus like particles or soluble cage structures, hi one embodiment, the plant cell is a Monocot or a Dicot.
  • the plant cell is Nicotiana tabacum. hi an alternative embodiment, the plant cell is Oryza sativa.
  • the recombinant peptide fused to the viral capsid protein is a therapeutic peptide useful for human or animal treatments.
  • the recombinant peptide is an antigenic peptide.
  • the antigenic peptide is a glycosylated antigenic peptide.
  • the plant cells or extracts containing capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal.
  • the purified capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal.
  • the heterologous peptide is an antimicrobial peptide.
  • the recombinant peptide is a peptide that is toxic to the plant host cell when in free monorneric form.
  • the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids in length.
  • the recombinant peptide fused to the capsid contains at least one monomer of a desired target peptide.
  • the recombinant peptide contains more than one monomer of a desired target peptide.
  • the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid.
  • the individual monomers in the concatameric peptide are linked by cleavable linker regions.
  • the recombinant peptide is inserted into at least one surface loop of the viral capsid.
  • the recombinant peptide is inserted into at least one surface loop of an icosahedral viral capsid.
  • At least one monomer is inserted into more than one surface loops of a viral capsid protein.
  • the recombinant peptide is inserted into at least one outer surface loop of the viral capsid.
  • the recombinant peptide is inserted into at least one inner surface loop of the viral capsid.
  • More than one loop of the virus like particle can be modified, i one particular embodiment, the recombinant peptide is expressed on at least two surface loops of the virus-like particle.
  • at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle.
  • At least three recombinant peptides are inserted into at least three surface loops of the virus-like particle.
  • the recombinant peptides in the surface loops can have the same amino acid sequence.
  • the amino acid sequence of the recombinant peptides in the surface loops differ.
  • the cell includes at least one additional nucleic acid encoding either a wild-type capsid or different capsid-recombinant peptide fusion peptide, wherein the multiple capsids can be assembled in vivo to produce chimeric virus like particles.
  • plant cells are provided that include a fusion protein of a viral capsid and a recombinant peptide.
  • the plant cell is a monocot. In an alternative embodiment, the plant cell is a dicot. In one embodiment, the capsid-recombinant peptide fusion protein assembles in vivo to form a virus like particle. In one embodiment of the present invention, the plant cells containing the nucleic acid construct encoding the capsid protein-recombinant peptide fusion peptide is obtained by nuclear transformation. In one embodiment, the plant cell is obtained by plastid transformation. In still another embodiment, the plant cell is obtained by chloroplast transformation.
  • the present invention further provides for non-infectious nucleic acid constructs containing an expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide.
  • the expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide is operably linked to a promoter and terminator.
  • the capsid is derived from a plant virus.
  • the capsid is derived from an icosahedral plant virus, hi a particular embodiment, the capsid is an icosahedral viral capsid derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
  • the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus capsid.
  • the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cell. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cells, and at least one terminator that functions in plant cells. In one embodiment, a nucleic acid sequence encoding a selection marker operably linked to a promoter and a terminator sequence is included in the nucleic acid construct. In an alternative embodiment, a selection marker operably linked to a promoter and a termination sequence is provided on a separate nucleic acid construct. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3' untranslated region (3' UTR) of the viral RNA.
  • 3' UTR 3' untranslated region
  • the nucleic acid construct includes at least one encapsidation signal derived from the viral RNA.
  • the non- infectious nucleic acid construct includes additional nucleic acid sequences derived from the viral RNA, wherein the additional sequences do not confer infectivity to the viral nucleic acids.
  • the present invention provides a process for producing a recombinant peptide including: a) providing a plant cell; b) providing a non-infectious nucleic acid encoding a fusion peptide, wherein the fusion is of at least one heterologous peptide and at least one viral capsid protein; c) transforming the plant cell, wherein the nucleic acid is subsequently integrated into the genome of the plant cell; d) expressing the nucleic acid in the plant cell, wherein the plant cells are grown in a suspension plant cell culture in a fermentation process; e) wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and f) isolating the virus like particles.
  • the process further includes: e) cleaving the fusion product to separate the recombinant peptide from the viral capsid protein, hi still another embodiment, the process further provides: f) following step (e), isolating the recombinant peptide.
  • the plant cell is selected from the group consisting of Oryza sativa and Nicotiana tabacum.
  • the nucleic acid encoding a recombinant peptide and a viral capsid protein is operably linked to a promoter sequence and a terminator sequence.
  • the process includes co-expressing another nucleic acid encoding a wild-type capsid or a different capsid-recombinant peptide fusion peptide, wherein the capsids are assembled in vivo to produce chimeric virus like particles.
  • an expression system for the production of recombinant peptides including: a) a plant cell capable of being propagated in a plant cell medium; b) a non-infectious nucleic acid encoding a fusion peptide; wherein the fusion peptide comprises at least one recombinant peptide, and at least one viral capsid, and wherein the nucleic acid is capable of genomic integration and expression in the plant cell; and c) a growth medium.
  • the nucleic acid encoding the fusion peptide can be operably linked to a promoter sequence and a terminator sequence. When expressed the fusion peptide can assemble into virus like particles within the cell, hi one embodiment, the promoter is a plant promoter.
  • Figure 1 illustrates a scheme for production of peptide monomers in Virus-Like Particles (NLP) in plant cells.
  • a sequence encoding a desired target peptide (“I") is inserted into a sequence encoding a viral coat protein ("CP") constructing a gene encoding recombinant viral coat protein "rCP”), which, as part of a vector, is transformed into the plant cell and expressed to form recombinant coat proteins ("rCP").
  • Optional cleavage sites (“*") are also shown.
  • a plant cell is transfected or transformed with a plant expression plasmid for with the rCP gene.
  • rCP can assemble into VLPs in plant cells.
  • the peptide insert is displayed on VLP surfaces.
  • Chimeric NLPs can be purified from the plant cells, and the desired target peptides can optionally be cleaved off the purified VLPs and purified.
  • Figure 2 shows expression of CCMN CP in tobacco ⁇ T1 cells transfected with infectious CCMV RKA1, R ⁇ A2, and one of the RNA3s transcribed from pDOW2124 (CCMV- RNA3-CP), pDOW2125 (CCMV-RNA3-CP63BamH ⁇ ), pDOW2126 (CCMV-RNA3- CP102BamH ⁇ ), pDOW2127 (CCMV-RNA3-CP114BamHI), pDOW2128 (CCMV-RNA3- CP129BamHI), and pDOW2129 (CCMV-RNA3-CP160BamHI)-
  • the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents Buffer only
  • Lane 2 represents RNAl and RNA2 only
  • Lane 3 represents RNAl and RNA2 + wt RNA3 transcribed from ⁇ DOW2124
  • Lane 4 represents RNAl and RNA2 + RNA3 transcribed from pDOW2125
  • Lane 5 represents RNAl and RNA2 + RNA3 transcribed from pDOW2126
  • Lane 6 represents RNAl and RNA2 + RNA3 transcribed from pDOW2127
  • Lane 7 represents RNAl and RNA2 + RNA3 transcribed from pDOW2128
  • Lane 8 represents RNAl and RNA2 + RNA3 transcribed from pDOW2129.
  • Figure 3 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNAl, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PAl, PA2. PA3, or PA4 at the position 63, 102, or 114.
  • the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents a size marker
  • Lane 2 represents Buffer only
  • Lane 3 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 63
  • Lane 4 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 63
  • Lane 5 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 63
  • Lane 6 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 63
  • Lane 7 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 102
  • Lane 8 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 102
  • Lane 9 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 102
  • Lane 10 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 102
  • Lane 11 represents RNA
  • Figure 4 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNAl, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PAl, PA2, PA3, or PA4 at the position 129 or 160.
  • the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents a size marker
  • Lane 2 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 129
  • Lane 3 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 129
  • Lane 4 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 129
  • Lane 5 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 129
  • Lane 6 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 160
  • Lane 7 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 160
  • Lane 8 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 160
  • Lane 9 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 160
  • Lane 10 represents RNAl + RNA2 + wt RNA3,
  • Figure 5 shows plasmid map of pDOW2160.
  • Figure 6 shows plasmid map ofpDOW2161.
  • Figure 7 shows plasmid map of pDOW2162.
  • Figure 8 shows plasmid map of pDO W2163.
  • Figure 9 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163.
  • the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents Buffer only
  • Lane 2-6 represent RNAl + RNA2 + wt RNA3 (control)
  • Lane 7 represents pDOW2160
  • Lane 8 represents pDOW2161
  • Lane 9 represents pDOW2162
  • Lane 10 represents pDOW2163.
  • Figure 10 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2169, pDOW2170, pDOW2171, and pDOW2172.
  • the plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents RNAl + RNA2 + RNA3 (control)
  • Lane 2 represents Buffer
  • Lane 3 represents pDOW2169
  • Lane 4 represents pDOW2170
  • Lane 5 represents pDOW2171
  • Lane 6 represents pDOW2172.
  • Figure 11 shows expression of chimeric CCMV CP in tobacco NT1 cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents Untransformed tobacco cells (negative control)
  • Lane 2 represents Transgenic tobacco cells transformed with pDOW2160
  • Lane 3 represents Transgenic tobacco cells transformed with pDOW2161
  • Lane 4 represents Transgenic tobacco cells transformed with pDOW2162
  • Lane 5 represents Transgenic tobacco cells transformed with pDOW2163.
  • Figure 12 shows expression of chimeric CCMV CP in rice cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies.
  • Lane 1 represents wt CCMV CP (positive control)
  • Lane 2 represents Size ladder
  • Lane 3 represents Non-transgenic rice cells (negative control)
  • Lane 4 represents Transgenic rice cells transformed with pDOW2160
  • Lane 5 represents wt CCMV CP (positive control)
  • Lane 6 represents Size ladder
  • Lane 7 represents Non-transgenic rice cells
  • Lane 8 represents Transgenic rice cells transformed with pDOW2161
  • Lane 9 represents wt CCMV CP (positive control)
  • Lane 10 represents Size ladder
  • Lane 11 represents Non-transgenic rice cells (negative control)
  • Lane 12 represents Transgenic rice cells transformed with pDOW2162
  • Lane 13 represents wt CCMV CP (positive control)
  • Lane 14 represents Size ladder
  • Lane 15 represents Non-transgenic rice cells (negative control)
  • Lane 16 represents Transgenic rice cells transformed with pDO W21 3.
  • Figure 13 shows detection of PCR products amplified from selected individual rice calli transformed with non-infectious plasmids pDOW2160, ⁇ DOW2161, pDOW2162, and pDOW2163.
  • 1.2 % agarose gel stained with EtBr showing PCR products amplified from selected individual rice calli. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.
  • Lane 1 represents Rice calli 46-5
  • Lane 2 represents Rice calli 46-11
  • Lane 3 represents Rice calli 46-17
  • Lane 4 represents Size Ladder
  • Lane 5 represents Rice calli 47-6
  • Lane 6 represents Rice calli 48-12
  • Lane 7 represents Rice calli 48-18
  • Lane 8 represents Rice calli 48-20
  • Lane 9 represents Rice calli 49-11
  • Lane 10 represents Rice calli 49- 18, and Lane 11 represents Negative control (non-transgenic rice cells).
  • Figure 14 shows western blot analysis of chimeric CCMV VLPs purified from rice cells stably transformed with non-infectious plasmid pDOW2160 by PEG precipitation and ultra- filtration and detection of chimeric CP-PA1 fusion proteins in the purified VLP samples.
  • Lane 1 represents Size ladder
  • Lane 2 represents Total cell lysate from rice suspension cells transgenic for CCMV CP-PAl fusion
  • Lane 3 represents First PEG supernatant
  • Lane 4 represents First PEG pellet
  • Lane 5 represents Second PEG pellet
  • Lane 6 represents Second PEG supernatant.
  • Figure 15 shows diagram of production process of chimeric VLPs in plant suspension cells by fermentation.
  • the present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture.
  • the viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles.
  • the present invention further provides plant cells and nucleic acid constructs for use in the process.
  • the invention provides plant cells, capable of propagation in suspension plant cell cultures, with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide.
  • the fusion peptide can be operably linked to a promoter sequence and a termination sequence.
  • the expression in the plant cell of the fusion peptide produces virus like particles or soluble cage structures.
  • the invention also provides nucleic acid constructs capable of integrating into the genome of the plant cell and encoding the fusion peptide of a viral capsid and a recombinant peptide, which can in one embodiment, be a therapeutic peptide useful for human and animal treatments.
  • the invention also provides a process for producing a recombinant peptide in a suspension plant cell culture by providing: a nucleic acid capable of genomic integration in a plant cell containing an expression cassette encoding a fusion peptide of a recombinant peptide and a viral capsid operably linked to a promoter sequence and a termination sequence; expressing the nucleic acid in the plant cell in a suspension plant cell culture, wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and isolating the virus like particles.
  • infectious means the ability of a virus particle to transfer its nucleic acid to a host or introduction of a viral nucleic acid into a host, wherein the viral nucleic acid is replicated, viral proteins are translated, and new viral particles capable of further transfer of nucleic acid to a host are assembled.
  • non-infectious means the inability of a virus-derived nucleic acid to replicate in a host after introduction into a host, wherein the viral proteins are translated, and new virus like particles assembled that are not capable of initiating viral infection process in a host.
  • peptide as used herein is not limited to any particular molecular weight, and can also include proteins or polypeptides.
  • the present invention provides plant cells that include a non-infectious nucleic acid construct capable of genomic integration and encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence.
  • the cells can be utilized in a process for producing recombinant peptides.
  • the plant cells can be derived by transforming the native plant cell with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence, wherein the nucleic acid construct is stably integrated into the host cell's genome.
  • Stable transformation depends on the integration of the foreign DNA into the genome.
  • the foreign DNA can be integrated into the nuclear or plastid genome of the plant.
  • the nucleic acid construct can be randomly inserted into the genome of the plant, or can be directed to a particular region of the genome through homologous recombination.
  • the plant cell can be obtained by any means known in the art, including nuclear transformation, plastid transformation, and chloroplast transformation.
  • the invention provides plant cells for use in a process for producing peptides by expression of the peptide fused to a viral capsid from a non-infectious plasmid stably integrated into the host genome.
  • the expression can result in the formation of at least one virus like particle (VLP) in the cell.
  • VLP virus like particle
  • Viruses can be classified into those with helical symmetry or icosahedral symmetry.
  • icosahedral including icosahedral proper, isometric, quasi-isometric, and geminate or "twinned”
  • polyhedral including spherical, ovoid, and lemon-shaped
  • bacilliform including rhabdo- or bullet-shaped, and fusiform or cigar- shaped
  • helical including rod, cylindrical, and filamentous; any of which may be tailed and/or may contain surface projections, such as spikes or knobs.
  • the amino acid sequence of the capsid is selected from the capsids of viruses classified as having any morphology.
  • the capsid is derived from a rod shaped virus.
  • the capsid is derived from a rod shaped plant virus.
  • the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus (TMV) and Potato Virus X (PVX).
  • TMV Tobacco Mosaic Virus
  • PVX Potato Virus X
  • TMV consists of a single plus-sense genomic RNA (6.5 kb) encapsidated with a unique coat protein (17.5 kDa) which results in rod-shaped particles (300 nm).
  • Potato Virus X are filamentous, non enveloped; usually flexuous viruses with a clear modal length of 515 nm and 13 nm wide (Brandes, 1964).
  • the capsid structure forms a basic helix with a pitch of 3.4 nm (Varma et al, 1968).
  • the capsid has an icosahedral morphology.
  • the capsid amino acid sequence will be selected from the capsids of entities that are icosahedral proper.
  • the capsid amino acid sequence will be selected from the capsids of icosahedral viruses.
  • the capsid amino acid sequence will be selected from the capsids of icosahedral plant viruses.
  • the viral capsid will be derived from an icosahedral virus not infectious to plants.
  • the virus is a virus infectious to mammals.
  • viral capsids of icosahedral viruses are composed of numerous protein sub- units arranged in icosahedral (cubic) symmetry.
  • Native icosahedral capsids can be built up, for example, with 3 subunits forming each triangular face of a capsid, resulting in 60 subunits forming a complete capsid. Representative of this small viral structure is e.g. bacteriophage 0X174. Many icosahedral virus capsids contain more than 60 subunits. Many capsids of icosahedral viruses contain an antiparallel, eight-stranded beta-ba ⁇ el folding motif. The motif has a wedge-shaped block with four beta strands (designated BIDG) on one side and four (designated CHEF) on the other.
  • BIDG beta strands
  • CHEF designated CHEF
  • a and B There are also two conserved alpha-helices (designated A and B), one is between betaC and betaD, the other between betaE and betaF. Enveloped viruses can exit an infected cell without its total destruction by extrusion (budding) of the particle through the membrane, during which the particle becomes coated in a lipid envelope derived from the cell membrane (See, e.g.: AJ Cann (ed.) (2001) Principles of Molecular Virology (Academic Press); A Granoff and RG Webster (eds.) (1999) Encyclopedia of Virology (Academic Press); DLD Caspar (1980) Biophys. J. 32:103; DLD Caspar and A Klug (1962) Cold Spring Harbor Symp. Quant. Biol. 27:1; J Grimes et al. (1988) Nature 395:470; JE Johnson (1996) Proc. Nat'l Acad. Sci. USA 93:27; and J Johnson and J Speir (1997) J. Mol. Biol.
  • Viruses Viral taxonomies recognize the following taxa of encapsidated-particle entities: • Group I Viruses, i.e. the dsDNA viruses; • Group II Viruses, i.e. the ssDNA viruses; • Group III Viruses, i.e. the dsRNA viruses; • Group TV Viruses, i.e. the ssRNA (+)-stranded viruses with no DNA stage; • Group V Viruses, i.e. the ssRNA (-)-stranded viruses; • Group VI Viruses, i.e. the RNA retroid viruses, which are ssRNA reverse transcribing viruses; • Group Nil Viruses, i.e.
  • D ⁇ A retroid viruses which are dsD ⁇ A reverse transcribing viruses; • Deltaviruses; • Viroids; and • Satellite phages and Satellite viruses, excluding Satellite nucleic acids and Prions.
  • D ⁇ A retroid viruses which are dsD ⁇ A reverse transcribing viruses; • Deltaviruses; • Viroids; and • Satellite phages and Satellite viruses, excluding Satellite nucleic acids and Prions.
  • Virus Taxonomy Seventh Report of the International Committee on Taxonomy of Viruses (2000) (Academic Press/Elsevier, Burlington Mass., USA); the Virus Taxonomy web-page of the University of Leicester (UK) Microbiology & Immunology Department at http://wwwmicro.msb.le.ac.uk/3035/ Virusgroups.html; and the online "Virus” and "Niroid" sections of the Taxonomy Browser of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine of the National Institutes of Health of the US Department of Health & Human Services (Washington, D.C., USA) at http://www.ncbi.nlm.nih.gov/Taxonomv/ tax.html.
  • NCBI National Center for Biotechnology Information
  • the amino acid sequence of the capsid may be selected from the capsids of any members of any of these taxa.
  • Amino acid sequences for capsids of the members of these taxa may be obtained from sources, including, but not limited to, e.g.: the on-line “Nucleotide” (Genbank), "Protein,” and “Structure” sections of the PubMed search facility offered by the NCBI at http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi.
  • the capsid amino acid sequence will be selected from taxa members that are specific for at least one of the following hosts: bacteria, fungi including yeasts, plants, protists including algae, invertebrate animals, vertebrate animals, and humans. In one embodiment, the capsid amino acid sequence will be selected from members of any one of the following taxa: Group I, Group II, Group III, Group IV, Group V, Group VII, Viroids, and Satellite Viruses. In one embodiment, the capsid amino acid sequence will be selected from members of any one of these seven taxa that are specific for at least one of the six above- described host types.
  • the capsid amino acid sequence will be selected from members of any one of Group II, Group III, Group IV, Group VII, and Satellite Viruses; or from any one of Group II, Group IN, Group VII, and Satellite Viruses.
  • the viral capsid is selected from Group IV or Group VII.
  • the viral capsid sequence can be derived from a virus not tropic to the cell.
  • the cell does not include viral proteins from the particular selected virus other than the desired icosahedral capsids.
  • the viral capsid is derived from a virus with a tropism to a different family of organisms than the cell.
  • the viral capsid is derived from a virus with a tropism to a different genus of organisms than the cell. In another embodiment, the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell. In a specific embodiment, the viral capsid is selected from a virus of Group IV. In one embodiment, the viral capsid is selected from rod-shaped plant viruses. In a more particular embodiment, the viral capsid is selected from the group consisting of Tobacco Mosaic Virus and Potato Virus X. In one embodiment, the viral capsid is selected form an icosahedral virus.
  • the icosahedral virus can be selected from a member of any of the Papillomaviridae, Totiviridae, Dicistroviridae, Hepadnaviridae, Togaviridiae, Polyomaviridiae, Nodaviridae, Tectiviridae, Leviviridae, Microviridae, Sipoviridae, Nodaviridae, Picornoviridae, Parvoviridae, Calciviridae, Tetraviridae, and Satellite viruses.
  • the sequence will be selected from members of any one of the taxa that are specific for at least one plant host.
  • the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Bunyaviridae, Reoviridae, Rhabdoviridae, Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa.
  • the icosahedral plant virus species is a plant-infectious virus species that is or is a member of any of the Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa.
  • the icosahedral plant virus species is a plant infectious virus species that is or is a member of any of the Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae.
  • the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae.
  • the icosahedral plant virus species will be a plant-infectious virus species that is a member of the Comoviridae or Bromoviridae family.
  • the viral capsid is derived from a Cowpea Mosaic Virus or a Cowpea Chlorotic Mottle Virus.
  • the viral capsid is derived from a species of the Bromoviridae taxa.
  • the capsid is derived from an Ilarvirus or an Alfamovirus.
  • the capsid is derived from a Tobacco streak virus, or an Alfalfa mosaic virus (AMV) (including AMV 1 or AMV 2).
  • VLP virus like particle
  • a virus like particle (VLP) or cage structure is formed in the host cell during or after expression of the viral capsid.
  • the VLP or cage structure also includes the peptide of interest, and in a particular embodiment, the peptide of interest is expressed on the surface of the VLP.
  • the expression system typically does not contain additional viral proteins that allow infectivity of the virus.
  • the expression system includes a host cell and a vector which codes for one or more viral capsids and an operably linked peptide of interest. The vector typically does not include additional viral proteins.
  • the VLP or cage structure is a multimeric assembly of capsids, including from three to about 1,000 capsids.
  • the VLP or cage structure includes at least 30, at least 50, at least 60, at least 90 or at least 120 capsids.
  • each VLP or cage structure includes at least 150 capsids, at least 160, at least 170, or at least 180 capsids.
  • the VLP is expressed as an icosahedral structure.
  • the VLP is expressed in the same geometry as the native virus that the capsid sequence is derived of.
  • the VLP does not have the identical geometry of the native virus.
  • the structure is produced in a particle formed of multiple capsids but not forming a native-type VLP.
  • a cage structure of as few as 3 viral capsids can be formed.
  • cage structures of about 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, or 60 capsids can be formed.
  • at least one of the capsids includes at least one peptide of interest.
  • the peptide is expressed within at least one internal loop, or in at least one external surface loop of the VLP. More than one loop of the viral capsid can be modified.
  • the recombinant peptide is expressed on at least two surface loops of the virus-like particle.
  • at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle.
  • at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle.
  • the recombinant peptides in the surface loops can have the same amino acid sequence.
  • the amino acid sequence of the recombinant peptides in the surface loops differs.
  • the host cell can be modified to improve assembly of the VLP.
  • the host cell can, for example, be modified to include chaperone proteins that promote the formation of VLPs from expressed viral capsids.
  • the host cell is modified to include a repressor protein to more efficiently regulate the expression of the capsid to promote regulated formation of the VLPs.
  • the nucleic acid sequence encoding the viral capsid or proteins can also be additionally modified to alter the formation of VLPs (see e.g. Brumf ⁇ eld, et al. (2004) J. Gen. Virol. 85: 1049-1053). For example, these modifications are designed to alter the interior, exterior or the interface between adjacent subunits in the assembled protein cage.
  • mutagenic primers can be used to: (i) alter the interior surface charge of the viral nucleic acid binding region by replacing basic residues (e.g. K, R) in the N terminus with acidic glutamic acids (Douglas et al., 2002b); (ii) delete interior residues from the N terminus (in CCMV, usually residues 4-37); (iii) insert a cDNA encoding an 11 amino acid peptide cell-targeting sequence (Graf et al., 1987) into a surface exposed loop ; and (iv) modify interactions between viral subunits by altering the metal binding sites (in CCMV, residues 81/148 mutant).
  • basic residues e.g. K, R
  • acidic glutamic acids Douglas et al., 2002b
  • delete interior residues from the N terminus in CCMV, usually residues 4-37
  • insert a cDNA encoding an 11 amino acid peptide cell-targeting sequence (Graf et al.
  • the peptides operably linked to a viral capsid sequence contain at least two amino acids.
  • the peptides are at least three, at least four, at least five, or at least six amino acids in length.
  • the peptides are at least seven amino acids long.
  • the peptides can also be at least eight, at least nine, at least ten, at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 45, 50, 60, 65, 75, 85, 95, 96, 99 or more amino acids long.
  • the peptides encoded are at least 25kD.
  • the peptide will contain from 2 to about 300 amino acids, or about 5 to about 250 amino acids, or about 5 to about 200 amino acids, or about 5 to about 150 amino acids, or about 5 to about 100 amino acids. In another embodiment, the peptide contains or about 10 to about 140 amino acids, or about 10 to about 120 amino acids, or about 10 to about 100 amino acids. In one embodiment, the peptides or proteins operably linked to a viral capsid sequence will contain about 500 amino acids. In one embodiment, the peptide will contain less than 500 amino acids.
  • the peptide will contain up to about 300 amino acids, or up to about 250, or up to about 200, or up to about 180, or up to about 160, or up to about 150, or up to about 140, or up to about 120, or up to about 110, or up to about 100, or up to about 90, or up to about 80, or up to about 70, or up to about 60, or up to about 50, or up to about 40 or up to about 30 amino acids.
  • the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids.
  • the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide.
  • the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid.
  • the individual monomers in the concatameric peptide are linked by cleavable linker regions.
  • the recombinant peptide is inserted into at least one surface loop of the icosahedral virus-like particle. In one embodiment, at least one monomer is inserted in a surface loop of the virus-like particle.
  • the peptides of interest that are fused to the viral capsids can be a heterologous protein that is not derived from the virus and, optionally, that is not derived from the same species as the cell.
  • the peptides of interest that are fused to the viral capsids can be functional peptides; structural peptides; antigenic peptides, toxic peptides, antimicrobial peptides, fragments thereof; precursors thereof; combinations of any of the foregoing; and or concatamers of any of the foregoing.
  • the recombinant peptide is a therapeutic peptide useful for human and animal treatments, including antigenic peptides used in a vaccine strategy.
  • the antigenic peptide is glycosylated in vivo.
  • Functional peptides include, but are not limited to, e.g.: bio-active peptides (i.e. peptides that exert, elicit, or otherwise result in the initiation, enhancement, prolongation, attenuation, termination, or prevention of a biological function or activity in or of a biological entity, e.g., an organism, cell, culture, tissue, organ, or organelle); catalytic peptides; microstructure- and nanostructure-active peptides (i.e.
  • peptides that form part of engineered micro- or nanostructures in which, or in conjunction with which, they perform an activity, e.g., motion, energy transduction); and stimulant peptides (e.g., peptide flavorings, colorants, odorants, pheromones, attractants, dete ⁇ ents, and repellants).
  • stimulant peptides e.g., peptide flavorings, colorants, odorants, pheromones, attractants, dete ⁇ ents, and repellants.
  • Bio-active peptides include, but are not limited to, e.g.: immunoactive peptides (e.g., antigenic peptides, allergenic peptides, peptide immunoregulators, peptide immunomodulators); signaling and signal transduction peptides (e.g., peptide hormones, cytokines, and neurotransmitters; receptors; agonist and antagonist peptides; peptide targeting and secretion signal peptides); and bio-inhibitory peptides (e.g., toxic, biocidal, or biostatic peptides, such as peptide toxins and antimicrobial peptides).
  • Structural peptides include, but are not limited to, e.g. : peptide aptamers; folding peptides
  • adhesion-promoting peptides e.g., adhesive peptides, cell-adhesion- promoting peptides
  • interfacial peptides e.g., peptide surfactants and emulsifiers
  • microstructure and nanostiucrure-architectural peptides i.e. structural peptides that form part of engineered micro- or nano-structures
  • pre-activation peptides e.g., leader peptides of pre-, pro-, and pre-pro-proteins and -peptides; inteins.
  • Catalytic Peptides include, e.g., apo B RNA-editing cytidine deaminase peptides; catalytic peptides of glutaminyl-tRNA synthetases; catalytic peptides of aspartate franscarbamoylases; plant Type 1 ribosome-inactivating peptides; viral catalytic peptides such as, e.g., the foot-and-mouth disease virus [FMDV-2A] catalytic peptide; matrix metalloproteinase peptides; and catalytic metallo-oligopeptides.
  • FMDV-2A foot-and-mouth disease virus
  • the peptide can also be a peptide epitope, hapten, or a related peptide (e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and or archaeal peptide; allergenic peptide and allergen desensitizing peptide).
  • a related peptide e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and or archaeal peptide; allergenic peptide and allergen desensitizing peptide.
  • the peptide can also be a peptide immunoregulators or immunomodulators (e.g., interferons, interleukins, peptide immunodepressants and immunopotentiators); an antibody peptides (e.g., single chain antibodies; single chain antibody fragments and constructs, e.g., single chain Fv molecules; antibody light chain molecules, antibody heavy chain molecules, domain-deleted antibody light or heavy chain molecules; single chain antibody domains and molecules, e.g., a CHI, CHl-3, CH3, CHl-4, CH4, VHCHl, CL, CDRl, or FR1-CDR1-FR2 domain; paratopic peptides; microantibodies); another binding peptide (e.g., peptide aptamers, intracellular and cell surface receptor proteins, receptor fragments; anti-tumor necrosis factor peptides).
  • an antibody peptides e.g., single chain antibodies; single chain antibody fragments and constructs, e.g.,
  • the peptide can also be an enzyme substrate peptide or an enzyme inhibitor peptide (e.g., caspase substrates and inhibitors, protein kinase substrates and inhibitors, fluorescence- resonance-energy transfer-peptide enzyme substrates).
  • the peptide can also be a cell surface receptor peptide ligand, agonist, and antagonist (e.g., caeruleins, dynorphins, orexins, pituitary adenylate cyclase activating peptides, tumor necrosis factor peptides; synthetic peptide ligands, agonists, and antagonists); a peptide hormone (e.g., endocrine, paracrine, and autocrine hormones, including, e.g.: amylins, angiotensins, bradykinins, calcitonins, cardioexcitatory neuropeptides, casomorphins, cholecystokinins, corticotropin
  • ocytocins parathyroid hormones, pleiotrophins, prolactins, relaxins, secretins, serotonins, sleep-inducing peptides, somatomedins, thymopoietins, thyroid stimulating hormones, thyrotropins, urotensins, vasoactive intestinal peptides, vasopressins); a peptide cyto ine, chemokine, virokine, and viroceptor hormone releasing and release-inhibiting peptide (e.g., corticotropin-releasing hormones, cortistatins, follicle-stimulating-hormone-releasing factors, gastric inhibitory peptides, gastrin releasing peptides, gonadotropin-releasing hormones, growth hormone releasing hormones, luteinizing hormone-releasing hormones, melanotropin- releasing hormones, melanotropin-release inhibiting factors; nocistatins
  • a peptide toxin contains no D-amino acids.
  • Toxin precursor peptides can be those that contain no D-amino acids and/or that have not been converted by postfranslational modification into a native toxin structure, such as, e.g., by action of a D configuration inducing agent (e.g., a peptide isomerase(s) or epimeras(e) or racemase(s) or fransaminase(s)) that is capable of introducing a D-configuration in an amino acid(s), and/or by action of a cyclizing agent (e.g., a peptide thioesterase, or a peptide ligase such as a trans- splicing protein or intern) that is capable of form a cyclic peptide structure.
  • a D configuration inducing agent e.g., a peptide isomerase(s) or epimeras(e) or racemase
  • Toxin peptide portions can be the linear or pre-cyclized oligo- and poly-peptide portions of peptide-containing toxins.
  • peptide toxins include, e.g., agatoxins, amatoxins, charybdotoxins, chlorotoxins, conotoxins, dendrotoxins, insectotoxins, margatoxins, mast cell degranulating peptides, saporins, sarafotoxins; and bacterial exotoxins such as, e.g., anthrax toxins, botulism toxins, diphtheria toxins, and tetanus toxins.
  • the peptide can also be a metabolism- and digestion-related peptide (e.g., cholecystokinin-pancreozymin peptides, peptide yy, pancreatic peptides, motilins); a cell adhesion modulating or mediating peptide, extracellular matrix peptide (e.g., adhesins, selectins, laminins); a neuroprotectant or myelination-promoting peptide; an aggregation inhibitory peptide (e.g., cell or platelet aggregation inhibitor peptides, amyloid formation or deposition inhibitor peptides); a joining peptide (e.g., cardiovascular joining neuropeptides, iga joining peptides); or a miscellaneous peptide (e.g., agouti-related peptides, amyloid peptides, bone-related peptides, cell-permeable peptides, conantokins, contryphan
  • the peptide can also be post-translationally modified in vivo.
  • the peptide may be, singularly or in combination, glycosylated, acetylated, acylated, phosphorylated, or garnma-carboxylated.
  • the peptide of interest is exogenous to the selected viral capsid.
  • Peptides may be either native or synthetic in sequence (and their coding sequences may be either native or synthetic nucleotide sequences). Thus, e.g., native, modified native, and entirely artificial sequences of amino acids are encompassed.
  • sequences of the nucleic acid molecules encoding these amino acid sequences likewise may be native, modified native, or entirely artificial nucleic acid sequences, and may be the result of, e.g., one or more rational or random mutation and or recombination and/or synthesis and/or selection process employed (i.e. applied by human agency) to obtain the nucleic acid molecules.
  • the coding sequence can be a native coding sequence for the target peptide, if available, but will more typically be a coding sequence that has been selected, improved, or optimized for use in the selected expression host cell: for example, by synthesizing the gene to reflect the codon use preference of a host species.
  • the host species is
  • Nicotiana tabacum and the codon preference of Nicotiana tabacum is taken into account when designing both the signal sequence and the peptide sequence.
  • the host species is Oryza sativa, and the codon preference of Oryza sativa is taken into account when designing both the signal sequence and the peptide sequence
  • an antigenic peptide is produced through expression with a viral capsid.
  • the antigenic peptide can be selected from those that are antigenic peptides of human or animal pathogenic agents, including infectious agents, parasites, cancer cells, and other pathogenic agents.
  • pathogenic agents also include the virulence factors and pathogenesis factors, e.g., exotoxins, endotoxins, et al, of those agents.
  • the pathogenic agents may exhibit any level of virulence, i.e. they may be, e.g., virulent, avirulent, pseudo-virulent, semi- virulent, and so forth.
  • the antigenic peptide will contain an epitopic amino acid sequence from the pathogenic agent(s).
  • the epitopic amino acid sequence will include that of at least a portion of a surface peptide of at least one such agent.
  • the capsid-recombinant peptide virus like particles can be used as a vaccine in a human or animal application. More than one antigenic peptide may be selected, in which case the resulting virus-like particles can present multiple different antigenic peptides. In a particularly embodiment of a multiple antigenic peptide format, the various antigenic peptides will all be selected from a plurality of epitopes from the same pathogenic agent.
  • the various antigenic peptides selected will all be selected from a plurality of closely related pathogenic agents, for example, different strains, subspecies, biovars, pathovars, serovars, or genovars of the same species or different species of the same genus.
  • the pathogenic agent(s) will belong to at least one of the following groups: Bacteria and Mycoplasma agents including, but not limited to, pathogenic: Bacillus spp., e.g., Bacillus anthracis; Bartonella spp., e.g., B.
  • Francisella spp. e.g., F. tularensis
  • Haemophilus spp. e.g., H. influenzae
  • Klebsiella spp. e.g., K. pneumoniae
  • Legionella spp. Listeria spp., e.g., L. monocytogenes
  • Meningococci and Gonococci e.g., Neisseria spp.
  • Moraxella spp. Mycobacterium spp., e.g., M. leprae, M. tuberculosis
  • Pneumococci e.g.
  • Diplococcus pneumoniae Pseudomonas spp., e.g., P. aeruginosa; Rickettsia spp., e.g., R. prowazekii, R. rickettsii, R. typhi; Salmonella spp., e.g., S. typhi; Staphylococcus spp., e.g., S. aureus; Streptococcus spp., including Group A Streptococci and hemolytic Streptococci, e.g., S. pneumoniae, S.
  • Fungus and Yeast agents including, but not limited to, pathogenic: Alternaria spp.; Aspergillus spp.; Blastomyces spp., e.g., B. dermatiditis; Candida spp., e.g., C. albicans; Cladosporium spp.; Coccidiodes spp., e.g., C.
  • the pathogenic agent(s) will be from a protist agent including, but not limited to, pathogenic: Amoebae, including Acanthamoeba spp., Amoeba spp., Naegleria spp., Entamoeba spp., e.g., E. histolytica; Cryptosporidium spp., e.g., C.
  • Cyclospora spp. Encephalitozoon spp., e.g., E. intestinalis; Enterocytozoon spp.; Giardia spp., e.g., G. lamblia; Isospora spp.; Microsporidium spp.; Plasmodium spp., e.g., P. falciparum, P. malariae, P. ovale, P. vivax; Toxoplasma spp., e.g., T. gondii; and Trypanosoma spp., e.g., T. brucei.
  • the pathogenic agent(s) will be from a parasitic agent (e.g., helminthic parasites) including, but not limited to, pathogenic: Ascaris spp., e.g., A. lumbricoides; Dracunculus spp., e.g., D. medinensis; Onchocerca spp., e.g., O. volvulus; Schistosoma spp.; Trichinella spp., e.g., T. spiralis; and Trichuris spp., e.g., T. trichiura.
  • a parasitic agent e.g., helminthic parasites
  • the pathogenic agent(s) will be from a viral agent including, but not limited to, pathogenic: Adenoviruses; Arenaviruses, e.g., Lassa Fever viruses; Astroviruses; Bunyaviruses, e.g., Hantaviruses, Rift Valley Fever viruses; Coronaviruses, Deltaviruses; Cytomegaloviruses, ⁇ pstein-Barr viruses, Herpes viruses, Varicella viruses; Filo viruses, e.g., Ebola viruses, Marburg viruses; Flaviruses, e.g., Dengue viruses, West Nile Fever viruses, Yellow Fever viruses; Hepatitis viruses; Influenzaviruses; Lentiviruses, T-Cell Lymphotropic viruses, other leukemia viruses; Norwalk viruses; Papillomaviruses, other tumor viruses; Paramyxoviruses, e.g., Measles viruses, Mumps viruses, Parainfluenzaviruses
  • the antigenic peptide is selected from the group consisting of a Canine parvovirus peptide, Bacillus anthracis protective antigen (PA) antigenic peptide, and an Eastern Equine Encephalitis virus antigenic peptide.
  • the antigenic peptide is the Bacillus antracis-de ⁇ ved peptide with the amino acid sequence selected from PAl (SEQ. ID. NO. 1), PA2 (SEQ. ID. NO. 2), PA3 (SEQ. ID. NO. 3), or PA4 (SEQ. ID. NO. 4).
  • the recombinant peptide is a peptide that is toxic to the host cell when in free monomeric form.
  • the peptide of interest expressed in conjunction with a viral capsid will be a host cell toxic peptide.
  • a host cell toxic peptide indicates a bio-inhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed, or to other cells in the cell culture or organism of which the host cell is a member, or to cells of the organism or species providing the host cells.
  • the host-cell-toxic peptide will be a bioinhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed.
  • Some examples of host-cell-toxic peptides include, but are not limited to: peptide toxins, anti-microbial peptides, and other antibiotic peptides.
  • the recombinant peptide is a peptide that is an antimicrobial peptide.
  • Anti-Microbial Peptides include, e.g., anti-bacterial peptides such as, e.g., magainins, betadefensins, some alpha-defensins; cathelicidins; histatins; anti-fungal peptides; antiprotozoal peptides; synthetic AMPs; peptide antibiotics or the linear or pre-cyclized oligo- or poly-peptide portions thereof; other antibiotic peptides (e.g., anthelmintic peptides, hemolytic peptides, tumoricidal peptides); and anti-viral peptides (e.g., some alpha-defensins; virucidal peptides; peptides that inhibit viral infection).
  • the antimicrobial peptide is selected from the group consisting of D2
  • the viral capsid will be one in which the expression of viral capsid does not allow replication or infection of the cell.
  • the viral capsid will be derived from a virus that does not infect the specific species of cell that the host cell is derived from.
  • the viral capsid is derived from an icosahedral plant virus and is expressed in a host cell of a plant species that is not the native trophic host of the virus.
  • the viral species infects mammals and the expression system includes a plant host cell.
  • the virus is a trophic virus of the particular plant species utilized as a host cell for expressing the capsid-recombinant peptide fusion.
  • the plant host cell may be any plant cell from the Tracheophyta, Euphyllophyta,
  • the plant cell is a Monocot, including, but not limited to, members of, e.g.: Arecaceae, e.g., Cocos spp., Elaeis spp.; Dioscoreaceae, e.g., Dioscorea spp.; Gramineae (Poaceae), e.g., Avena spp., Hordeum spp., Oryza spp., Panicum spp., Triticum spp., Zea spp.; and Musaceae, e.g., Musa spp.
  • the plant cell is a member of the Dicots, including, but not limited to, e.g.: Amaranthaceae, e.g., Amaranthus spp., Beta spp., Chenopodium spp.; Apiaceae (Umbelliferae), e.g., Daucus spp., Pastinaca spp.; Brassicaceae (Cruciferae), e.g., Arabidopsis spp., Brassica spp.; Compositae, e.g., Helianthus spp.; Convolvulaceae, e.g., Ipomoea spp.; Cucurbitaceae, e.g., Citrullus spp., Cucumis spp., Cucurbita spp.; Euphorbiaceae; Leguminosae (Fabaceae), e.g, Glycine spp., Lens spp
  • the host cell is selected from the group consisting of Aradiposis thialiana, Taxus cuspidate, Catharanthus roseus, Nicotiana tabacum, Oryza sativa, Lycopersicum esculentum, and Glycine max.
  • the present invention further provides non-infectious nucleic acid constructs capable of stably integrating into the host cell's genome and encoding a fusion peptide of a capsid and a recombinant peptide.
  • the fusion peptide can be operably linked to a promoter sequence and a termination sequence.
  • a nucleic acid construct for use in transforming plant host cells including a) a nucleic acid sequence encoding a recombinant peptide, and b) a nucleic acid sequence encoding a viral capsid is provided, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein is stably inserted into the genome of the plant host cell, wherein it is expressed in the plant cell.
  • the vector can include sequence for multiple capsids, or for multiple peptides of interest.
  • the vector can include at least two different capsid-peptide coding sequences.
  • the coding sequences are linked to the same promoter.
  • the coding sequences are separated by an internal ribosomal binding site.
  • the coding sequences are linked by a linker sequence that allows the formation of virus like particles in the cell.
  • the coding sequences are linked to different promoters. These promoters may be constitutive or driven by the same or different induction conditions.
  • multiple vectors capable of insertion into the genome and encoding different capsid-peptide combinations are provided. The multiple vectors can include promoters that are constitutive or driven by the same induction conditions, or by different induction conditions.
  • the viral capsid is derived from an icosahedral viral capsid.
  • the coding sequence for a peptide of interest can be inserted into the coding sequence for a viral capsid or capsid in a predetermined site.
  • the peptide can also be inserted at a non- predetermined site and cells screened for production of VLPs.
  • the peptide is inserted into the capsid coding sequence so as to be expressed as a loop during formation of a VLP.
  • one peptide coding sequence is included in the vector, however in other embodiments, multiple sequences are included.
  • the multiple sequences can be in the form of concatamers, for example concatamers linked by cleavable linker sequences.
  • Peptides may be inserted at more than one insertion site in a capsid.
  • peptides may be inserted in more than one surface loop motif of a capsid; peptides may also be inserted at multiple sites within a given loop motif.
  • the individual functional and/or structural peptide(s) of the insert(s), and/or the entire peptide insert(s), may be separated by cleavage sites, i.e. sites at which an agent that cleaves or hydrolyzes protein can act to separate the peptide(s) from the remainder of the capsid structure or assemblage.
  • Peptides may be inserted within external-facing loop(s) and/or within internal-facing loop(s), i.e. within loops of the capsid that face respectively away from or toward the center of the capsid.
  • any amino acid or peptide bond in a surface loop of a capsid can serve as an insertion for the peptide.
  • the insertion site will be selected at about the center of the loop, i.e. at about the position located most distal from the center of the tertiary structure of the folded capsid peptide.
  • the peptide coding sequence may be operably inserted within the position of the capsid coding sequence corresponding to this approximate center of the selected loop(s). This includes the retention of the reading frame for that portion of the peptide sequence of the capsid that is synthesized downstream from the peptide insertion site.
  • the peptide can be inserted at the amino terminus of the capsid.
  • the peptide can be linked to the capsid through one or more linker sequences, including the cleavable linkers described above.
  • the peptide can be inserted at the carboxy terminus of the capsid.
  • the peptide can also be linked to the carboxy terminus through one or more linkers, which can be cleavable by chemical or enzymatic hydrolysis.
  • peptide sequences are linked at both the amino and carboxy termini, or at one terminus and at at least one internal location, such as a location that is expressed on the surface of the capsid in its three dimensional conformation.
  • the peptide can be inserted into the capsid from a Cowpea Chlorotic Mosaic Virus.
  • the peptide can be inserted at amino acid 129 of the CCMN coat protein. In one embodiment, the peptide sequence can be inserted at amino acid 63, 102, 114, 129, or 160 of the CCMV coat protein, hi another embodiment, the peptide sequence can be inserted at amino acids 60, 61, 62 or 63 of the CCMV coat protein, hi still another embodiment, the peptide can be inserted at both amino acids 129 and amino acids 60-63 of the CCMV protein.
  • the present invention provides a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell.
  • a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell.
  • Other capsids and recombinant peptides useful in constructing the nucleic acid construct are disclosed above.
  • the nucleic acid construct includes a promoter sequence operably attached to the nucleic acid sequence encoding the capsid-recombinant peptide fusion peptide.
  • An operable attachment or linkage refers to any configuration in which the transcriptional and any franslational regulatory elements are covalently attached to the described sequence so that by action of the host cell, the regulatory elements can direct the expression of the sequence of interest.
  • the nucleic acid construct encoding the capsid fusion product can be inserted in frame with a host cell native promoter utilizing a gene trapping strategy. In a fermentation process, once fermentation begins, it is ideal to have a high level of production in order to maximize efficiency of the expression system.
  • the promoter initiates transcription and is generally positioned 1-100 nucleotides upstream of the transcription start site.
  • a promoter will be strong enough to allow for a large amount of recombinant peptide accumulation.
  • the promoters used in accordance with the present invention may be constitutive promoters or regulated promoters.
  • useful regulated promoters used in the art include: ethanol-inducible promoters; iron deficiency-inducible promoters; wound-inducible promoters; and hormone-inducible, e.g., auxin-inducible, promoters.
  • useful constitutive promoters include the ubiquitin promoter, the actin promoter, the tubulin promoter, and the Cassava Vein Mosaic Virus promoter.
  • tissue-specific promoters such as corn sucrose synthetase 1 (Yang el al., 1990), corn alcohol dehydrogenase 1 (Vogel et al., 1989), corn light harvesting complex (Simpson, 1986), corn heat shock protein (Odell et al., 1985), pea small subunit RuBP carboxylase (Poulsen et al., 1986; Cashmore et al., 1983), Ti plasmid mannopine synthase (Langridge et al, 1989), Ti plasmid nopaline synthase (Langridge et al., 1989), petunia chalcone isomerase (Van Tunen et al., 1988), bean glycine rich protein 1 (Keller et al., 1989), CaMV 35s transcript (Odell et al., 1985) and Potato patatin (Wenzler et al., 1989).
  • tissue-specific promoters such as corn sucrose synthe
  • Prefe ⁇ ed promoters are the cauliflower mosaic virus (CaMV 35S) promoter, the rice alpha-amylase RAmy3D promoter, and the S-E9 small subunit RuBP carboxylase promoter.
  • CaMV 35S cauliflower mosaic virus
  • RAmy3D rice alpha-amylase RAmy3D promoter
  • S-E9 small subunit RuBP carboxylase promoter a variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals can be used for expression of an operably linked gene in plant cells, including promoters regulated by (1) heat (Callis et al., Plant Physiol.
  • hormones such as abscisic acid (Marcotte et al., Plant Cell 1:969, 1989), (4) wounding (e.g., wunl, Siebertz et al., Plant Cell 1:961, 1989); or (5) chemicals such as methyl jasmonate, salicylic acid, or Safener.
  • (6) organ-specific promoters e.g., Roshal et al., EMBO J. 6:1155, 1987; Schernthaner et al., EMBO J. 7:1249, 1988; Bustos et al., Plant Cell 1:839, 1989).
  • Additional promoters useful in the present invention include those described in WO 97/48819; the phaseolin promoters described in US Patent Number 5,591,605; rice actin promoters described in US Patent Number 5,641,876; the per5 promoter described in WO 98/56921; the gamma zein promoters described in WO 00/12681; and other promoters as described in US Patent Number 6,825,006, US Patent Number 6,660,911, and plant promoters described the plant promoter sequence database PlantProm, described in Shahmuradov et al. (2003), "PlantProm: a database of plant promoter sequences," Nucleic Acid Res.
  • Additional promoters may also include cauliflower mosaic virus (CaMV) 35S promoter or its enhanced version, the hybrid (ocs) ⁇ ,mas promoter, and ubiquitin promoters from maize or A. ihaliana.
  • CaMV cauliflower mosaic virus
  • a promoter having the nucleotide sequence of a promoter native to the selected plant host cell can also be used to control expression of the transgene encoding the target peptide.
  • Tandem promoters may also be used in which more than one promoter is covalently attached to another, whether the same or different in sequence.
  • a promoter having the nucleotide sequence derived from a virus can also be used to direct expression of the transgene encoding the target peptide.
  • Regulated promoters can utilize promoter regulatory proteins in order to control transcription of the gene of which the promoter is a part. Where a regulated promoter is used herein, a corresponding promoter regulatory protein will also be part of an expression system according to the present invention. Many regulated-promoter/promoter-regulatory-protein pairs are known in the art.
  • regulatory elements can be included in a nucleic acid construct. Such elements include, but are not limited to, for example, franscriptional enhancer sequences, franslational enhancer sequences, other promoters, activators, franslational start and stop signals, transcription terminators, cistronic regulators, polycistronic regulators, tag sequences, such as nucleotide sequence "tags" and "tag" peptide coding sequences, which facilitates identification, separation, purification, or isolation of an expressed peptide, including His-tag, Flag-tag, T7-tag, S-tag, HSV-tag, B-tag, Strep-tag, polyarginine, polycysteine, polyphenylalanine, polyaspartic acid, (Ala-Trp-Trp-Pro)n, thioredoxin, beta-galactosidase, chloramphenicol acetyltransferase, cyclomaltodextrin gluconofran
  • the nucleic acid construct further comprises a tag sequence adjacent to the coding sequence for the recombinant peptide of interest, or linked to a coding sequence for a viral capsid. In one embodiment, this tag sequence allows for purification of the protein.
  • the tag sequence can be an affinity tag, such as a hexa-histidine affinity tag.
  • the affinity tag can be a glutathione-S-transferase molecule.
  • the tag can also be a fluorescent molecule, such as YFP or GFP, or analogs of such fluorescent proteins.
  • the tag can also be a portion of an antibody molecule, or a known antigen or ligand for a known binding partner useful for purification.
  • the present invention can include, in addition to the capsid-recombinant peptide coding sequence, the following regulatory elements operably linked thereto: a promoter, a transcription terminator, franslational start and stop signals.
  • the nucleic acid construct includes additional nucleic acid sequences derived from the 3' untranslated region (3' UTR) of the viral genomic nucleic acid sequence utilized to derive the viral capsid protein.
  • the 3 'UTR contains sequences that play a role in regulation of translation or capsid formation in the wild type virus.
  • the 3 'UTR sequences are upstream pseudoknot domains (UPD).
  • the 3 'UTR are derived from the 3 'UTR of the viral capsid encoding region of the viral genome.
  • the 3 'UTR is derived from the cowpea chlorotic mosaic virus RNA3 3' untranslated region.
  • the 3 'UTR sequence includes an encapsidation signal.
  • the nucleic acid construct includes at least one encapsidation signal derived from a viral nucleic acid sequence.
  • the encapsidation signal can be derived from 5 'UTR, 3 'UTR, or internal sequence of the viral genomic sequence.
  • the nucleic acid construct is encapsidated in the VLP.
  • the non-infectious nucleic acid construct also includes other sequences derived from the viral or non-viral nucleic acid sequence other than the viral capsid protein sequence.
  • Vectors useful expression vectors for use in plant cells in stably integrating into the host cell genome and expressing capsid-recombinant peptide fusion peptides are constructed by inserting a structural DNA sequence encoding a desired target peptide fused with a capsid peptide together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.
  • the vector may also comprise one or more phenotypic selectable or screenable markers to allow for selection of host cells. Alternatively, the selectable or screenable markers can be provided on a separate plasmid.
  • a wide variety of vectors and/or carriers are known in the art as useful for transforming a target plant host cell with recombinant capsid-encoding nucleic acid for expression, and any of these may be used for expressing the genes according to the present invention. See, e.g., IJ Goderis IJ et al., "A set of modular plant transformation vectors allowing flexible insertion of up to six expression units," Plant Mol. Biol. 50(l):17-27 (2002); AH Christensen & PH Quail, "Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants," Transgenic Res.
  • Examples of some vectors that may be used include, but are not limited to, pRTlOl, pRTlOl-MCS, pRT104, pRT104.24LS, pRT104.N-myc, pRT104.C-myc, pRT104.N-3HA, pRT104-N3HAdAsp, pRT104.N-6HA, pRT104-N6HAdAsp, pRT104.C-3HA, pRT104-GST, pRT104 NES(A2), pRT103-3HA, pRTd35S-Luci(-),pRTd35S- Luci-NES, pRTd35S-GFP, pRTd35S-GFP.Sad, pRTdS GFP.Bglll, pRTd35S-Ds-Red, pRTd35S-profillin, pBIGal4DBD, pRT-3HAxHsfA2DBD, pRT
  • the vector is pIL-Tab.
  • the vector is pIL-Tab encoding for the coat protein from Cowpea Chlorotic Mosaic Virus (CCMV).
  • CCMV Cowpea Chlorotic Mosaic Virus
  • the vector is pIL-Tab, and the heterologous peptide is selected from the group consisting of PAl, PA2, PA3 or PA4.
  • the vector is selected from the group consisting of pDOW2160 (Seq. ID. No. 5), pDOW 2161 (Seq. ID. No.
  • carriers may be used, such as liposomes, dendrimers, cationic polymers, and cationic polymer-lipid complexes, all of which have been employed in widely published methods for delivery of nucleic acids to cells or protoplasts.
  • naked DNA or naked RNA may be delivered to the plant host.
  • the vector, carrier, or naked nucleic acid may be directly transformed into a plant cell or protoplast by any method known effective therefore in the art.
  • any of the following methods may be used to transform the plant target host with the recombinant capsid- encoding nucleic acid: Agrobacterium spp.; microparticle bombardment as described by V. Vasil et al., Bio/Technology 9, 743 (1991); electroporation of protoplasts as described, for example, for lettuce by MC Chupeau et al., Bio/Technology 7, 503 (1989); surface abrasion using, e.g., silicon carbide whiskers, glass, or carborundum; liposome fusion with protoplasts as described, for example, by A.
  • the present invention also provides a process for producing a recombinant peptide.
  • the process includes: a) providing a plant cell; b) providing a non-infectious nucleic acid containing an expression cassette encoding a fusion peptide; wherein the fusion is of a recombinant peptide and an icosahedral capsid; c) expressing the nucleic acid in the plant cell, wherein the expression in the cell provides for in vivo assembly of the fusion peptide into virus like particles; and d) isolating the virus like particles.
  • the fusion peptide is operably linked to a promoter sequence and a terminator sequence.
  • the process further comprises: e) cleaving the recombinant peptide from the viral capsid protein.
  • the process further comprises: f) isolating the recombinant peptide from step e. See, for example, Figure 1.
  • Peptides may be expressed as single-copy peptide inserts within a capsid peptide (i.e. expressed as individual inserts from recombinant capsid peptide coding sequences that are mono-cistronic for the peptide) or may be expressed as di-, tri-, or multi-copy peptide inserts (i.e.
  • concatemeric inserts from recombinant capsid peptide coding sequences that are poly-cistronic for the peptide; the concatemeric insert(s) may contain multiple copies of the same exogenous peptide of interest or may contain copies of different exogenous peptides of interest). Concatemers may be homo- or hetero-concatemers.
  • the isolated virus like particle can be administered to a human or animal in a vaccine strategy.
  • the nucleic acid construct can be co-expressed with another nucleic acid encoding a wild type capsid.
  • the co-expressed capsid/capsid-recombinant peptide fusion particles assemble in vivo to form a chimeric virus like particle.
  • the chimeric VLP is a virus like particle including capsids or capsid-peptide fusions encoded by at least two different nucleic acid constructs.
  • the nucleic acid construct can be co-expressed with another nucleic acid encoding a different capsid-recombinant peptide fusion particle.
  • the co-expressed capsid fusion particles will assemble in vivo to form a chimeric virus like particle.
  • a second nucleic acid which is designed to express a different peptide, such as a chaperone protein, can be expressed concomitantly with the nucleic acid encoding the fusion peptide.
  • a different peptide such as a chaperone protein
  • the expressed viral capsid-heterologous peptide fusion product is expressed in soluble form in the cell.
  • the expressed viral capsid-recombinant heterologous fusion product is assembled into VLPs in the cell.
  • a portion of the expressed viral capsid- heterologous peptide fusion product of interest is formed in an insoluble aggregate in the cell.
  • the peptide of interest can be renatured from the insoluble aggregate.
  • the process further provides: e) cleaving the fusion product to separate the recombinant peptide from the capsid.
  • a cleavable linkage sequence can be included between the viral protein and the recombinant peptide.
  • agents that can cleave such sequences include, but are not limited to chemical reagents such as acids (HCI, formic acid), CNBr, hydroxylamine (for asparagine-glycine), 2-Nitro-5- thiocyanobenzoate, O-Iodosobenzoate, and enzymatic agents, such as endopeptidases, endoproteases, trypsin, clostripain, and Staphylococcal protease.
  • Cleavable linkage sequences are well known in the art. In the present invention, any cleavable linkage sequence recognized by cleavage agents, including dipeptide cleavage sequences such as Asp-Pro, can be utilized.
  • the process of the invention optimally leads to the increased production of desired capsid-fusion products in a plant host cell in the desired sequence and conformation.
  • the increased production alternatively can be an increased level of desired peptide per gram of protein produced, per gram of host protein, or as a percentage of total recombinant peptide produced.
  • the increased production can also be an increased level of recoverable peptide, such as soluble protein, produced per gram of recombinant or per gram of host cell protein.
  • the increased production can also be any combination of increased total level and increased active or soluble level of protein.
  • the improved expression of recombinant protein can be through expression of the protein as a capsid fusion protein and subsequently inserted in VLPs.
  • At least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, or at least 180 copies of a peptide of interest are expressed in each VLP.
  • the VLPs can be produced and recovered from the cytoplasm, periplasm or extracellular medium of the host cell.
  • the peptide can be insoluble in the cell.
  • the soluble or insoluble peptide is produced in a particle formed of multiple capsids but not forming a native-type VLP. For example, a cage structure of as few as 3 viral capsids can be formed.
  • the capsid structure includes more than one copy of a peptide of interest and in certain embodiments, includes at least ten, at least 20, or at least 30 copies.
  • the peptide is formed in the vacuole of the plant cell.
  • the peptide or viral capsid sequence can also include one or more targeting sequences or sequences to assist purification. These can be an affinity tag. These can also be targeting sequences directing the assembly of capsids into a VLP .
  • Plant Growth Transformation of the plant host cells with the vector(s) may be performed using any transformation methodology known in the art, and the plant host cells may be transformed as intact cells or as protoplasts. Exemplary transformation methodologies have been described above. As used herein, the term “fermentation” includes both embodiments in which literal fermentation is employed and embodiments in which other, non-fermentative culture modes are employed. Fermentation may be performed at any scale. Any method generally known in the art may be utilized in fermentation. See, for example, Hellwig et al. (2004) "Plant cell cultures for the production of recombinant proteins," Nature Biotech 22(11): 1415-1422; Sajc et al. (2000) “Bioreactors for plant engineering: an outlook for further research," Biochem Engin. J.
  • the fermentation medium may be selected from among any viable plant cell culture media.
  • additives to the medium can include, for example, PVP, BSA, NaCl, BrefeldinA, reducing manganese, pluronic antifoam, polyethylene glycol, gelatin, protease inhibitors, redox co-factors, and dimethylsulfoxide.
  • the expression system according to the present invention can be cultured in any fermentation format. For example, batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein.
  • the expression systems according to the present invention are useful for transgene expression at any scale (i.e. volume) of fermentation.
  • microliter-scale, centiliter scale, and deciliter scale fermentation volumes may be used; and 1 Liter scale and larger fermentation volumes can be used.
  • the fermentation volume will be at or above 1 Liter.
  • the fermentation volume will be at or above 5 Liters, 10 Liters, 15 Liters, 20 Liters, 25 Liters, 50 Liters, 75 Liters, 100 Liters, 200 Liters, 500 Liters, 1,000 Liters, 2,000 Liters, 5,000 Liters, 10,000 Liters or 50,000 Liters.
  • growth, culturing, and/or fermentation of the transformed host cells is performed within a temperature range permitting survival of the host cells, preferably a temperature within the range of about 4°C to about 55°C, inclusive.
  • Plant cell expressions systems according to the present invention can provide a cell density or comparable packed wet cell density of about from about 20 g/L (2% packed cell volume) to more than 550 g L (55% packed cell volume). In one embodiment, the packed cell volume is between 2% to about 60%. In another embodiment, the packed cell volume is 2%, 5%, 10%, 15%, 20%, 25%, 35%, 40%, 50%, 55%, 60%, 70%, or 85%.
  • the invention provides a process for improving the recovery of peptides of interest by protection of the peptide during expression through linkage and co- expression with a viral capsid.
  • the viral capsid fusion forms a VLP, which can be readily separated from the cell lysate.
  • proteins of this invention may be isolated and purified to substantial purity by standard techniques well known in the art, including, but not limited to, PEG precipitation, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, detergent solubilization, selective precipitation with such substances as column chromatography, immunopurification methods, and others.
  • proteins having established molecular adhesion properties can be reversibly fused to a ligand.
  • the protein can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form.
  • the fused protein can then be removed by enzymatic or other activity.
  • protein can be purified using immunoaffinity columns or Ni-NTA columns.
  • General techniques are further described in, for example, R. Scopes, Protein Purification: Principles and Practice, Springer- Verlag: N.Y. (1982); Deutscher, Guide to Protein Purification, Academic Press (1990); U.S. Pat. No. 4,511,503; S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc.
  • Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence.
  • appropriate segments e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence.
  • VLPs can be isolated and purified to substantial purity by standard techniques well known in the art.
  • Techniques for isolation of VLPs include, in addition to those described above, precipitation techniques such as polyethylene glycol or salt precipitation.
  • Separation techmques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, immunopurification methods, centrifugation, ultracentrifugation, density gradient centrifugation (for example, on a sucrose or on a cesium chloride (CsCl) gradient), ultrafilfration through a size exclusion filter, and any other protein isolation methods known in the art.
  • precipitation techniques such as polyethylene glycol or salt precipitation.
  • Separation techmques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose
  • the invention can also improve recovery of active recombinant peptides.
  • Levels of active protein can be measured, for example, by measuring the interaction between an identified and a parent peptide, peptide variant, segment-substituted peptide and/or residue-substituted peptide by any convenient in vitro or in vivo assay.
  • in vitro assays can be used to determine any detectable interaction between an identified protein and a peptide of interest, e.g. between enzyme and subsfrate, between hormone and hormone receptor, between antibody and antigen, etc.
  • Such detection can include the measurement of colorirnetric changes, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion processes, etc.
  • In vivo assays include, but are not limited to, assays to detect physiological effects, e.g. weight gain, change in electrolyte balance, change in blood clotting time, changes in clot dissolution and the induction of antigenic response.
  • any in vivo assay can be used so long as a variable parameter exists so as to detect a change in the interaction between the identified and the peptide of interest. See, for example, U.S. Patent No. 5,834,250.
  • Detection of the expressed protein is achieved by methods known in the art and includes, for example, radioirnmunoassays, Western blotting techniques or immunoprecipitation.
  • An initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest.
  • One such example can be ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations.
  • a typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20- 30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures.
  • the molecular weight of a recombinant protein can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes).
  • the protein mixture can be ulfrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest.
  • the retentate of the ultrafiltration can then be ulfrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest.
  • the recombinant protein will pass through the membrane into the filtrate.
  • the filtrate can then be chromatographed.
  • Recombinant proteins can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands.
  • antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
  • Renaturation and Refolding Insoluble protein can be renatured or refolded to generate secondary and tertiary protein structure conformation. Protein refolding steps can be used, as necessary, in completing configuration of the recombinant product. Refolding and renaturation can be accomplished using an agent that is known in the art to promote dissociation/association of proteins. For example, the protein can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea.
  • a refolding agent such as urea.
  • Recombinant protein can also be renatured, for example, by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.
  • PBS phosphate-buffered saline
  • the protein can be refolded while immobilized on a column, such as the Ni NTA column by using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, and 20 mM Tris/HCl pH 7.4, containing protease inhibitors.
  • the renaturation can be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM immidazole.
  • hnmidazole can be removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl.
  • the purified protein can be stored at room temperature, 4°C or frozen at -20°C to -80°C.
  • Other methods include, for example, those that may be described in MH Lee et al., Protein Expr. Purifi, 25(1): p. 166-73 (2002), W.K. Cho et al., J. Biotechnology, 77(2-3): p. 169- 78 (2000), Ausubel, et al. (1987 and periodic supplements), Academicr (1990) "Guide to Protein Purification," Methods in Enzymology vol.
  • Active proteins can have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native peptide that the sequence is derived from.
  • the subsfrate specificity (k cat K m ) is optionally substantially similar to the native peptide.
  • k cat /K m will be at least 30%, 40%, or 50%, that of the native peptide; and more preferably at least 60%, 70%, 80%, or 90%.
  • the activity of a recombinant peptide produced in accordance with the present invention by can be measured by any protein specific conventional or standard in vitro or in vivo assay known in the art.
  • the activity of the plant cell host produced recombinant peptide can be compared with the activity of the corresponding native protein to determine whether the recombinant protein exhibits substantially similar or equivalent activity to the activity generally observed in the native peptide under the same or similar physiological conditions.
  • the activity of the recombinant protein can be compared with a previously established native peptide standard activity.
  • the activity of the recombinant peptide can be determined in a simultaneous, or substantially simultaneous, comparative assay with the native peptide.
  • an in vitro assays can be used to determine any detectable interaction between a recombinant peptide and a target, e.g. between an expressed enzyme and subsfrate, between expressed hormone and hormone receptor, between expressed antibody and antigen, etc.
  • a target e.g. between an expressed enzyme and subsfrate, between expressed hormone and hormone receptor, between expressed antibody and antigen, etc.
  • detection can include the measurement of colorimetric changes, proliferation changes, cell death, cell repelling, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion methods, phosphorylation abilities, antibody specificity assays such as ELISA assays, etc.
  • in vivo assays include, but are not limited to, assays to detect physiological effects of the plant host cell produced peptide in comparison to physiological effects of the native peptide, e.g. antigenic response.
  • any in vitro or in vivo assay can be used to determine the active nature of the recombinant peptide that allows for a comparative analysis to the native peptide so long as such activity is assayable.
  • the peptides produced in the present invention can be assayed for the ability to stimulate or inhibit interaction between the peptide and a molecule that no ⁇ nally interacts with the peptide, e.g. a substrate or a component of the signal pathway that the native protein normally interacts.
  • Such assays can typically include the steps of combining the protein with a substrate molecule under conditions that allow the peptide to interact with the target molecule, and detect the biochemical consequence of the interaction with the protein and the target molecule.
  • Assays that can be utilized to determine peptide activity are described, for example, in Ralph, P. J., et al. (1984) J. Immunol. 132:1858 or Saiki et al. (1981) J. Immunol. 127:1044, .Steward, W. E. U (1980) The friterferon Systems. Springer- Verlag, Vienna and New York, Broxmeyer, H. E., et al.
  • CCMV cowpea chlorotic mottle virus
  • CCMV cowpea chlorotic mottle virus
  • Bromoviruses are 25-28 nm diameter icosahedral viruses with a four-component, positive sense, single-stranded RNA genome.
  • RNAl and RNA2 code for replicase enzymes.
  • RNA3 codes for a protein involved in viral movement within plant hosts.
  • RNA4 (a subgenomic RNA derived from RNA 3), i.e.
  • sgRNA4 codes for the 20 kDa coat protein (CP) (SEQ ID NO: 13) (Table 1). Each CCMV particle contains 180 copies of the CCMV CP. An exemplary DNA sequence encoding the CCMV CP is shown in SEQ ID NO:14 (Table 2).
  • Table 1 Wild type CCMV coat protein encoded by sgRNA4 (Seq. ID No. 13)
  • Table 2 Exemplary DNA Sequence Encoding the CCMV CP (Seq. ID. No. 14) atg tct aca gtc gga aca ggg aag tta act cgt gca caa cga agg get gcg gcc cgt aag aac aag egg aac act cgt gtg gtc caa cct gtt art gta gaa ccc ate get tea ggc caa ggc aag get art aaa gca tgg ace ggt tac age gta teg aag tgg ace gcc tct tgc gcgcc gaa get aaa gta ace teg get ata act ate tct etc ct aat gag eta
  • CCMV coat proteins can be genetically modified to carry heterologous peptides without interfering with their ability to form particles.
  • a number of suitable insertion sites have been identified.
  • a total of up to 180 copies of a heterologous peptide unit (whether as individual peptide units or in concatameric units) can be inserted into the CCMV particle at a single insertion site in the CCMV CP. Insertion sites identified within CCMV CP to date can accommodate peptides of various lengths.
  • Example 1 Production of Antigenic Peptides in CCMV Virus Particles in Whole Cowpea Plants Inoculated with CCMV RNAl, RNA2, and Chimeric RNA3
  • CCMV cowpea chlorotic mottle virus
  • CP capsid proteins
  • DNA having the nucleotide sequence of CCMV RNA 1 and DNA having the nucleotide sequence of CCMV RNA 2 were each separately subcloned in the cloning vector pUC19 downstream from, and under the confrol of, a T7 promoter and upstream from a unique Xba I site. This produced plasmids pDOW2122 (CCMV RNAl) and pDOW2123 (CCMV RNA2).
  • BamH I restriction enzyme cleavage sites was further engineered for production of the recombinant capsid protein-encoding nucleic acid.
  • Four DNA molecules, each encoding a different one of four exogenous peptides (four different antigenic peptides from Bacillus anthracis Protective Antigen PA) were each synthesized by SOE (splicing-by-overlap-extension) of synthetic oligonucleotides.
  • SOE splicing-by-overlap-extension
  • Each PA DNA fragment was restricted with BamHI restriction enzyme and independently inserted into the coat protein at one of the five different engineered restriction enzyme cleavage sites in the CCMV coat protein coding sequence: BamHI at codon 63, BamHI at codon 102, BamHI at codon 114, BamHI at codon 129, and BamHI at codon 160.
  • the four different peptides were PAl (SEQ ID NO:l encoded by SEQ ID NO: 15), PA2 (SEQ ID NO: 2, encoded by SEQ ID NO: 16), PA3 (SEQ ID NO: 3, encoded by SEQ ED NO: 17), and PA4 (SEQ ID NO:4, encoded by SEQ ID NO: 18).
  • Table 4 Bacillus anthracis antigenic nucleic acid and amino acid sequences.
  • pDOW2125 pUC-CCMV RNA3-CP635 ⁇ »2Hi
  • pDOW2126 pUC-CCMV-RNA3-1025 ⁇ mHi
  • pDOW2127 pUC- CCMN-RNA3-CP1145 ⁇ mH7
  • pDOW2128 ⁇ UC-CCMV-RNA3-CP129#amH7/>
  • pDOW2129 pUC-CCMV-RNA3-CPl 60BamHI
  • Plasmids pDOW2135 (pUC-CCMV-RNA3-CP635 ⁇ ? «H/-PAl), pDOW2139 (pUC-CCMV-RNA3- CP102Bamffl- ⁇ A ⁇ ), pDOW2143 (pUC-CCMV-RNA3-CP1145 ⁇ mH/-PAl), pDOW2147 (pUC- CCMV-RNA3-CP129£ 7 ⁇ HT-PAl), and pDOW2151 (pUC-CCMV-RNA3-CP160# mH/-PAl) are examples of chimeric RNA3 having a PAl insert at position 63, 102, 114, 129, and 160.
  • RNA3 construct was separately sub-cloned in the cloning vector pUC19 downstream from and under the control of a T7 promoter, and upstream from a unique Xba I site.
  • Each of the three classes of plasmids was cloned in E. coli. Plasmids were isolated, linearized by Xba I restriction enzyme digestion, and then one microgram of each was transcribed into RNA in vitro using a mMESSAGE mMACHINE T7 Kit (RNA transcription kit, from Ambion, Inc., Austin, TX, USA).
  • RNAl RNA-based RNA
  • RNA2, RNA3 or chimeric RNA3s containing a PA insert were used to infect cowpea plants.
  • Cowpea plants were sprouted from Cowpea California Blackeye #5 seeds (Ferry-Morse Seed Co. KY).
  • Sprouts were transplanted singly into 6 inch pots with Miracle-Gro potting mix (Miracle-Gro Lawn Products OH). Cowpea plants were infected at 2- leaf stage (approximately 7 days post germination).
  • Carborundum powder 400grit (Fisher Scientific cat.409-21-2) was applied onto one leaf of each plant.
  • RNA cocktail mixes were applied onto the carborundum layer. Leaves were abraded by gentle rubbing with a gloved finger. Infections were established 7-14 days post inoculation. Unexpectedly, in this whole plant system, even though the native host plant was used, the chimeric coat proteins reverted to the wild type or in some cases, the desired exogenous antigen peptide was partially deleted. This was verified by sequencing the virus progeny.
  • RNA3 progeny derived from pDOW2128 containing the PAl insert the coat protein contained a small, unrecognized nucleotide insert (5 '-CGTATTTCTGATCCTCTC-3 ') that was translated as RISDPL instead of the PAl insert amino acid sequence.
  • the inserted nucleotide sequence kept the rest of the coat protein in frame. It has been determined that the engineered CCMV RNA3 is unstable upon expression in the whole plant, easily undergoes recombinations, and that the whole plant system is not useful for production of epitopes on chimeric CCMV virus particles.
  • Example 2 Production of Antigenic Peptides in CCMV Virus Particles in Tobacco Suspension Culture Inoculated with CCMV RNAl, RNA2, and Chimeric RNA3
  • CCMV-peptide-encoding constructs were performed in plant cell suspension culture. Nicotiana tabacum N l cells were transfected by elecfroporation with RNA transcripts of CCMV RNA 3 coding for the chimeric CCMV coat proteins and CCMV RNA 1 and 2 coding for the replicase genes. Wild-type CCMV coat protein-encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing the appropriate BamHI restriction site but no inserts were used as controls. 24 different RNA varieties were obtained by in vitro RNA transcription as described in the Example 1: one for RNAl, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls. In 22 different groups, two micrograms of each of three resulting RNAs (RNAl, RNA2, and one of the RNA3s) were transformed into tobacco cells by elecfroporation.
  • Purified water was added to the solution to bring volume up to 1 liter. The pH was adjusted to 5.8, and the solution was autoclaved. Mannitol Wash Solution 0.4M: 36.43 Mannitol (Sigma cat. M-1902) was added to small amount of purified water. Purified water was added to bring volume up to 500 ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize. Enzyme solution: 0.4M mannitol, and 0.02M MES were mixed in a small amount of water. Purified water was added to bring volume up to 500ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize, and the solution was stored at 4°C.
  • Tobacco cell line NTl was partially digested prior to electroporation as following.
  • a robust cell line was maintained by sub-culturing weekly, cells were grown in NTl media at 24°C or 28°C with gentle shaking, and three days before digestion, 5ml of cell suspension was sub-cultured into 50ml of NTl media and incubated at 28°C. Cells were spun down in 50ml tubes for 5 minutes at 800 rpm. The enzyme solution was prepared, and cells were washed in the mannitol wash solution (approx. 40ml). Cells were spun for 5 minutes at 800 rpm, and 3 volumes of enzyme solution were added to the cells.
  • Cells were resuspended by inversion; transfe ⁇ ed into 10cm petri dishes by pouring, and the dish was shaken very slowly at room temperature while wrapped in aluminum foil for 60-120 minutes. The cells were then fransfe ⁇ ed back into 50ml plastic tubes; and spun for 5 minutes at 800 rpm. Cells were washed with 40ml mannitol wash solution and spun again, washed with elecfroporation buffer, and spun. Three volumes of electroporation buffer (total volume is usually 20ml) were added to the cells; and the cells were stored at 4°C wrapped in aluminum foil.
  • Electroporation of partially digested cells protocol lml of digested cells were aliquoted into electroporation cuvettes (4mm gap). 2 ⁇ g each RNA transcript - CCMV RNAl, RNA2, and Chimeric RNA3 - were added to the cuvettes and placed on ice for 5 minutes. 10ml of NTl plating media were added (NTI+0.4M mannitol) to each Petri dish. The cells were elecfroporated at 500 ⁇ F, 250V, and the cuvettes were placed back on ice. The cells were then transfe ⁇ ed into Petri dishes, and incubate at room temperature in darkness with no shaking. The cells were then collected for analysis at 48 hours post transfection.
  • chimeric coat protein was analyzed by Western blot using anti-CCMV coat protein polyclonal antibody. Also, RNA was extracted from each of the cultures and the chimeric CCMV RNA4 was reverse transcribed into cDNA, which was then amplified by PCR. The PCR products were sequenced as described in Example 1. All samples were positive on the western blot except for the negative control that was transfected with only RNAl and 2. Compared to control CCMV capsid proteins, the chimeric coat proteins had greater size and slower mobility on the gel indicating that the chimeric coat proteins contained PA inserts. This was verified by sequencing of the viral RNA progeny.
  • FIG. 2 shows the expression of CCMV CP in cells transfected with CCMV RNAl, RNA2, and RNA3 transcribed from pDOW2125 (CCMV63BamHI), pDOW2126 (CCMV102BamHI), pDOW2127 (CCMV114BamHI), pDOW2128 (CCMV129BamHI) and pDOW2129 (CCMV160BamHI).
  • CCMV CP is expressed from all RNA3s with engineered BamHI site in different positions in the CP. All 4 PA peptides (PAl, PA2, PA3, and PA4) fused to CCMV coat protein at the 63, 102, 114, 129, and 160 BamHI site were successfully produced in tobacco cells.
  • Figure 3 and Figure 4 show the expression of chimeric CCMV CP in cells transfected with CCMV RNAl, RNA2, and chimeric RNA3 containing CP with the four PA peptide inserts in the position 63, 102, 114, 129, and 160.
  • Figure 3 demonstrates that the fusion protein of CCMV CP with PAl, PA2, PA3, or PA4 peptide that has been inserted at the position 63, 102, or 114, is expressed in the tobacco plant cells with the exception of PA2 peptide that has been inserted into the CCMP CP at the position 63.
  • Figure 4 demonstrates that the fusion protein of CCMV CP with PAl, PA2, PA3, or PA4 peptide that has been inserted at the position 129 or 160, is expressed in the tobacco plant cells.
  • Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were Xbal and EcoRI. This plasmid contains the Cassava Vein Mosaic
  • CCMV CP-PA fusions were amplified by PCR out of pDOW2147 (pUC-CCMV-RNA3- Pl29BamHI-?Al), pDOW2148 (pUC-CCMV-RNA3-CP1295fl H/-PA2), pDOW2149 (pUC- CCMV-RNA3-CP1295flmH/-PA3), pDOW2150 (pUC-CCMV-RNA3-CP1295 H/-PA4) using primers CCMV-CP-Xbal (SEQ ID NO:22) and CCMV-CP-EcoRI (SEQ ID NO: 23) to create pDOW2160 (pIL-Tab-CCMV1295 ⁇ ?wH7-PAl) (SEQ ID NO: 5), pDOW2161 (pIL-Tab- CCMV129 J 8 ⁇ / «H/--
  • Plant cells were transfected with lO ⁇ g of plasmid pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Plant cell transfection was performed as in Example 2.
  • Example 4 Provide of 4 Antigenic Peptides as CCMV CP fusions in Virus-like Particles in Tobacco Suspension Culture Transfected with Plant Expression Plasmids Encoding the Chimeric CCMV CPs and 3 'UTR (CCMVRNA3 3 ' untranslated region) 1) Vector construction. Plasmid ⁇ IL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were Xba and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the Xbal site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with Xbal and EcoRI and depshophorylated before litigation with the inserts.
  • CCMV CP-PA fusions containing the 3'UTRof RNA3 were amplified by PCR out of pDOW2147, pDOW2148, pDOW2149, and pDOW2150 using primers CCMV-CP-Xbal and CCMV-CP-EcoRI-3'UTR (SEQ ID NO: 24) to create pDOW2169 (pIL-Tab-CP129J? ⁇ mH/-
  • PA1-3'UTR (SEQ ID NO: 9), pDOW2170 (pIL-Tab-CP1295 « H/-PA2-3'UTR) (SEQ ID NO: 10), pDOW2171 (pIL-Tab-CP1295 ⁇ H7-PA3-3'UTR) (SEQ ID NO:ll), and pDOW2172 (pIL- Tab-CP1295 ⁇ mHi-PA4-3'UTR) (SEQ ID NO: 12).
  • Plant cells were transfected with 10/xg of plasmid pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Plant cell transfection was performed as in Example 2.
  • Tobacco cell line NTl was maintained by subculruring weekly. Cells were grown in NTl media at 24°C or 28°C with gentle shaking. Three days before transformation, 5ml of cell suspension was subcultured into 50ml of NTl media and incubated at 28°C.
  • Plant cell fransformation by particle bombardment Plasmids pDOW2160, pDOW2161, pDOW2162, ⁇ DOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter (pBBV) were used for NTl tobacco cells transformation by micro-particle bombardment.
  • the plasmid ratio used was 1: 6 pBBV:pDOW2160, pBBV: ⁇ DOW2161, pBBV:pDOW2162, or pBBV: ⁇ DOW2163. Total of 5ug of plasmid DNAs were sufficient for 6 bombardments.
  • Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
  • Plating Bombarded cells were transfe ⁇ ed on non-selective NTl media agar plates for 4 hours before transferring to NTl media agar plate with 25ug/ml of Glufosinate-ammonium (Sigma cat#45520). 3) Selecting transgenic calli. After 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome. Transgenic calli expressing chimeric CCMV CPs were transferred to liquid NTl media. Cells were grown in NTl media at
  • Results Figure 11 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163.
  • the CP fusion was detected by polyclonal antibodies for CCMV. Expression of all four chimeric coat protein fransgenes was detected.
  • Example 6 Production of 4 Antigenic Peptides as CCMV CP fusions in CCMV Virus-like Particles in Transgenic Rice Suspension Culture Transformed with Plant Expression Plasmids Encoding the Chimeric CCMV CPs
  • Plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter were used for rice cells fransformation by microparticle bombardment.
  • the plasmid ratio used was 1: 6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5ug of plasmid DNAs were sufficient for 6 bombardments.
  • Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
  • Bombarded cells were transfe ⁇ ed to NB media agar plates with 25ug/ml of Glufosinate- ammonium (Sigma cat#45520) for selection.
  • Results Figure 12 shows the expression of chimeric CCMV CP in cells stably transformed with ⁇ DOW2160, pDOW2161, pDOW2162, and pDOW2163 as detected by polyclonal antibodies to CCMV. Expression of all four chimeric coat protein transgenes was detected. The following protocol has been used to extract genomic DNA and test for integration of promoter-CP fusion gene-terminator cassette into the plant genome by PCR. Qiagen DNeasy Plant Mini was used to extract genomic DNA following the manufacturer directions. Approximately 50 — 100 mg of fresh rice callus was placed into a 1.5ml tube. The tissue was frozen in liquid N 2 for immediate DNA extraction or placed in -80°C freezer for storage.
  • the tissue Prior to DNA extraction the tissue was manually disrupted by grinding with a micropestle. The sample was placed on ice and the genomic DNA was extracted as described in Qiagen DNeasy Plant Mini Kit manual. The Access Quick Master Mix 2x (Promega cat#A1720) was used to set up the PCR reaction as follows:
  • Figure 13 shows a PCR products amplified from selected individual rice calli. The samples that contained a PCR product of predicted size were scored as positive for stable transformation and integration of the chimeric CP transgene into the plant genome.
  • Transgenic calli expressing chimeric CCMV CPs were transfe ⁇ ed to liquid NB media to create a cell suspension culture suitable for scale up fermentation. Cells were grown in NB media at 28 °C with gentle shaking and subcultured weekly.
  • VLP extraction Chimeric VLPs were precipitated by lysis of shake-flask culture samples, followed by
  • PEG polyethylene glycol
  • the resuspended samples were centrifuged for 10 min at 15,000xG at 4°C, the supernatant was recovered and subjected to the second round of PEG precipitation.
  • PEG8000 was added to final concentration of 15% and sti ⁇ ed at 4°C for 2 hours.
  • the solution was then centrifuged at 15,000xG for 10 mins and the pellet was resuspended in small volume of virus buffer.
  • the resuspended VLP solution was loaded on to Centricon Plus-20 with 300K molecular weight cut-off and spun at 4,000xG for 5 mins.
  • the concentrated VLP sample was then analyzed by western blotting with polyclonal anti-CCMV antibodies (see Figure 14). Chimeric CP-PAl fusion proteins were detected in the resuspended and size-filtered second PEG pellets, but not in the supernatant, indicating the chimeric CP assembled into VLPs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides an improved process for the production of recombinant peptides. In particular, the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures. The invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production.

Description

HIGH EFFICIENCY PEPTIDE PRODUCTION IN PLANT CELLS
CROSS REFERENCE To RELATED APPLICATIONS This application claims priority to U.S. Provisional patent application serial No. 60/548,744, filed February 27, 2004, entitled "High Efficiency Peptide Production in Plant Cells."
STATEMENT OF GOVERNMENT INTEREST This application is under a United States Government contract with the National Institutes of Health, National Institute of Allergy and Infectious Disease (NIAID), Cooperative Agreement No. 1-U01-AI054641-01.
FIELD OF THE INVENTION The present invention provides an improved process for the production of recombinant peptides. In particular, the present invention provides an improved process for the production of recombinant peptides in the form of viral capsid fusion proteins which can be assembled in vivo in plant cell suspension cultures. The invention also includes plasmids, sequences, and plant cells which allow for non-infectious viral capsid fusion peptide production. BACKGROUND OF THE INVENTION Bacterial, yeast, plant, insect, and mammalian cell expression systems are currently used to produce recombinant peptides, with varying degrees of success. One goal in creating expression systems for the production of heterologous peptides is to provide broad based, flexible, efficient, economic, and practical platforms and processes that can be utilized in commercial, therapeutic, and vaccine applications. For example, for the production of certain peptides, it would be ideal to have an expression system capable of producing, in an efficient and inexpensive manner, large quantities of final, desirable products in vivo in order to eliminate or reduce downstream reassembly costs. Currently, bacteria are the most widely used expression system for the production of recombinant peptides because of their potential to produce abundant quantities of recombinant peptides. Bacteria generally do not glycosylate, acetylate, acylate, phosphorylate, or gam a- carboxylate eukaryotic proteins, and, therefore, are limited in their capacities to produce, in vivo, certain types of heterologous eukaryotic peptides that require post-translational modifications. Additional steps modifying the bacterially produced eukaryotic peptides are likely to increase the time and reduce the overall yield of peptide production, diluting many of the advantages of the bacterial host expression system. Therefore, alternative non-bacterial expression systems have been utilized to overcome the inherent limitations of bacterial expression systems. One particular host expression systems analyzed for their ability to produce heterologous peptides has been whole plants and plant cell suspension cultures. The safe and inexpensive culture of plants provides an improved alternative host for the cost effective production of certain peptides. This alternative is particularly attractive where the protein is complex, requires glycosylation, needs to be free of human or animal infectious viruses, and bacterial toxins. Whole plants offer the advantages of being relatively inexpensive to grow in vast quantities, with the potential for a great yield of the desired recombinant protein from the large biomass of the harvested transgenic or viral infected plants. As a result, whole plants have been developed as expression systems for commercial production of biopharmaceutical proteins intended for human or veterinary administration. Significant time and resources have been spent on trying to improve the cost of production and yield of heterologous proteins in non-bacterial systems in order to take advantage of the inherent abilities of these systems. While progress has been made in both of these areas, additional processes and platforms for the production of heterologous peptides in non-bacterial expression systems would be beneficial.
Viruses and Virus Like Particles One approach for improving peptide production in host cell expression systems is to make use of the properties of infectious recombinant viruses to produce recombinant peptides of interest. The use of infectious viruses in plant host systems is particularly well known. See, for example, Porta & Lomonossoff, (2002) "Viruses as vectors for the expression of foreign sequences in plants," Biotechnology and Genetic Enginering Reviews 19: 245-291. Recent strategies have focused on the production of heterologous peptides in virus like particle (NLP) structures. In general, encapsidated viruses include a protein coat or "capsid" that is assembled to contain the viral nucleic acid. Many viruses have capsids that can be "self- assembled" from the individually expressed capsids, both within the cell the capsid is expressed in ("in vivo assembly"), and outside of the cell after isolation and purification ("in vitro assembly"). Ideally, capsids are modified to contain a target recombinant peptide, generating a recombinant viral capsid-peptide fusion. The fusion peptide can then be expressed in a cell, and, ideally, assembled in vivo to form recombinant viral or virus-like particles. The production of heterologous proteins via virus capsid fusion proteins assembled into VLPs in plants has been met with varying success. See, for example, C Marusic et al, J Virol. 75(18):8434-39 (Sep 2001) (use of infectious helical potato virus X in whole Nicotiana benthamiana to express virus capsids terminally fused to an antigenic, six amino acid HIV peptide, with in vivo formation of the recombinant virus particles); FR Brennan et al, Vaccine 17(15-16):1846-57 (09 Apr 1999) (use of infectious cowpea mosaic virus or helical potato virus X capsids terminally fused to an antigenic, Staphylococcus aureus peptide, with in vivo formation of recombinant virus particles expression in whole cowpea plants (Vigna uniquiculata)).; C Porta et al., Intervirology 39(l-2):79-84 (1996) (describing an infectious cowpea mosaic virus expressing a chimeric coat protein including an antigenic HIV sequence in whole plants). US Patent No. 5,874,087 to Lomonossoff & Johnson describes production of infectious plant viruses, in plant cells or whole plants, wherein the viral capsids are engineered to contain a biologically active peptide, such as a hormone, growth factor, or antigenic peptide. A virus selected from the genera Comovirus, Tombusvirus, Sobemovirus, and Nepovirus is engineered to contain the exogenous peptide encoding sequence and the entire engineered genome of the virus is expressed to produce the recombinant virus. The specification stresses that multiplication of the modified virus is a central part of the invention. . U.S. Patent No. 6,232,099 to Chapman et al. describes the use of infective, rod-shaped viruses to produce foreign proteins connected to viral capsid subunits in whole plants. Rod- shaped viruses, also classified as helical viruses, such as potato virus X (PVX) have recombinant peptides of interest inserted into the genome of the virus to create recombinant viral capsid- peptide fusions. The recombinant, infective virus is then used to infect a plant cell of a whole plant, wherein, the virus actively replicates in the plant cell and further infects other cells, ultimately infecting the entire host plant. Ultimately, the recombinant viral capsid-peptide fusion is purified from the plant. Chapman et al. also teaches that a limited insertion size is tolerated by icosahedral viruses. Chapman et al. cite WO 92/18618, which limits the size of the recombinant peptide in an icosahedral virus for expression in a plant host cell to 26 amino acids in length, in supporting his assertion. Chapman et al. theorize that a larger peptide present in the internal insertion site in the capsid of icosahedral viruses may result in disruption of the geometry of the protein and/or its ability to successfully interact with other capsids leading to failure of the chimeric virus to assemble. U.S. Patent 6,042,832 to Koprowski et al. describes fusion capsid proteins comprising a plant virus capsid protein fused to an antigenic polypeptide. The resultant particles are produced in whole plants. The utilization of infectious recombinant viruses to produce heterologous proteins in capsid fusion proteins is not, however, without its drawbacks. One particularly froubling aspect is the ability of these viruses to mutate in vivo, resulting in capsid proteins that are essentially wild type revertants without the fused heterologous protein of interest, or mutated, non-desirable recombination capsid fusion protein products. See, or example, Porta & Lomonossoff (1996) "Use of viral replicons for the expression of genes in plants," Molecular Biotechnology 5:209- 221 ; Dolja et al. (1993) "Spontaneous mutagenesis of a plant potyvirus genome after insertion of a foreign gene," J. Virol. 67(10):5968-5975; Dawson et al. (2001) "Assessment of recombinants that arise from the use of a TMV-based transient expression vector," Virol. 284(2): 182-189 (describing the deletion of the foreign inserted gene in inoculated whole plants). The lack of stability of these viral vectors in whole plants potentially reduces the yield of overall protein product, and may lead to inconsistencies and irregularities in the capsid-fusion product. Such iπegularities may be particularly troublesome wherein the integrity of the protein product is essential for a particular desired physio-chemical characteristic in the peptide. As a result of the inherent instability of infectious recombinant viruses in plants, there is still a need in the field of commercial recombinant protein production for an efficient peptide production system that offers plant-system-type benefits. In addition, the use of whole plants for the production of recombinant peptides also presents potential problems. For instance, long development times, batch to batch variations in product yield, containment issues, the difficulty of applying good manufacturing practice to the early stages of production, the possibility of contamination with agrochemicals and fertilizers, as well as the impact of pests, disease and variable cultivation conditions due to microclimate and soil differences all result in a potential inconsistent host system for the production of recombinant peptides. Therefore, it is an object of the present invention to provide a stable and consistent plant cell expression system for the production of virus like particles containing capsid fusion proteins. It is another object of the present invention to provide plant cells for use as host cells in a stable expression system for the production of virus like particles containing capsid fusion proteins. It is still another object of the present invention to provide processes for the improved production of virus like particles containing capsid fusion proteins in plant cells, including plant cell suspension cultures. It is yet another object of the present invention to provide novel constructs and nucleic acids for use in plant cell expression system for the production of virus like particles containing capsid fusion proteins. SUMMARY OF THE INVENTION The present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture. The viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles. The present invention does not require the utilization of an infective viral agent; rather, non-infectious nucleic acid encoding a capsid- heterologous peptide fusion product is stably inserted into the genome of a plant cell, which can be cultured in a fermentation process to produce the peptide of interest. Such a process results in a less variable, and more stable host system for the expression of capsid fusion proteins containing heterologous peptides. It has been discovered that infectious viruses containing capsid-heterologous peptide fusion proteins utilized to express heterologous peptides of interest in whole plants exhibit genetic instability in the whole plant that results in mutations in the recombinant capsid protein nucleic acid, and the expressed mutant capsid either cannot assemble into virus particles or contains a mutated target peptide. The present invention provides increased stability of the resultant heterologous peptide, with the additional benefits of precise control over growth conditions, batch to batch consistency, a high level of containment, and the ability to produce recombinant proteins in compliance with good manufacturing practices. The capsid-fusion protein products can form virus like particles within the cell. The virus like particle may result in the improved efficiency of achieving a high purity of the recovered peptide. The virus like particles produced in the cell typically are not capable of infecting the plant cell. The viral capsid sequence can be derived from both trophic and non-trophic viruses, wherein trophism is determined by the specific plant cell utilized as the expression host. In one embodiment, the viral capsid protein is derived from a virus that exhibits a native or natural trophism towards the plant cell utilized to express the fusion product. In one embodiment, the viral capsid protein is derived from a virus that does not exhibit a native or natural trophism towards the plant cell utilized to express the fusion product. In one embodiment, the cell does not include artificially introduced viral proteins other than the desired capsid protein sequences utilized to produce the fusion product. In another embodiment, the cell includes artificially introduced viral proteins or nucleic acids other than the desired capsid protein sequences utilized to produce the fusion product, wherein the additional viral proteins or nucleic acids do not confer infectivity to the nucleic acid sequences. In one embodiment, the viral capsid is derived from a virus with a tropism to a different family of organisms than the plant cell expression host. In another embodiment, the viral capsid is derived from a virus with a tropism to a different genus of organisms than the plant cell expression host. In another embodiment, the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell utilized to express the fusion product. In one embodiment of the present invention, the capsid is derived from a rod shaped plant virus. In a particular embodiment, the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus and Potato Virus X (PVX). In one embodiment of the present invention, the capsid protein is derived from an icosahedral virus. In a particular embodiment, the capsid is derived from a plant icosahedral virus. In a more particular embodiment, the icosahedral capsid is derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. The present invention also provides plant cells that include a non-infectious nucleic acid construct containing an expression cassette encoding for a fusion protein of a virus capsid and a recombinant peptide. The fusion peptide of the virus capsid and recombinant peptide is operably linked to a promoter and terminator that functions in plant cells. In one specific embodiment, the nucleic acid is genomically integrated in the plant cell, wherein the integration results in the stable inheritance and expression of the nucleic acid encoding the capsid fusion protein from generation to generation. In one specific embodiment of the present invention, the capsid protein is derived from an icosahedral virus. In one embodiment the cell produces virus like particles or soluble cage structures, hi one embodiment, the plant cell is a Monocot or a Dicot. In a particular embodiment, the plant cell is Nicotiana tabacum. hi an alternative embodiment, the plant cell is Oryza sativa. In one embodiment of the present invention, the recombinant peptide fused to the viral capsid protein is a therapeutic peptide useful for human or animal treatments. In one particular embodiment, the recombinant peptide is an antigenic peptide. In a particular embodiment, the antigenic peptide is a glycosylated antigenic peptide. In one embodiment, the plant cells or extracts containing capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal. In an alternative embodiment, the purified capsid-recombinant peptide virus like particles containing an antigenic peptide can be administered as a vaccine to a human or animal. In one embodiment, the heterologous peptide is an antimicrobial peptide. In another particular embodiment, the recombinant peptide is a peptide that is toxic to the plant host cell when in free monorneric form. In one embodiment, the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids in length. In one embodiment of the present invention, the recombinant peptide fused to the capsid contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the viral capsid. In one embodiment, the recombinant peptide is inserted into at least one surface loop of an icosahedral viral capsid. In one embodiment, at least one monomer is inserted into more than one surface loops of a viral capsid protein. In still another embodiment, the recombinant peptide is inserted into at least one outer surface loop of the viral capsid. In an alternative embodiment, the recombinant peptide is inserted into at least one inner surface loop of the viral capsid. More than one loop of the virus like particle can be modified, i one particular embodiment, the recombinant peptide is expressed on at least two surface loops of the virus-like particle. In another embodiment, at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle. In another embodiment, at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle. The recombinant peptides in the surface loops can have the same amino acid sequence. In separate embodiments, the amino acid sequence of the recombinant peptides in the surface loops differ. In still another embodiment, the cell includes at least one additional nucleic acid encoding either a wild-type capsid or different capsid-recombinant peptide fusion peptide, wherein the multiple capsids can be assembled in vivo to produce chimeric virus like particles. In one aspect of the present invention, plant cells are provided that include a fusion protein of a viral capsid and a recombinant peptide. In one specific embodiment of the present invention, the plant cell is a monocot. In an alternative embodiment, the plant cell is a dicot. In one embodiment, the capsid-recombinant peptide fusion protein assembles in vivo to form a virus like particle. In one embodiment of the present invention, the plant cells containing the nucleic acid construct encoding the capsid protein-recombinant peptide fusion peptide is obtained by nuclear transformation. In one embodiment, the plant cell is obtained by plastid transformation. In still another embodiment, the plant cell is obtained by chloroplast transformation. The present invention further provides for non-infectious nucleic acid constructs containing an expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide. In one embodiment of the present invention, the expression cassette encoding for a fusion protein of a viral capsid and a recombinant peptide is operably linked to a promoter and terminator. In one embodiment of the present invention, the capsid is derived from a plant virus. In one embodiment of the present invention, the capsid is derived from an icosahedral plant virus, hi a particular embodiment, the capsid is an icosahedral viral capsid derived from the group selected from Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. In one embodiment of the present invention, the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus capsid. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cell. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences including at least one promoter that functions in plant cells, and at least one terminator that functions in plant cells. In one embodiment, a nucleic acid sequence encoding a selection marker operably linked to a promoter and a terminator sequence is included in the nucleic acid construct. In an alternative embodiment, a selection marker operably linked to a promoter and a termination sequence is provided on a separate nucleic acid construct. In another embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3' untranslated region (3' UTR) of the viral RNA. In still another embodiment, the nucleic acid construct includes at least one encapsidation signal derived from the viral RNA. fn still another embodiment, the non- infectious nucleic acid construct includes additional nucleic acid sequences derived from the viral RNA, wherein the additional sequences do not confer infectivity to the viral nucleic acids. In one aspect, the present invention provides a process for producing a recombinant peptide including: a) providing a plant cell; b) providing a non-infectious nucleic acid encoding a fusion peptide, wherein the fusion is of at least one heterologous peptide and at least one viral capsid protein; c) transforming the plant cell, wherein the nucleic acid is subsequently integrated into the genome of the plant cell; d) expressing the nucleic acid in the plant cell, wherein the plant cells are grown in a suspension plant cell culture in a fermentation process; e) wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and f) isolating the virus like particles. In one embodiment, the process further includes: e) cleaving the fusion product to separate the recombinant peptide from the viral capsid protein, hi still another embodiment, the process further provides: f) following step (e), isolating the recombinant peptide. See, for example, Figure 1. In one embodiment of the present invention, the plant cell is selected from the group consisting of Oryza sativa and Nicotiana tabacum. The nucleic acid encoding a recombinant peptide and a viral capsid protein is operably linked to a promoter sequence and a terminator sequence. In one embodiment, the process includes co-expressing another nucleic acid encoding a wild-type capsid or a different capsid-recombinant peptide fusion peptide, wherein the capsids are assembled in vivo to produce chimeric virus like particles. In another aspect of the present invention, an expression system for the production of recombinant peptides is provided including: a) a plant cell capable of being propagated in a plant cell medium; b) a non-infectious nucleic acid encoding a fusion peptide; wherein the fusion peptide comprises at least one recombinant peptide, and at least one viral capsid, and wherein the nucleic acid is capable of genomic integration and expression in the plant cell; and c) a growth medium. The nucleic acid encoding the fusion peptide can be operably linked to a promoter sequence and a terminator sequence. When expressed the fusion peptide can assemble into virus like particles within the cell, hi one embodiment, the promoter is a plant promoter.
Brief Description of the Figures Figure 1 illustrates a scheme for production of peptide monomers in Virus-Like Particles (NLP) in plant cells. A sequence encoding a desired target peptide ("I") is inserted into a sequence encoding a viral coat protein ("CP") constructing a gene encoding recombinant viral coat protein "rCP"), which, as part of a vector, is transformed into the plant cell and expressed to form recombinant coat proteins ("rCP"). Optional cleavage sites ("*") are also shown. A plant cell is transfected or transformed with a plant expression plasmid for with the rCP gene. rCP can assemble into VLPs in plant cells. The peptide insert is displayed on VLP surfaces. Chimeric NLPs can be purified from the plant cells, and the desired target peptides can optionally be cleaved off the purified VLPs and purified. Figure 2 shows expression of CCMN CP in tobacco ΝT1 cells transfected with infectious CCMV RKA1, RΝA2, and one of the RNA3s transcribed from pDOW2124 (CCMV- RNA3-CP), pDOW2125 (CCMV-RNA3-CP63BamHΪ), pDOW2126 (CCMV-RNA3- CP102BamHι), pDOW2127 (CCMV-RNA3-CP114BamHI), pDOW2128 (CCMV-RNA3- CP129BamHI), and pDOW2129 (CCMV-RNA3-CP160BamHI)- The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents Buffer only, Lane 2 represents RNAl and RNA2 only, Lane 3 represents RNAl and RNA2 + wt RNA3 transcribed from ρDOW2124, Lane 4 represents RNAl and RNA2 + RNA3 transcribed from pDOW2125, Lane 5 represents RNAl and RNA2 + RNA3 transcribed from pDOW2126, Lane 6 represents RNAl and RNA2 + RNA3 transcribed from pDOW2127, Lane 7 represents RNAl and RNA2 + RNA3 transcribed from pDOW2128, Lane 8 represents RNAl and RNA2 + RNA3 transcribed from pDOW2129. Figure 3 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNAl, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PAl, PA2. PA3, or PA4 at the position 63, 102, or 114. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents a size marker, Lane 2 represents Buffer only, Lane 3 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 63, Lane 4 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 63, Lane 5 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 63, Lane 6 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 63, Lane 7 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 102, Lane 8 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 102, Lane 9 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 102, Lane 10 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 102, Lane 11 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 114, Lane 12 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 114, Lane 13 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 114, and Lane 14 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 114. Figure 4 shows expression of CCMV CP in tobacco NT1 cells transfected with infectious CCMV RNAl, RNA2, and one of the engineered RNA3s containing the CCMV CP fusion with antigenic peptide PAl, PA2, PA3, or PA4 at the position 129 or 160. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents a size marker, Lane 2 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 129, Lane 3 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 129, Lane 4 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 129, Lane 5 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 129, Lane 6 represents RNAl + RNA2 + chimeric RNA3 with PAl in CP at position 160, Lane 7 represents RNAl + RNA2 + chimeric RNA3 with PA2 in CP at position 160, Lane 8 represents RNAl + RNA2 + chimeric RNA3 with PA3 in CP at position 160, Lane 9 represents RNAl + RNA2 + chimeric RNA3 with PA4 in CP at position 160, Lane 10 represents RNAl + RNA2 + wt RNA3, and Lane 11 represents Buffer only. Figure 5 shows plasmid map of pDOW2160. Figure 6 shows plasmid map ofpDOW2161. Figure 7 shows plasmid map of pDOW2162. Figure 8 shows plasmid map of pDO W2163. Figure 9 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents Buffer only, Lane 2-6 represent RNAl + RNA2 + wt RNA3 (control), Lane 7 represents pDOW2160, Lane 8 represents pDOW2161, Lane 9 represents pDOW2162, and Lane 10 represents pDOW2163. Figure 10 shows expression of chimeric CCMV CP in tobacco NT1 cells transfected with non-infectious plasmids pDOW2169, pDOW2170, pDOW2171, and pDOW2172. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents RNAl + RNA2 + RNA3 (control), Lane 2 represents Buffer, Lane 3 represents pDOW2169, Lane 4 represents pDOW2170, Lane 5 represents pDOW2171, and Lane 6 represents pDOW2172. Figure 11 shows expression of chimeric CCMV CP in tobacco NT1 cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents Untransformed tobacco cells (negative control), Lane 2 represents Transgenic tobacco cells transformed with pDOW2160, Lane 3 represents Transgenic tobacco cells transformed with pDOW2161, Lane 4 represents Transgenic tobacco cells transformed with pDOW2162, and Lane 5 represents Transgenic tobacco cells transformed with pDOW2163. Figure 12 shows expression of chimeric CCMV CP in rice cells stably transformed with non-infectious plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting for to test for CP expression. The plant cell extracts were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents wt CCMV CP (positive control), Lane 2 represents Size ladder, Lane 3 represents Non-transgenic rice cells (negative control), Lane 4 represents Transgenic rice cells transformed with pDOW2160, Lane 5 represents wt CCMV CP (positive control), Lane 6 represents Size ladder, Lane 7 represents Non-transgenic rice cells, Lane 8 represents Transgenic rice cells transformed with pDOW2161, Lane 9 represents wt CCMV CP (positive control), Lane 10 represents Size ladder, Lane 11 represents Non-transgenic rice cells (negative control), Lane 12 represents Transgenic rice cells transformed with pDOW2162, Lane 13 represents wt CCMV CP (positive control), Lane 14 represents Size ladder, Lane 15 represents Non-transgenic rice cells (negative control), and Lane 16 represents Transgenic rice cells transformed with pDO W21 3. Figure 13 shows detection of PCR products amplified from selected individual rice calli transformed with non-infectious plasmids pDOW2160, ρDOW2161, pDOW2162, and pDOW2163. 1.2 % agarose gel stained with EtBr showing PCR products amplified from selected individual rice calli. After selection for 21 days, calli that had white fluffy cell growth were selected for analysis by PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome. Lane 1 represents Rice calli 46-5, Lane 2 represents Rice calli 46-11, Lane 3 represents Rice calli 46-17, Lane 4 represents Size Ladder, Lane 5 represents Rice calli 47-6, Lane 6 represents Rice calli 48-12, Lane 7 represents Rice calli 48-18, Lane 8 represents Rice calli 48-20, Lane 9 represents Rice calli 49-11, Lane 10 represents Rice calli 49- 18, and Lane 11 represents Negative control (non-transgenic rice cells). Figure 14 shows western blot analysis of chimeric CCMV VLPs purified from rice cells stably transformed with non-infectious plasmid pDOW2160 by PEG precipitation and ultra- filtration and detection of chimeric CP-PA1 fusion proteins in the purified VLP samples. The samples were run on SDS-PAGE gel and probed with anti-CCMV polyclonal antibodies. Lane 1 represents Size ladder, Lane 2 represents Total cell lysate from rice suspension cells transgenic for CCMV CP-PAl fusion, Lane 3 represents First PEG supernatant, Lane 4 represents First PEG pellet, Lane 5 represents Second PEG pellet, and Lane 6 represents Second PEG supernatant. Figure 15 shows diagram of production process of chimeric VLPs in plant suspension cells by fermentation.
DETAILED DESCRIPTION
The present invention provides a process for the production of recombinant peptides, wherein non-infectious plasmids encoding fusion peptides comprising a viral capsid and a recombinant peptide of interest are stably inserted into the genome of a host plant cell and expressed in a suspension plant cell culture. The viral capsid-heterologous peptide fusion products can be expressed in vivo as virus like particles. The present invention further provides plant cells and nucleic acid constructs for use in the process. Specifically, the invention provides plant cells, capable of propagation in suspension plant cell cultures, with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide. The fusion peptide can be operably linked to a promoter sequence and a termination sequence. In one embodiment, the expression in the plant cell of the fusion peptide produces virus like particles or soluble cage structures. The invention also provides nucleic acid constructs capable of integrating into the genome of the plant cell and encoding the fusion peptide of a viral capsid and a recombinant peptide, which can in one embodiment, be a therapeutic peptide useful for human and animal treatments. The invention also provides a process for producing a recombinant peptide in a suspension plant cell culture by providing: a nucleic acid capable of genomic integration in a plant cell containing an expression cassette encoding a fusion peptide of a recombinant peptide and a viral capsid operably linked to a promoter sequence and a termination sequence; expressing the nucleic acid in the plant cell in a suspension plant cell culture, wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into virus like particles; and isolating the virus like particles. The term "infectious" as used herein means the ability of a virus particle to transfer its nucleic acid to a host or introduction of a viral nucleic acid into a host, wherein the viral nucleic acid is replicated, viral proteins are translated, and new viral particles capable of further transfer of nucleic acid to a host are assembled. The term "non-infectious" as used herein means the inability of a virus-derived nucleic acid to replicate in a host after introduction into a host, wherein the viral proteins are translated, and new virus like particles assembled that are not capable of initiating viral infection process in a host. The term "peptide" as used herein is not limited to any particular molecular weight, and can also include proteins or polypeptides.
I. RECOMBINANT PLANT CELLS
The present invention provides plant cells that include a non-infectious nucleic acid construct capable of genomic integration and encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence. The cells can be utilized in a process for producing recombinant peptides. The plant cells can be derived by transforming the native plant cell with a nucleic acid construct containing an expression cassette encoding a fusion peptide of a viral capsid and a recombinant peptide operably linked to a promoter sequence and a termination sequence, wherein the nucleic acid construct is stably integrated into the host cell's genome. Stable transformation depends on the integration of the foreign DNA into the genome. The foreign DNA can be integrated into the nuclear or plastid genome of the plant. The nucleic acid construct can be randomly inserted into the genome of the plant, or can be directed to a particular region of the genome through homologous recombination. The plant cell can be obtained by any means known in the art, including nuclear transformation, plastid transformation, and chloroplast transformation. See, for example, US 6,218,145; EP 012345149; WO 0121782; US 6,515,206; WO 99/10513; US 5,693,507; WO 02055651; WO 0170939; 6,472,586; WO 02057466; US 5,057,422; WO 0120974 Staub, J.M. and Maliga, P, (1992) "Long regions of homologous DNA are incorporated into the tobacco plastid genome by transformation," Plant Cell 4: 39-45.
Viral Capsids In one embodiment, the invention provides plant cells for use in a process for producing peptides by expression of the peptide fused to a viral capsid from a non-infectious plasmid stably integrated into the host genome. The expression can result in the formation of at least one virus like particle (VLP) in the cell. Viruses can be classified into those with helical symmetry or icosahedral symmetry.
Generally recognized capsid morphologies include: icosahedral (including icosahedral proper, isometric, quasi-isometric, and geminate or "twinned"), polyhedral (including spherical, ovoid, and lemon-shaped), bacilliform (including rhabdo- or bullet-shaped, and fusiform or cigar- shaped), and helical (including rod, cylindrical, and filamentous); any of which may be tailed and/or may contain surface projections, such as spikes or knobs.
Morphology In one embodiment of the invention, the amino acid sequence of the capsid is selected from the capsids of viruses classified as having any morphology. In one embodiment, the capsid is derived from a rod shaped virus. In a particular embodiment, the capsid is derived from a rod shaped plant virus. In a more particular embodiment, the capsid is a rod shaped viral capsid derived from the group selected from Tobacco Mosaic Virus (TMV) and Potato Virus X (PVX).
TMV consists of a single plus-sense genomic RNA (6.5 kb) encapsidated with a unique coat protein (17.5 kDa) which results in rod-shaped particles (300 nm). Potato Virus X are filamentous, non enveloped; usually flexuous viruses with a clear modal length of 515 nm and 13 nm wide (Brandes, 1964). The capsid structure forms a basic helix with a pitch of 3.4 nm (Varma et al, 1968). In one embodiment, the capsid has an icosahedral morphology. In one embodiment, the capsid amino acid sequence will be selected from the capsids of entities that are icosahedral proper. In another embodiment, the capsid amino acid sequence will be selected from the capsids of icosahedral viruses. In one particular embodiment, the capsid amino acid sequence will be selected from the capsids of icosahedral plant viruses. However, in another embodiment, the viral capsid will be derived from an icosahedral virus not infectious to plants. For example, in one embodiment, the virus is a virus infectious to mammals. Generally, viral capsids of icosahedral viruses are composed of numerous protein sub- units arranged in icosahedral (cubic) symmetry. Native icosahedral capsids can be built up, for example, with 3 subunits forming each triangular face of a capsid, resulting in 60 subunits forming a complete capsid. Representative of this small viral structure is e.g. bacteriophage 0X174. Many icosahedral virus capsids contain more than 60 subunits. Many capsids of icosahedral viruses contain an antiparallel, eight-stranded beta-baπel folding motif. The motif has a wedge-shaped block with four beta strands (designated BIDG) on one side and four (designated CHEF) on the other. There are also two conserved alpha-helices (designated A and B), one is between betaC and betaD, the other between betaE and betaF. Enveloped viruses can exit an infected cell without its total destruction by extrusion (budding) of the particle through the membrane, during which the particle becomes coated in a lipid envelope derived from the cell membrane (See, e.g.: AJ Cann (ed.) (2001) Principles of Molecular Virology (Academic Press); A Granoff and RG Webster (eds.) (1999) Encyclopedia of Virology (Academic Press); DLD Caspar (1980) Biophys. J. 32:103; DLD Caspar and A Klug (1962) Cold Spring Harbor Symp. Quant. Biol. 27:1; J Grimes et al. (1988) Nature 395:470; JE Johnson (1996) Proc. Nat'l Acad. Sci. USA 93:27; and J Johnson and J Speir (1997) J. Mol. Biol.
269:665).
Viruses Viral taxonomies recognize the following taxa of encapsidated-particle entities: • Group I Viruses, i.e. the dsDNA viruses; • Group II Viruses, i.e. the ssDNA viruses; • Group III Viruses, i.e. the dsRNA viruses; • Group TV Viruses, i.e. the ssRNA (+)-stranded viruses with no DNA stage; • Group V Viruses, i.e. the ssRNA (-)-stranded viruses; • Group VI Viruses, i.e. the RNA retroid viruses, which are ssRNA reverse transcribing viruses; • Group Nil Viruses, i.e. the DΝA retroid viruses, which are dsDΝA reverse transcribing viruses; • Deltaviruses; • Viroids; and • Satellite phages and Satellite viruses, excluding Satellite nucleic acids and Prions. Members of these taxa are well known to one of ordinary skill in the art and are reviewed in: H.N. Nan Regenmortel et al. (eds.), Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses (2000) (Academic Press/Elsevier, Burlington Mass., USA); the Virus Taxonomy web-page of the University of Leicester (UK) Microbiology & Immunology Department at http://wwwmicro.msb.le.ac.uk/3035/ Virusgroups.html; and the online "Virus" and "Niroid" sections of the Taxonomy Browser of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine of the National Institutes of Health of the US Department of Health & Human Services (Washington, D.C., USA) at http://www.ncbi.nlm.nih.gov/Taxonomv/ tax.html. The amino acid sequence of the capsid may be selected from the capsids of any members of any of these taxa. Amino acid sequences for capsids of the members of these taxa may be obtained from sources, including, but not limited to, e.g.: the on-line "Nucleotide" (Genbank), "Protein," and "Structure" sections of the PubMed search facility offered by the NCBI at http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi. In one embodiment, the capsid amino acid sequence will be selected from taxa members that are specific for at least one of the following hosts: bacteria, fungi including yeasts, plants, protists including algae, invertebrate animals, vertebrate animals, and humans. In one embodiment, the capsid amino acid sequence will be selected from members of any one of the following taxa: Group I, Group II, Group III, Group IV, Group V, Group VII, Viroids, and Satellite Viruses. In one embodiment, the capsid amino acid sequence will be selected from members of any one of these seven taxa that are specific for at least one of the six above- described host types. In a more specific embodiment, the capsid amino acid sequence will be selected from members of any one of Group II, Group III, Group IV, Group VII, and Satellite Viruses; or from any one of Group II, Group IN, Group VII, and Satellite Viruses. In another embodiment, the viral capsid is selected from Group IV or Group VII. The viral capsid sequence can be derived from a virus not tropic to the cell. In one embodiment, the cell does not include viral proteins from the particular selected virus other than the desired icosahedral capsids. In one embodiment, the viral capsid is derived from a virus with a tropism to a different family of organisms than the cell. In another embodiment, the viral capsid is derived from a virus with a tropism to a different genus of organisms than the cell. In another embodiment, the viral capsid is derived from a virus with a tropism to a different species of organisms than the cell. In a specific embodiment, the viral capsid is selected from a virus of Group IV. In one embodiment, the viral capsid is selected from rod-shaped plant viruses. In a more particular embodiment, the viral capsid is selected from the group consisting of Tobacco Mosaic Virus and Potato Virus X. In one embodiment, the viral capsid is selected form an icosahedral virus. The icosahedral virus can be selected from a member of any of the Papillomaviridae, Totiviridae, Dicistroviridae, Hepadnaviridae, Togaviridiae, Polyomaviridiae, Nodaviridae, Tectiviridae, Leviviridae, Microviridae, Sipoviridae, Nodaviridae, Picornoviridae, Parvoviridae, Calciviridae, Tetraviridae, and Satellite viruses. In a particular embodiment, the sequence will be selected from members of any one of the taxa that are specific for at least one plant host. In one embodiment the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Bunyaviridae, Reoviridae, Rhabdoviridae, Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa. In one embodiment, the icosahedral plant virus species is a plant-infectious virus species that is or is a member of any of the Luteoviridae, Nanoviridae, Partitiviridae, Sequiviridae, Tymoviridae, Ourmiavirus, Tobacco Necrosis Virus Satellite, Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae taxa. In specific embodiments, the icosahedral plant virus species is a plant infectious virus species that is or is a member of any of the Caulimoviridae, Geminiviridae, Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae. In more particular embodiments, the icosahedral plant virus species will be a plant-infectious virus species that is or is a member of any of the Comoviridae, Sobemovirus, Tombusviridae, or Bromoviridae. In more particular embodiments, the icosahedral plant virus species will be a plant-infectious virus species that is a member of the Comoviridae or Bromoviridae family. In a particular embodiment the viral capsid is derived from a Cowpea Mosaic Virus or a Cowpea Chlorotic Mottle Virus. In another embodiment, the viral capsid is derived from a species of the Bromoviridae taxa. In a specific embodiment, the capsid is derived from an Ilarvirus or an Alfamovirus. In a more specific embodiment, the capsid is derived from a Tobacco streak virus, or an Alfalfa mosaic virus (AMV) (including AMV 1 or AMV 2).
VLP The viral capsid of the invention is non-infective in the host cells described. In one embodiment, a virus like particle (VLP) or cage structure is formed in the host cell during or after expression of the viral capsid. In one embodiment, the VLP or cage structure also includes the peptide of interest, and in a particular embodiment, the peptide of interest is expressed on the surface of the VLP. The expression system typically does not contain additional viral proteins that allow infectivity of the virus. In a typical embodiment, the expression system includes a host cell and a vector which codes for one or more viral capsids and an operably linked peptide of interest. The vector typically does not include additional viral proteins. The invention is derived from the discovery that viral capsids form to a greater extent in certain host cells and allow for more efficient recovery of recombinant peptide. In one embodiment, the VLP or cage structure is a multimeric assembly of capsids, including from three to about 1,000 capsids. In one embodiment, the VLP or cage structure includes at least 30, at least 50, at least 60, at least 90 or at least 120 capsids. In another embodiment, each VLP or cage structure includes at least 150 capsids, at least 160, at least 170, or at least 180 capsids. In one embodiment, the VLP is expressed as an icosahedral structure. In another embodiment, the VLP is expressed in the same geometry as the native virus that the capsid sequence is derived of. In a separate embodiment, however, the VLP does not have the identical geometry of the native virus. In certain embodiments, for example, the structure is produced in a particle formed of multiple capsids but not forming a native-type VLP. For example, a cage structure of as few as 3 viral capsids can be formed. In separate embodiments, cage structures of about 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, or 60 capsids can be formed. In one embodiment, at least one of the capsids includes at least one peptide of interest. In one embodiment, the peptide is expressed within at least one internal loop, or in at least one external surface loop of the VLP. More than one loop of the viral capsid can be modified. In one particular embodiment, the recombinant peptide is expressed on at least two surface loops of the virus-like particle. In another embodiment, at least two different peptides are inserted into at least two surface loops of the viral capsid, cage or virus-like particle. In another embodiment, at least three recombinant peptides are inserted into at least three surface loops of the virus-like particle. The recombinant peptides in the surface loops can have the same amino acid sequence. In separate embodiments, the amino acid sequence of the recombinant peptides in the surface loops differs. In certain embodiments, the host cell can be modified to improve assembly of the VLP. The host cell can, for example, be modified to include chaperone proteins that promote the formation of VLPs from expressed viral capsids. In another embodiment, the host cell is modified to include a repressor protein to more efficiently regulate the expression of the capsid to promote regulated formation of the VLPs. The nucleic acid sequence encoding the viral capsid or proteins can also be additionally modified to alter the formation of VLPs (see e.g. Brumfϊeld, et al. (2004) J. Gen. Virol. 85: 1049-1053). For example, these modifications are designed to alter the interior, exterior or the interface between adjacent subunits in the assembled protein cage. To accomplish this, mutagenic primers can be used to: (i) alter the interior surface charge of the viral nucleic acid binding region by replacing basic residues (e.g. K, R) in the N terminus with acidic glutamic acids (Douglas et al., 2002b); (ii) delete interior residues from the N terminus (in CCMV, usually residues 4-37); (iii) insert a cDNA encoding an 11 amino acid peptide cell-targeting sequence (Graf et al., 1987) into a surface exposed loop ; and (iv) modify interactions between viral subunits by altering the metal binding sites (in CCMV, residues 81/148 mutant).
Recombinant Peptides Size In one embodiment, the peptides operably linked to a viral capsid sequence contain at least two amino acids. In another embodiment, the peptides are at least three, at least four, at least five, or at least six amino acids in length. In a separate embodiment, the peptides are at least seven amino acids long. The peptides can also be at least eight, at least nine, at least ten, at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 45, 50, 60, 65, 75, 85, 95, 96, 99 or more amino acids long. In one embodiment, the peptides encoded are at least 25kD. In one embodiment, the peptide will contain from 2 to about 300 amino acids, or about 5 to about 250 amino acids, or about 5 to about 200 amino acids, or about 5 to about 150 amino acids, or about 5 to about 100 amino acids. In another embodiment, the peptide contains or about 10 to about 140 amino acids, or about 10 to about 120 amino acids, or about 10 to about 100 amino acids. In one embodiment, the peptides or proteins operably linked to a viral capsid sequence will contain about 500 amino acids. In one embodiment, the peptide will contain less than 500 amino acids. In another embodiment, the peptide will contain up to about 300 amino acids, or up to about 250, or up to about 200, or up to about 180, or up to about 160, or up to about 150, or up to about 140, or up to about 120, or up to about 110, or up to about 100, or up to about 90, or up to about 80, or up to about 70, or up to about 60, or up to about 50, or up to about 40 or up to about 30 amino acids. In one embodiment, the recombinant peptide fused to the capsid is at least 7, at least 8, at least, 9, at least 10, at least 12, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, at least 85, at least 95, at least 99, or at least 100 amino acids. In one embodiment of the present invention, the recombinant peptide contains at least one monomer of a desired target peptide. In an alternative embodiment, the recombinant peptide contains more than one monomer of a desired target peptide. In certain embodiments, the peptide is composed of at least two, at least 5, at least 10, at least 15 or at least 20 separate monomers that are operably linked as a concatameric peptide to the capsid. In another embodiment, the individual monomers in the concatameric peptide are linked by cleavable linker regions. In still another embodiment, the recombinant peptide is inserted into at least one surface loop of the icosahedral virus-like particle. In one embodiment, at least one monomer is inserted in a surface loop of the virus-like particle.
Classification The peptides of interest that are fused to the viral capsids can be a heterologous protein that is not derived from the virus and, optionally, that is not derived from the same species as the cell. The peptides of interest that are fused to the viral capsids can be functional peptides; structural peptides; antigenic peptides, toxic peptides, antimicrobial peptides, fragments thereof; precursors thereof; combinations of any of the foregoing; and or concatamers of any of the foregoing. In one embodiment of the present invention, the recombinant peptide is a therapeutic peptide useful for human and animal treatments, including antigenic peptides used in a vaccine strategy. In a particular embodiment, the antigenic peptide is glycosylated in vivo. Functional peptides include, but are not limited to, e.g.: bio-active peptides (i.e. peptides that exert, elicit, or otherwise result in the initiation, enhancement, prolongation, attenuation, termination, or prevention of a biological function or activity in or of a biological entity, e.g., an organism, cell, culture, tissue, organ, or organelle); catalytic peptides; microstructure- and nanostructure-active peptides (i.e. peptides that form part of engineered micro- or nanostructures in which, or in conjunction with which, they perform an activity, e.g., motion, energy transduction); and stimulant peptides (e.g., peptide flavorings, colorants, odorants, pheromones, attractants, deteπents, and repellants). Bio-active peptides include, but are not limited to, e.g.: immunoactive peptides (e.g., antigenic peptides, allergenic peptides, peptide immunoregulators, peptide immunomodulators); signaling and signal transduction peptides (e.g., peptide hormones, cytokines, and neurotransmitters; receptors; agonist and antagonist peptides; peptide targeting and secretion signal peptides); and bio-inhibitory peptides (e.g., toxic, biocidal, or biostatic peptides, such as peptide toxins and antimicrobial peptides). Structural peptides include, but are not limited to, e.g. : peptide aptamers; folding peptides
(e.g., peptides promoting or inducing formation or retention of a physical conformation in another molecule); adhesion-promoting peptides (e.g., adhesive peptides, cell-adhesion- promoting peptides); interfacial peptides (e.g., peptide surfactants and emulsifiers); microstructure and nanostiucrure-architectural peptides (i.e. structural peptides that form part of engineered micro- or nano-structures); and pre-activation peptides (e.g., leader peptides of pre-, pro-, and pre-pro-proteins and -peptides; inteins). Catalytic Peptides include, e.g., apo B RNA-editing cytidine deaminase peptides; catalytic peptides of glutaminyl-tRNA synthetases; catalytic peptides of aspartate franscarbamoylases; plant Type 1 ribosome-inactivating peptides; viral catalytic peptides such as, e.g., the foot-and-mouth disease virus [FMDV-2A] catalytic peptide; matrix metalloproteinase peptides; and catalytic metallo-oligopeptides. The peptide can also be a peptide epitope, hapten, or a related peptide (e.g., antigenic viral peptide; virus related peptide, e.g., HIV-related peptide, hepatitis-related peptide; antibody idiotypic domain; cell surface peptide; antigenic human, animal, protist, plant, fungal, bacterial, and or archaeal peptide; allergenic peptide and allergen desensitizing peptide). The peptide can also be a peptide immunoregulators or immunomodulators (e.g., interferons, interleukins, peptide immunodepressants and immunopotentiators); an antibody peptides (e.g., single chain antibodies; single chain antibody fragments and constructs, e.g., single chain Fv molecules; antibody light chain molecules, antibody heavy chain molecules, domain-deleted antibody light or heavy chain molecules; single chain antibody domains and molecules, e.g., a CHI, CHl-3, CH3, CHl-4, CH4, VHCHl, CL, CDRl, or FR1-CDR1-FR2 domain; paratopic peptides; microantibodies); another binding peptide (e.g., peptide aptamers, intracellular and cell surface receptor proteins, receptor fragments; anti-tumor necrosis factor peptides). The peptide can also be an enzyme substrate peptide or an enzyme inhibitor peptide (e.g., caspase substrates and inhibitors, protein kinase substrates and inhibitors, fluorescence- resonance-energy transfer-peptide enzyme substrates). The peptide can also be a cell surface receptor peptide ligand, agonist, and antagonist (e.g., caeruleins, dynorphins, orexins, pituitary adenylate cyclase activating peptides, tumor necrosis factor peptides; synthetic peptide ligands, agonists, and antagonists); a peptide hormone (e.g., endocrine, paracrine, and autocrine hormones, including, e.g.: amylins, angiotensins, bradykinins, calcitonins, cardioexcitatory neuropeptides, casomorphins, cholecystokinins, corticotropins and corticotropin-related peptides, differentiation factors, endorphins, endothelins, enkephalins, erythropoietins, exendins, follicle-stimulating hormones, galanins, gastrins, glucagons and glucagon-like peptides, gonadotropins, growth hormones and growth factors, insulins, kallidins, kinins, leptins, Hpofropic hormones, luteinizing hormones, melanocyte stimulating hormones, melatonins, natriuretic peptides, neurokinins, neuromedins, nociceptins, osteocalcins, oxytocins (i.e. ocytocins), parathyroid hormones, pleiotrophins, prolactins, relaxins, secretins, serotonins, sleep-inducing peptides, somatomedins, thymopoietins, thyroid stimulating hormones, thyrotropins, urotensins, vasoactive intestinal peptides, vasopressins); a peptide cyto ine, chemokine, virokine, and viroceptor hormone releasing and release-inhibiting peptide (e.g., corticotropin-releasing hormones, cortistatins, follicle-stimulating-hormone-releasing factors, gastric inhibitory peptides, gastrin releasing peptides, gonadotropin-releasing hormones, growth hormone releasing hormones, luteinizing hormone-releasing hormones, melanotropin- releasing hormones, melanotropin-release inhibiting factors; nocistatins, pancreastatins, prolactinreleasing peptides, prolactin release-inhibiting factors; somatostatins; thyrofropin releasing hormones); a peptide neurotransmitter or channel blocker (e.g., bombesins, neuropeptide Y, neurotensins, substance P) a peptide toxin, toxin precursor peptide, or toxin peptide portion. In certain embodiments, a peptide toxin contains no D-amino acids. Toxin precursor peptides can be those that contain no D-amino acids and/or that have not been converted by postfranslational modification into a native toxin structure, such as, e.g., by action of a D configuration inducing agent (e.g., a peptide isomerase(s) or epimeras(e) or racemase(s) or fransaminase(s)) that is capable of introducing a D-configuration in an amino acid(s), and/or by action of a cyclizing agent (e.g., a peptide thioesterase, or a peptide ligase such as a trans- splicing protein or intern) that is capable of form a cyclic peptide structure. Toxin peptide portions can be the linear or pre-cyclized oligo- and poly-peptide portions of peptide-containing toxins. Examples of peptide toxins include, e.g., agatoxins, amatoxins, charybdotoxins, chlorotoxins, conotoxins, dendrotoxins, insectotoxins, margatoxins, mast cell degranulating peptides, saporins, sarafotoxins; and bacterial exotoxins such as, e.g., anthrax toxins, botulism toxins, diphtheria toxins, and tetanus toxins. The peptide can also be a metabolism- and digestion-related peptide (e.g., cholecystokinin-pancreozymin peptides, peptide yy, pancreatic peptides, motilins); a cell adhesion modulating or mediating peptide, extracellular matrix peptide (e.g., adhesins, selectins, laminins); a neuroprotectant or myelination-promoting peptide; an aggregation inhibitory peptide (e.g., cell or platelet aggregation inhibitor peptides, amyloid formation or deposition inhibitor peptides); a joining peptide (e.g., cardiovascular joining neuropeptides, iga joining peptides); or a miscellaneous peptide (e.g., agouti-related peptides, amyloid peptides, bone-related peptides, cell-permeable peptides, conantokins, contryphans, contulakins, myelin basic protein, and others). The peptide can also be post-translationally modified in vivo. In particular embodiments, the peptide may be, singularly or in combination, glycosylated, acetylated, acylated, phosphorylated, or garnma-carboxylated. In certain embodiments, the peptide of interest is exogenous to the selected viral capsid. Peptides may be either native or synthetic in sequence (and their coding sequences may be either native or synthetic nucleotide sequences). Thus, e.g., native, modified native, and entirely artificial sequences of amino acids are encompassed. The sequences of the nucleic acid molecules encoding these amino acid sequences likewise may be native, modified native, or entirely artificial nucleic acid sequences, and may be the result of, e.g., one or more rational or random mutation and or recombination and/or synthesis and/or selection process employed (i.e. applied by human agency) to obtain the nucleic acid molecules. The coding sequence can be a native coding sequence for the target peptide, if available, but will more typically be a coding sequence that has been selected, improved, or optimized for use in the selected expression host cell: for example, by synthesizing the gene to reflect the codon use preference of a host species. In one embodiment of the invention, the host species is
Nicotiana tabacum, and the codon preference of Nicotiana tabacum is taken into account when designing both the signal sequence and the peptide sequence. In an alternative embodiment of the invention, the host species is Oryza sativa, and the codon preference of Oryza sativa is taken into account when designing both the signal sequence and the peptide sequence
Antigenic Peptides (Peptide Epitopes) In one embodiment, an antigenic peptide is produced through expression with a viral capsid. The antigenic peptide can be selected from those that are antigenic peptides of human or animal pathogenic agents, including infectious agents, parasites, cancer cells, and other pathogenic agents. Such pathogenic agents also include the virulence factors and pathogenesis factors, e.g., exotoxins, endotoxins, et al, of those agents. The pathogenic agents may exhibit any level of virulence, i.e. they may be, e.g., virulent, avirulent, pseudo-virulent, semi- virulent, and so forth. In one embodiment, the antigenic peptide will contain an epitopic amino acid sequence from the pathogenic agent(s). In one embodiment, the epitopic amino acid sequence will include that of at least a portion of a surface peptide of at least one such agent. . In one embodiment, the capsid-recombinant peptide virus like particles can be used as a vaccine in a human or animal application. More than one antigenic peptide may be selected, in which case the resulting virus-like particles can present multiple different antigenic peptides. In a particularly embodiment of a multiple antigenic peptide format, the various antigenic peptides will all be selected from a plurality of epitopes from the same pathogenic agent. In a particular embodiment of a multi- antigenic-peptide format, the various antigenic peptides selected will all be selected from a plurality of closely related pathogenic agents, for example, different strains, subspecies, biovars, pathovars, serovars, or genovars of the same species or different species of the same genus. In one embodiment, the pathogenic agent(s) will belong to at least one of the following groups: Bacteria and Mycoplasma agents including, but not limited to, pathogenic: Bacillus spp., e.g., Bacillus anthracis; Bartonella spp., e.g., B. quintana; Brucella spp.; Burkholderia spp., e.g., B. pseudomallei; Campylobacter spp.; Clostridium spp., e.g., C. tetani, C. botulinum; Coxiella spp., e.g., C. burnetii; Edwardsiella spp., e.g., E. tarda; Enterobacter spp., e.g., E. cloacae; Enterococcus spp., e.g., E. faecalis, E. faecium; Escherichia spp., e.g., E. coli; Francisella spp., e.g., F. tularensis; Haemophilus spp., e.g., H. influenzae; Klebsiella spp., e.g., K. pneumoniae; Legionella spp.; Listeria spp., e.g., L. monocytogenes; Meningococci and Gonococci, e.g., Neisseria spp.; Moraxella spp.; Mycobacterium spp., e.g., M. leprae, M. tuberculosis; Pneumococci, e.g. , Diplococcus pneumoniae; Pseudomonas spp., e.g., P. aeruginosa; Rickettsia spp., e.g., R. prowazekii, R. rickettsii, R. typhi; Salmonella spp., e.g., S. typhi; Staphylococcus spp., e.g., S. aureus; Streptococcus spp., including Group A Streptococci and hemolytic Streptococci, e.g., S. pneumoniae, S. pyogenes; Streptomyces spp.; Shigella spp.; Vibrio spp., e.g., V. cholerae; and Yersinia spp., e.g., Y. pestis, Y. enter ocolitica. Fungus and Yeast agents including, but not limited to, pathogenic: Alternaria spp.; Aspergillus spp.; Blastomyces spp., e.g., B. dermatiditis; Candida spp., e.g., C. albicans; Cladosporium spp.; Coccidiodes spp., e.g., C. immitis; Cryptococcus spp., e.g., C. neoformans; Histoplasma spp., e.g., H. capsulatum; and Sporothrix spp., e.g., S. schenckii. In one embodiment, the pathogenic agent(s) will be from a protist agent including, but not limited to, pathogenic: Amoebae, including Acanthamoeba spp., Amoeba spp., Naegleria spp., Entamoeba spp., e.g., E. histolytica; Cryptosporidium spp., e.g., C. parvum; Cyclospora spp.; Encephalitozoon spp., e.g., E. intestinalis; Enterocytozoon spp.; Giardia spp., e.g., G. lamblia; Isospora spp.; Microsporidium spp.; Plasmodium spp., e.g., P. falciparum, P. malariae, P. ovale, P. vivax; Toxoplasma spp., e.g., T. gondii; and Trypanosoma spp., e.g., T. brucei. In one embodiment, the pathogenic agent(s) will be from a parasitic agent (e.g., helminthic parasites) including, but not limited to, pathogenic: Ascaris spp., e.g., A. lumbricoides; Dracunculus spp., e.g., D. medinensis; Onchocerca spp., e.g., O. volvulus; Schistosoma spp.; Trichinella spp., e.g., T. spiralis; and Trichuris spp., e.g., T. trichiura. In another embodiment, the pathogenic agent(s) will be from a viral agent including, but not limited to, pathogenic: Adenoviruses; Arenaviruses, e.g., Lassa Fever viruses; Astroviruses; Bunyaviruses, e.g., Hantaviruses, Rift Valley Fever viruses; Coronaviruses, Deltaviruses; Cytomegaloviruses, Εpstein-Barr viruses, Herpes viruses, Varicella viruses; Filo viruses, e.g., Ebola viruses, Marburg viruses; Flaviruses, e.g., Dengue viruses, West Nile Fever viruses, Yellow Fever viruses; Hepatitis viruses; Influenzaviruses; Lentiviruses, T-Cell Lymphotropic viruses, other leukemia viruses; Norwalk viruses; Papillomaviruses, other tumor viruses; Paramyxoviruses, e.g., Measles viruses, Mumps viruses, Parainfluenzaviruses, Pneumoviruses, Sendai viruses; Parvoviruses; Picomaviruses, e.g., Cardioviruses, Coxsackie viruses, Echoviruses, Poliomyelitis viruses, Rhinoviruses, Other Entero viruses; Poxviruses, e.g., Variola viruses, Vaccinia viruses, Parapoxviruses; Reoviruses, e.g., Coltiviruses, Orbiviruses, Rotaviruses; Rhabdo viruses, e.g., Lyssaviruses, Vesicular Stomatitis viruses; and Togaviruses, e.g., Rubella viruses, Sindbis viruses, Western Encephalitis viruses. In one particular embodiment, the antigenic peptide is selected from the group consisting of a Canine parvovirus peptide, Bacillus anthracis protective antigen (PA) antigenic peptide, and an Eastern Equine Encephalitis virus antigenic peptide. In a particular embodiment, the antigenic peptide is the Bacillus antracis-deήved peptide with the amino acid sequence selected from PAl (SEQ. ID. NO. 1), PA2 (SEQ. ID. NO. 2), PA3 (SEQ. ID. NO. 3), or PA4 (SEQ. ID. NO. 4).
Host-Cell Toxic Peptide In another particular embodiment, the recombinant peptide is a peptide that is toxic to the host cell when in free monomeric form. In certain embodiments, the peptide of interest expressed in conjunction with a viral capsid will be a host cell toxic peptide. A host cell toxic peptide indicates a bio-inhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed, or to other cells in the cell culture or organism of which the host cell is a member, or to cells of the organism or species providing the host cells. In one embodiment, the host-cell-toxic peptide will be a bioinhibitory peptide that is biostatic, biocidal, or toxic to the host cell in which it is expressed. Some examples of host-cell-toxic peptides include, but are not limited to: peptide toxins, anti-microbial peptides, and other antibiotic peptides.
Antimicrobial Peptides In another particular embodiment, the recombinant peptide is a peptide that is an antimicrobial peptide. Anti-Microbial Peptides include, e.g., anti-bacterial peptides such as, e.g., magainins, betadefensins, some alpha-defensins; cathelicidins; histatins; anti-fungal peptides; antiprotozoal peptides; synthetic AMPs; peptide antibiotics or the linear or pre-cyclized oligo- or poly-peptide portions thereof; other antibiotic peptides (e.g., anthelmintic peptides, hemolytic peptides, tumoricidal peptides); and anti-viral peptides (e.g., some alpha-defensins; virucidal peptides; peptides that inhibit viral infection). In one embodiment, the antimicrobial peptide is selected from the group consisting of D2A21 antimicrobial peptides.
Cells for use in Expressing the VLP The cell used as a host for the expression of the viral capsid or viral capsid fusion peptide
(also refeπed to as "host cell") of the invention will be one in which the expression of viral capsid does not allow replication or infection of the cell. In one embodiment, the viral capsid will be derived from a virus that does not infect the specific species of cell that the host cell is derived from. For example, in one embodiment, the viral capsid is derived from an icosahedral plant virus and is expressed in a host cell of a plant species that is not the native trophic host of the virus. In another embodiment, the viral species infects mammals and the expression system includes a plant host cell. In an alternative embodiment, the virus is a trophic virus of the particular plant species utilized as a host cell for expressing the capsid-recombinant peptide fusion. The plant host cell may be any plant cell from the Tracheophyta, Euphyllophyta,
Spermatophyta, or Angiospermophyta. In a particular embodiment, the plant cell is a Monocot, including, but not limited to, members of, e.g.: Arecaceae, e.g., Cocos spp., Elaeis spp.; Dioscoreaceae, e.g., Dioscorea spp.; Gramineae (Poaceae), e.g., Avena spp., Hordeum spp., Oryza spp., Panicum spp., Triticum spp., Zea spp.; and Musaceae, e.g., Musa spp. In an alternative embodiment, the plant cell is a member of the Dicots, including, but not limited to, e.g.: Amaranthaceae, e.g., Amaranthus spp., Beta spp., Chenopodium spp.; Apiaceae (Umbelliferae), e.g., Daucus spp., Pastinaca spp.; Brassicaceae (Cruciferae), e.g., Arabidopsis spp., Brassica spp.; Compositae, e.g., Helianthus spp.; Convolvulaceae, e.g., Ipomoea spp.; Cucurbitaceae, e.g., Citrullus spp., Cucumis spp., Cucurbita spp.; Euphorbiaceae; Leguminosae (Fabaceae), e.g, Glycine spp., Lens spp., Medicago spp., Phaseolus spp., Pisum spp., Trifolium spp., Vicia spp., Vigna spp.; Linaceae, e.g., Linum spp.; and Solanaceae, e.g, Capsicum spp., Lycopersicon spp., Nicotiana spp., Solarium spp. In a particular embodiment, the host cell is selected from the group consisting of Aradiposis thialiana, Taxus cuspidate, Catharanthus roseus, Nicotiana tabacum, Oryza sativa, Lycopersicum esculentum, and Glycine max.
II. NUCLEIC ACID CONSTRUCTS
The present invention further provides non-infectious nucleic acid constructs capable of stably integrating into the host cell's genome and encoding a fusion peptide of a capsid and a recombinant peptide. The fusion peptide can be operably linked to a promoter sequence and a termination sequence. In one embodiment, a nucleic acid construct for use in transforming plant host cells including a) a nucleic acid sequence encoding a recombinant peptide, and b) a nucleic acid sequence encoding a viral capsid is provided, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein is stably inserted into the genome of the plant host cell, wherein it is expressed in the plant cell. In certain embodiments, the vector can include sequence for multiple capsids, or for multiple peptides of interest. In one embodiment, the vector can include at least two different capsid-peptide coding sequences. In one embodiment, the coding sequences are linked to the same promoter. In certain embodiments, the coding sequences are separated by an internal ribosomal binding site. In other embodiments, the coding sequences are linked by a linker sequence that allows the formation of virus like particles in the cell. In another embodiment, the coding sequences are linked to different promoters. These promoters may be constitutive or driven by the same or different induction conditions. In another embodiment, multiple vectors capable of insertion into the genome and encoding different capsid-peptide combinations are provided. The multiple vectors can include promoters that are constitutive or driven by the same induction conditions, or by different induction conditions. In one embodiment, the viral capsid is derived from an icosahedral viral capsid. The coding sequence for a peptide of interest can be inserted into the coding sequence for a viral capsid or capsid in a predetermined site. The peptide can also be inserted at a non- predetermined site and cells screened for production of VLPs. In one embodiment, the peptide is inserted into the capsid coding sequence so as to be expressed as a loop during formation of a VLP. In one embodiment, one peptide coding sequence is included in the vector, however in other embodiments, multiple sequences are included. The multiple sequences can be in the form of concatamers, for example concatamers linked by cleavable linker sequences. Peptides may be inserted at more than one insertion site in a capsid. Thus, peptides may be inserted in more than one surface loop motif of a capsid; peptides may also be inserted at multiple sites within a given loop motif. The individual functional and/or structural peptide(s) of the insert(s), and/or the entire peptide insert(s), may be separated by cleavage sites, i.e. sites at which an agent that cleaves or hydrolyzes protein can act to separate the peptide(s) from the remainder of the capsid structure or assemblage. Peptides may be inserted within external-facing loop(s) and/or within internal-facing loop(s), i.e. within loops of the capsid that face respectively away from or toward the center of the capsid. Any amino acid or peptide bond in a surface loop of a capsid can serve as an insertion for the peptide. Typically, the insertion site will be selected at about the center of the loop, i.e. at about the position located most distal from the center of the tertiary structure of the folded capsid peptide. The peptide coding sequence may be operably inserted within the position of the capsid coding sequence corresponding to this approximate center of the selected loop(s). This includes the retention of the reading frame for that portion of the peptide sequence of the capsid that is synthesized downstream from the peptide insertion site. In another embodiment, the peptide can be inserted at the amino terminus of the capsid.
The peptide can be linked to the capsid through one or more linker sequences, including the cleavable linkers described above. In yet another embodiment, the peptide can be inserted at the carboxy terminus of the capsid. The peptide can also be linked to the carboxy terminus through one or more linkers, which can be cleavable by chemical or enzymatic hydrolysis. In one embodiment, peptide sequences are linked at both the amino and carboxy termini, or at one terminus and at at least one internal location, such as a location that is expressed on the surface of the capsid in its three dimensional conformation. In one embodiment, the peptide can be inserted into the capsid from a Cowpea Chlorotic Mosaic Virus. In one particular embodiment, the peptide can be inserted at amino acid 129 of the CCMN coat protein. In one embodiment, the peptide sequence can be inserted at amino acid 63, 102, 114, 129, or 160 of the CCMV coat protein, hi another embodiment, the peptide sequence can be inserted at amino acids 60, 61, 62 or 63 of the CCMV coat protein, hi still another embodiment, the peptide can be inserted at both amino acids 129 and amino acids 60-63 of the CCMV protein. In a particular embodiment, the present invention provides a nucleic acid construct including a) a nucleic acid encoding an antigenic peptide, and b) a nucleic acid encoding a viral capsid, wherein the nucleic acid of a) and the nucleic acid of b) are operably linked to form a fusion protein when expressed in a cell. Other capsids and recombinant peptides useful in constructing the nucleic acid construct are disclosed above.
Promoters In one embodiment, the nucleic acid construct includes a promoter sequence operably attached to the nucleic acid sequence encoding the capsid-recombinant peptide fusion peptide. An operable attachment or linkage refers to any configuration in which the transcriptional and any franslational regulatory elements are covalently attached to the described sequence so that by action of the host cell, the regulatory elements can direct the expression of the sequence of interest. In alternative embodiment, the nucleic acid construct encoding the capsid fusion product can be inserted in frame with a host cell native promoter utilizing a gene trapping strategy. In a fermentation process, once fermentation begins, it is ideal to have a high level of production in order to maximize efficiency of the expression system. The promoter initiates transcription and is generally positioned 1-100 nucleotides upstream of the transcription start site.
Ideally, a promoter will be strong enough to allow for a large amount of recombinant peptide accumulation. The promoters used in accordance with the present invention may be constitutive promoters or regulated promoters. Common examples of useful regulated promoters used in the art include: ethanol-inducible promoters; iron deficiency-inducible promoters; wound-inducible promoters; and hormone-inducible, e.g., auxin-inducible, promoters. Common examples of useful constitutive promoters include the ubiquitin promoter, the actin promoter, the tubulin promoter, and the Cassava Vein Mosaic Virus promoter. Other types of promoters useful in the present invention include tissue-specific promoters such as corn sucrose synthetase 1 (Yang el al., 1990), corn alcohol dehydrogenase 1 (Vogel et al., 1989), corn light harvesting complex (Simpson, 1986), corn heat shock protein (Odell et al., 1985), pea small subunit RuBP carboxylase (Poulsen et al., 1986; Cashmore et al., 1983), Ti plasmid mannopine synthase (Langridge et al, 1989), Ti plasmid nopaline synthase (Langridge et al., 1989), petunia chalcone isomerase (Van Tunen et al., 1988), bean glycine rich protein 1 (Keller et al., 1989), CaMV 35s transcript (Odell et al., 1985) and Potato patatin (Wenzler et al., 1989). Prefeπed promoters are the cauliflower mosaic virus (CaMV 35S) promoter, the rice alpha-amylase RAmy3D promoter, and the S-E9 small subunit RuBP carboxylase promoter. In addition, a variety of plant gene promoters that are regulated in response to environmental, hormonal, chemical, and/or developmental signals can be used for expression of an operably linked gene in plant cells, including promoters regulated by (1) heat (Callis et al., Plant Physiol. 88:965, 1988), (2) light (e.g., pea rbcS-3A promoter, Kuhlemeier et al., Plant Cell 1:471, 1989; maize rbcS promoter, Schaffiier and Sheen, Plant Cell 3:997, 1991; or chlorophyll a/b-binding protein promoter, Simpson et al., EMBO J. 4:2723, 1985), (3) hormones, such as abscisic acid (Marcotte et al., Plant Cell 1:969, 1989), (4) wounding (e.g., wunl, Siebertz et al., Plant Cell 1:961, 1989); or (5) chemicals such as methyl jasmonate, salicylic acid, or Safener. It may also be advantageous to employ (6) organ-specific promoters (e.g., Roshal et al., EMBO J. 6:1155, 1987; Schernthaner et al., EMBO J. 7:1249, 1988; Bustos et al., Plant Cell 1:839, 1989). Additional promoters useful in the present invention include those described in WO 97/48819; the phaseolin promoters described in US Patent Number 5,591,605; rice actin promoters described in US Patent Number 5,641,876; the per5 promoter described in WO 98/56921; the gamma zein promoters described in WO 00/12681; and other promoters as described in US Patent Number 6,825,006, US Patent Number 6,660,911, and plant promoters described the plant promoter sequence database PlantProm, described in Shahmuradov et al. (2003), "PlantProm: a database of plant promoter sequences," Nucleic Acid Res. 31(1): 114-117, and available at http://mendel.cs.rhul.ac.uk/mendel.php?topic=:τ>lantprom. Additional promoters may also include cauliflower mosaic virus (CaMV) 35S promoter or its enhanced version, the hybrid (ocs)τ,mas promoter, and ubiquitin promoters from maize or A. ihaliana. A promoter having the nucleotide sequence of a promoter native to the selected plant host cell can also be used to control expression of the transgene encoding the target peptide. Tandem promoters may also be used in which more than one promoter is covalently attached to another, whether the same or different in sequence. A promoter having the nucleotide sequence derived from a virus can also be used to direct expression of the transgene encoding the target peptide. Regulated promoters can utilize promoter regulatory proteins in order to control transcription of the gene of which the promoter is a part. Where a regulated promoter is used herein, a corresponding promoter regulatory protein will also be part of an expression system according to the present invention. Many regulated-promoter/promoter-regulatory-protein pairs are known in the art.
Other Elements Other regulatory elements can be included in a nucleic acid construct. Such elements include, but are not limited to, for example, franscriptional enhancer sequences, franslational enhancer sequences, other promoters, activators, franslational start and stop signals, transcription terminators, cistronic regulators, polycistronic regulators, tag sequences, such as nucleotide sequence "tags" and "tag" peptide coding sequences, which facilitates identification, separation, purification, or isolation of an expressed peptide, including His-tag, Flag-tag, T7-tag, S-tag, HSV-tag, B-tag, Strep-tag, polyarginine, polycysteine, polyphenylalanine, polyaspartic acid, (Ala-Trp-Trp-Pro)n, thioredoxin, beta-galactosidase, chloramphenicol acetyltransferase, cyclomaltodextrin gluconofransferase, CTP:CMP-3-deoxy-D-manno-octulosonate cytidyltransferase, trpE or trpLE. avidin, streptavidin, T7 gene 10, T4 gp55, Staphylococcal protein A, streptococcal protein G, GST, DHFR, CBP, MBP, galactose binding domain, Calmodulin binding domain, GFP, KSI, c-myc, ompT, ompA, pelB, , NusA, ubiquitin, and hemosylin A. In one embodiment, the nucleic acid construct further comprises a tag sequence adjacent to the coding sequence for the recombinant peptide of interest, or linked to a coding sequence for a viral capsid. In one embodiment, this tag sequence allows for purification of the protein. The tag sequence can be an affinity tag, such as a hexa-histidine affinity tag. In another embodiment, the affinity tag can be a glutathione-S-transferase molecule. The tag can also be a fluorescent molecule, such as YFP or GFP, or analogs of such fluorescent proteins. The tag can also be a portion of an antibody molecule, or a known antigen or ligand for a known binding partner useful for purification. The present invention can include, in addition to the capsid-recombinant peptide coding sequence, the following regulatory elements operably linked thereto: a promoter, a transcription terminator, franslational start and stop signals. Further examples of translation and transcription elements, and other elements useful in the present invention are described in: JD Watson et al. (eds.), Recombinant DNA, pp. 273-92 (1992) (Scientific American Books, W. H. Freeman and Co., New York, NY, USA); and I
Mitsuhara et al., "Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants," Plant Cell Physiol. 37(l):49-59 (1996). In one particular embodiment, the nucleic acid construct includes additional nucleic acid sequences derived from the 3' untranslated region (3' UTR) of the viral genomic nucleic acid sequence utilized to derive the viral capsid protein. In one particular embodiment, the 3 'UTR contains sequences that play a role in regulation of translation or capsid formation in the wild type virus. In one embodiment, the 3 'UTR sequences are upstream pseudoknot domains (UPD).
See, for example, Leathers et al. (1993) "A phylogenetically conserved sequence within viral 3' untranslated RNA pseudoknots regulates translation," Mol. Cell Biol. 13(9): 5331-5347. In a particular embodiment, the 3 'UTR are derived from the 3 'UTR of the viral capsid encoding region of the viral genome. In a more particular embodiment, the 3 'UTR is derived from the cowpea chlorotic mosaic virus RNA3 3' untranslated region. In one embodiment, the 3 'UTR sequence includes an encapsidation signal. In an alternative embodiment, the nucleic acid construct includes at least one encapsidation signal derived from a viral nucleic acid sequence. The encapsidation signal can be derived from 5 'UTR, 3 'UTR, or internal sequence of the viral genomic sequence. In one embodiment, the nucleic acid construct is encapsidated in the VLP. In one embodiment, the non-infectious nucleic acid construct also includes other sequences derived from the viral or non-viral nucleic acid sequence other than the viral capsid protein sequence.
Vectors Useful expression vectors for use in plant cells in stably integrating into the host cell genome and expressing capsid-recombinant peptide fusion peptides are constructed by inserting a structural DNA sequence encoding a desired target peptide fused with a capsid peptide together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector may also comprise one or more phenotypic selectable or screenable markers to allow for selection of host cells. Alternatively, the selectable or screenable markers can be provided on a separate plasmid. A wide variety of vectors and/or carriers are known in the art as useful for transforming a target plant host cell with recombinant capsid-encoding nucleic acid for expression, and any of these may be used for expressing the genes according to the present invention. See, e.g., IJ Goderis IJ et al., "A set of modular plant transformation vectors allowing flexible insertion of up to six expression units," Plant Mol. Biol. 50(l):17-27 (2002); AH Christensen & PH Quail, "Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants," Transgenic Res. 5(3):213-18 (1996); JD Jones et al, "Effective vectors for transformation, expression of heterologous genes, and assaying transposon excision in transgenic plants," Transgenic Res. l(6):285-97 (1992); AP Gleave AP, "A versatile binary vector system with a T-DNA organisational structure conducive to efficient integration of cloned DNAinto the plant genome," Plant Mol. Biol. 20(6):1203-07 (1992). Thus, plasmids, fransposons, genomic DNA, genomic RNA, plant artificial chromosomes, and other nucleic acid vectors may be used. Examples of some vectors that may be used include, but are not limited to, pRTlOl, pRTlOl-MCS, pRT104, pRT104.24LS, pRT104.N-myc, pRT104.C-myc, pRT104.N-3HA, pRT104-N3HAdAsp, pRT104.N-6HA, pRT104-N6HAdAsp, pRT104.C-3HA, pRT104-GST, pRT104 NES(A2), pRT103-3HA, pRTd35S-Luci(-),pRTd35S- Luci-NES, pRTd35S-GFP, pRTd35S-GFP.Sad, pRTdS GFP.Bglll, pRTd35S-Ds-Red, pRTd35S-profillin, pBIGal4DBD, pRT-3HAxHsfA2DBD, pRT-3HAxGal4DBD, pUC, pIL- TAB, pET, pME, pBBR, and pROKII. When particle bombardment is used to introduce the vector into the cell, any DNA plasmid or DNA molecule may be utilized in the present invention. In a particular embodiment, the vector is pIL-Tab. In a more particular embodiment, the vector is pIL-Tab encoding for the coat protein from Cowpea Chlorotic Mosaic Virus (CCMV). In a particular embodiment, the vector is pIL-Tab, and the heterologous peptide is selected from the group consisting of PAl, PA2, PA3 or PA4. In a still further embodiment, the vector is selected from the group consisting of pDOW2160 (Seq. ID. No. 5), pDOW 2161 (Seq. ID. No. 6), pDOW2162 (Seq. ID. No. 7), pDOW2163 (Seq. ID. No. 8), pDOW 2169 (Seq. ID. No. 9), ρDOW2170 (Seq. ID. No. 10), pDOW2171 (Seq. ID. No. 11), and pDOW2172 (Seq. ID. No. 12). Alternatively, or in addition, carriers may be used, such as liposomes, dendrimers, cationic polymers, and cationic polymer-lipid complexes, all of which have been employed in widely published methods for delivery of nucleic acids to cells or protoplasts. Alternatively, naked DNA or naked RNA may be delivered to the plant host. The vector, carrier, or naked nucleic acid may be directly transformed into a plant cell or protoplast by any method known effective therefore in the art. For example, any of the following methods may be used to transform the plant target host with the recombinant capsid- encoding nucleic acid: Agrobacterium spp.; microparticle bombardment as described by V. Vasil et al., Bio/Technology 9, 743 (1991); electroporation of protoplasts as described, for example, for lettuce by MC Chupeau et al., Bio/Technology 7, 503 (1989); surface abrasion using, e.g., silicon carbide whiskers, glass, or carborundum; liposome fusion with protoplasts as described, for example, by A. Deshayes et al., EMBO J. 4, p.2731-2737 (1985); cell-cell (protoplast-protoplast) fusion; and endogenous plant virus infection, i.e. transformation of the plant target host with an engineered virus vector, the engineered virus vector being of a type of virus for which the selected plant target host is its native host and wherein the virus has been engineered to contain a recombinant capsid-protein-encoding nucleic acid (wherein the capsid- protein-nucleic acid from which the recombinant is made is selected from a virus for which the plant target host is not its native host); polyethylene glycol mediated transformations as described by, for example, I. Potrykus et al., Mol. Gen. Genetics, 197, 183-188; and microinjection as described by, for example, R. Griesbach, Biotechnology 3, p.348-350 and CK Shewmaker Mol. Gen. Genetics, 202 p. 179-185 (1986).
III. EXPRESSION OF CAPSID FUSION PRODUCTS IN PLANT CELLS The present invention also provides a process for producing a recombinant peptide. The process includes: a) providing a plant cell; b) providing a non-infectious nucleic acid containing an expression cassette encoding a fusion peptide; wherein the fusion is of a recombinant peptide and an icosahedral capsid; c) expressing the nucleic acid in the plant cell, wherein the expression in the cell provides for in vivo assembly of the fusion peptide into virus like particles; and d) isolating the virus like particles. The fusion peptide is operably linked to a promoter sequence and a terminator sequence. In one embodiment, the process further comprises: e) cleaving the recombinant peptide from the viral capsid protein. In still another embodiment, the process further comprises: f) isolating the recombinant peptide from step e. See, for example, Figure 1. Peptides may be expressed as single-copy peptide inserts within a capsid peptide (i.e. expressed as individual inserts from recombinant capsid peptide coding sequences that are mono-cistronic for the peptide) or may be expressed as di-, tri-, or multi-copy peptide inserts (i.e. expressed as concatemeric inserts from recombinant capsid peptide coding sequences that are poly-cistronic for the peptide; the concatemeric insert(s) may contain multiple copies of the same exogenous peptide of interest or may contain copies of different exogenous peptides of interest). Concatemers may be homo- or hetero-concatemers. In one embodiment, the isolated virus like particle can be administered to a human or animal in a vaccine strategy. In another embodiment, the nucleic acid construct can be co-expressed with another nucleic acid encoding a wild type capsid. In a particular embodiment, the co-expressed capsid/capsid-recombinant peptide fusion particles assemble in vivo to form a chimeric virus like particle. The chimeric VLP is a virus like particle including capsids or capsid-peptide fusions encoded by at least two different nucleic acid constructs. In still another embodiment, the nucleic acid construct can be co-expressed with another nucleic acid encoding a different capsid-recombinant peptide fusion particle. In a particular embodiment, the co-expressed capsid fusion particles will assemble in vivo to form a chimeric virus like particle. In still another embodiment, a second nucleic acid, which is designed to express a different peptide, such as a chaperone protein, can be expressed concomitantly with the nucleic acid encoding the fusion peptide. The plant cells, capsids, and recombinant peptides useful for the present invention are discussed above. In one embodiment, the expressed viral capsid-heterologous peptide fusion product is expressed in soluble form in the cell. In one embodiment, the expressed viral capsid-recombinant heterologous fusion product is assembled into VLPs in the cell. In a separate embodiment, a portion of the expressed viral capsid- heterologous peptide fusion product of interest is formed in an insoluble aggregate in the cell. In one embodiment, the peptide of interest can be renatured from the insoluble aggregate.
Cleavage of Peptide of Interest In one embodiment, the process further provides: e) cleaving the fusion product to separate the recombinant peptide from the capsid. A cleavable linkage sequence can be included between the viral protein and the recombinant peptide. Examples of agents that can cleave such sequences include, but are not limited to chemical reagents such as acids (HCI, formic acid), CNBr, hydroxylamine (for asparagine-glycine), 2-Nitro-5- thiocyanobenzoate, O-Iodosobenzoate, and enzymatic agents, such as endopeptidases, endoproteases, trypsin, clostripain, and Staphylococcal protease. Cleavable linkage sequences are well known in the art. In the present invention, any cleavable linkage sequence recognized by cleavage agents, including dipeptide cleavage sequences such as Asp-Pro, can be utilized.
Expression The process of the invention optimally leads to the increased production of desired capsid-fusion products in a plant host cell in the desired sequence and conformation. The increased production alternatively can be an increased level of desired peptide per gram of protein produced, per gram of host protein, or as a percentage of total recombinant peptide produced. The increased production can also be an increased level of recoverable peptide, such as soluble protein, produced per gram of recombinant or per gram of host cell protein. The increased production can also be any combination of increased total level and increased active or soluble level of protein. The improved expression of recombinant protein can be through expression of the protein as a capsid fusion protein and subsequently inserted in VLPs. In certain embodiments, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, or at least 180 copies of a peptide of interest are expressed in each VLP. The VLPs can be produced and recovered from the cytoplasm, periplasm or extracellular medium of the host cell. In another embodiment, the peptide can be insoluble in the cell. In certain embodiments, the soluble or insoluble peptide is produced in a particle formed of multiple capsids but not forming a native-type VLP. For example, a cage structure of as few as 3 viral capsids can be formed. In certain embodiments, the capsid structure includes more than one copy of a peptide of interest and in certain embodiments, includes at least ten, at least 20, or at least 30 copies. In certain embodiments, the peptide is formed in the vacuole of the plant cell. The peptide or viral capsid sequence can also include one or more targeting sequences or sequences to assist purification. These can be an affinity tag. These can also be targeting sequences directing the assembly of capsids into a VLP .
Cell Growth Transformation of the plant host cells with the vector(s) may be performed using any transformation methodology known in the art, and the plant host cells may be transformed as intact cells or as protoplasts. Exemplary transformation methodologies have been described above. As used herein, the term "fermentation" includes both embodiments in which literal fermentation is employed and embodiments in which other, non-fermentative culture modes are employed. Fermentation may be performed at any scale. Any method generally known in the art may be utilized in fermentation. See, for example, Hellwig et al. (2004) "Plant cell cultures for the production of recombinant proteins," Nature Biotech 22(11): 1415-1422; Sajc et al. (2000) "Bioreactors for plant engineering: an outlook for further research," Biochem Engin. J. 4:89-99. In one embodiment, the fermentation medium may be selected from among any viable plant cell culture media. Optionally, additives to the medium can include, for example, PVP, BSA, NaCl, BrefeldinA, reducing manganese, pluronic antifoam, polyethylene glycol, gelatin, protease inhibitors, redox co-factors, and dimethylsulfoxide. The expression system according to the present invention can be cultured in any fermentation format. For example, batch, fed-batch, semi-continuous, and continuous fermentation modes may be employed herein. The expression systems according to the present invention are useful for transgene expression at any scale (i.e. volume) of fermentation. Thus, e.g., microliter-scale, centiliter scale, and deciliter scale fermentation volumes may be used; and 1 Liter scale and larger fermentation volumes can be used. In one embodiment, the fermentation volume will be at or above 1 Liter. In another embodiment, the fermentation volume will be at or above 5 Liters, 10 Liters, 15 Liters, 20 Liters, 25 Liters, 50 Liters, 75 Liters, 100 Liters, 200 Liters, 500 Liters, 1,000 Liters, 2,000 Liters, 5,000 Liters, 10,000 Liters or 50,000 Liters. In the present invention, growth, culturing, and/or fermentation of the transformed host cells is performed within a temperature range permitting survival of the host cells, preferably a temperature within the range of about 4°C to about 55°C, inclusive.
Cell Density (Packed wet cells) Plant cell expressions systems according to the present invention can provide a cell density or comparable packed wet cell density of about from about 20 g/L (2% packed cell volume) to more than 550 g L (55% packed cell volume). In one embodiment, the packed cell volume is between 2% to about 60%. In another embodiment, the packed cell volume is 2%, 5%, 10%, 15%, 20%, 25%, 35%, 40%, 50%, 55%, 60%, 70%, or 85%.
Isolation of VLP or Peptide of Interest In certain embodiments, the invention provides a process for improving the recovery of peptides of interest by protection of the peptide during expression through linkage and co- expression with a viral capsid. In certain embodiments, the viral capsid fusion forms a VLP, which can be readily separated from the cell lysate. The proteins of this invention may be isolated and purified to substantial purity by standard techniques well known in the art, including, but not limited to, PEG precipitation, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, detergent solubilization, selective precipitation with such substances as column chromatography, immunopurification methods, and others. For example, proteins having established molecular adhesion properties can be reversibly fused to a ligand. With the appropriate ligand, the protein can be selectively adsorbed to a purification column and then freed from the column in a relatively pure form. The fused protein can then be removed by enzymatic or other activity. In addition, protein can be purified using immunoaffinity columns or Ni-NTA columns. General techniques are further described in, for example, R. Scopes, Protein Purification: Principles and Practice, Springer- Verlag: N.Y. (1982); Deutscher, Guide to Protein Purification, Academic Press (1990); U.S. Pat. No. 4,511,503; S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc. (1996); AK Patra et al, Protein Expr Purif, 18(2): p/ 182-92 (2000); and R. Mukhija, et al., Gene 165(2): p. 303-6 (1995). See also, for example, Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification," Methods in Enzymology vol. 182, and other volumes in this series; Coligan, et al. (1996 and periodic Supplements) Current Protocols in Protein Science Wiley/Greene, NY; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, N.J., or Bio-Rad, Richmond, Calif. Combination with recombinant techniques allow fusion to appropriate segments, e.g., to a FLAG sequence or an equivalent which can be fused via a protease-removable sequence. See also, for example., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) QIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, Calif. Similarly, the virus-like particles or cage-like structures can be isolated and purified to substantial purity by standard techniques well known in the art. Techniques for isolation of VLPs include, in addition to those described above, precipitation techniques such as polyethylene glycol or salt precipitation. Separation techmques include anion or cation exchange chromatography, size exclusion chromatograph, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, nickel chromatography, hydroxylapatite chromatography, reverse phase chromatography, lectin chromatography, preparative electrophoresis, immunopurification methods, centrifugation, ultracentrifugation, density gradient centrifugation (for example, on a sucrose or on a cesium chloride (CsCl) gradient), ultrafilfration through a size exclusion filter, and any other protein isolation methods known in the art. The invention can also improve recovery of active recombinant peptides. Levels of active protein can be measured, for example, by measuring the interaction between an identified and a parent peptide, peptide variant, segment-substituted peptide and/or residue-substituted peptide by any convenient in vitro or in vivo assay. Thus, in vitro assays can be used to determine any detectable interaction between an identified protein and a peptide of interest, e.g. between enzyme and subsfrate, between hormone and hormone receptor, between antibody and antigen, etc. Such detection can include the measurement of colorirnetric changes, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion processes, etc. In vivo assays include, but are not limited to, assays to detect physiological effects, e.g. weight gain, change in electrolyte balance, change in blood clotting time, changes in clot dissolution and the induction of antigenic response. Generally, any in vivo assay can be used so long as a variable parameter exists so as to detect a change in the interaction between the identified and the peptide of interest. See, for example, U.S. Patent No. 5,834,250. Detection of the expressed protein is achieved by methods known in the art and includes, for example, radioirnmunoassays, Western blotting techniques or immunoprecipitation. An initial salt fractionation can separate many of the unwanted host cell proteins (or proteins derived from the cell culture media) from the recombinant protein of interest. One such example can be ammonium sulfate. Ammonium sulfate precipitates proteins by effectively reducing the amount of water in the protein mixture. Proteins then precipitate on the basis of their solubility. The more hydrophobic a protein is, the more likely it is to precipitate at lower ammonium sulfate concentrations. A typical protocol includes adding saturated ammonium sulfate to a protein solution so that the resultant ammonium sulfate concentration is between 20- 30%. This concentration will precipitate the most hydrophobic of proteins. The precipitate is then discarded (unless the protein of interest is hydrophobic) and ammonium sulfate is added to the supernatant to a concentration known to precipitate the protein of interest. The precipitate is then solubilized in buffer and the excess salt removed if necessary, either through dialysis or diafiltration. Other methods that rely on solubility of proteins, such as cold ethanol precipitation, are well known to those of skill in the art and can be used to fractionate complex protein mixtures. The molecular weight of a recombinant protein can be used to isolated it from proteins of greater and lesser size using ultrafiltration through membranes of different pore size (for example, Amicon or Millipore membranes). As a first step, the protein mixture can be ulfrafiltered through a membrane with a pore size that has a lower molecular weight cut-off than the molecular weight of the protein of interest. The retentate of the ultrafiltration can then be ulfrafiltered against a membrane with a molecular cut off greater than the molecular weight of the protein of interest. The recombinant protein will pass through the membrane into the filtrate. The filtrate can then be chromatographed. Recombinant proteins can also be separated from other proteins on the basis of its size, net surface charge, hydrophobicity, and affinity for ligands. In addition, antibodies raised against proteins can be conjugated to column matrices and the proteins immunopurified. All of these methods are well known in the art. It will be apparent to one of skill that chromatographic techniques can be performed at any scale and using equipment from many different manufacturers (e.g., Pharmacia Biotech).
Renaturation and Refolding Insoluble protein can be renatured or refolded to generate secondary and tertiary protein structure conformation. Protein refolding steps can be used, as necessary, in completing configuration of the recombinant product. Refolding and renaturation can be accomplished using an agent that is known in the art to promote dissociation/association of proteins. For example, the protein can be incubated with dithiothreitol followed by incubation with oxidized glutathione disodium salt followed by incubation with a buffer containing a refolding agent such as urea. Recombinant protein can also be renatured, for example, by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be refolded while immobilized on a column, such as the Ni NTA column by using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, and 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation can be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM immidazole. hnmidazole can be removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein can be stored at room temperature, 4°C or frozen at -20°C to -80°C. Other methods include, for example, those that may be described in MH Lee et al., Protein Expr. Purifi, 25(1): p. 166-73 (2002), W.K. Cho et al., J. Biotechnology, 77(2-3): p. 169- 78 (2000), Ausubel, et al. (1987 and periodic supplements), Deutscher (1990) "Guide to Protein Purification," Methods in Enzymology vol. 182, and other volumes in this series, Coligan, et al. (1996 and periodic Supplements) Cuπent Protocols in Protein Science Wiley/Greene, NY, S. Roe, Protein Purification Techniques: A Practical Approach (Practical Approach Series), Oxford Press (2001); D. Bollag, et al., Protein Methods, Wiley-Lisa, Inc. (1996)
Active Peptide Analysis Active proteins can have a specific activity of at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95% that of the native peptide that the sequence is derived from. Further, the subsfrate specificity (kcat Km) is optionally substantially similar to the native peptide. Typically, kcat /Km will be at least 30%, 40%, or 50%, that of the native peptide; and more preferably at least 60%, 70%, 80%, or 90%. Methods of assaying and quantifying measures of protein and peptide activity and substrate specificity (kc_t/Km), are well known to those of skill in the art. The activity of a recombinant peptide produced in accordance with the present invention by can be measured by any protein specific conventional or standard in vitro or in vivo assay known in the art. The activity of the plant cell host produced recombinant peptide can be compared with the activity of the corresponding native protein to determine whether the recombinant protein exhibits substantially similar or equivalent activity to the activity generally observed in the native peptide under the same or similar physiological conditions. The activity of the recombinant protein can be compared with a previously established native peptide standard activity. Alternatively, the activity of the recombinant peptide can be determined in a simultaneous, or substantially simultaneous, comparative assay with the native peptide. For example, an in vitro assays can be used to determine any detectable interaction between a recombinant peptide and a target, e.g. between an expressed enzyme and subsfrate, between expressed hormone and hormone receptor, between expressed antibody and antigen, etc. Such detection can include the measurement of colorimetric changes, proliferation changes, cell death, cell repelling, changes in radioactivity, changes in solubility, changes in molecular weight as measured by gel electrophoresis and/or gel exclusion methods, phosphorylation abilities, antibody specificity assays such as ELISA assays, etc. In addition, in vivo assays include, but are not limited to, assays to detect physiological effects of the plant host cell produced peptide in comparison to physiological effects of the native peptide, e.g. antigenic response. Generally, any in vitro or in vivo assay can be used to determine the active nature of the recombinant peptide that allows for a comparative analysis to the native peptide so long as such activity is assayable. Alternatively, the peptides produced in the present invention can be assayed for the ability to stimulate or inhibit interaction between the peptide and a molecule that noπnally interacts with the peptide, e.g. a substrate or a component of the signal pathway that the native protein normally interacts. Such assays can typically include the steps of combining the protein with a substrate molecule under conditions that allow the peptide to interact with the target molecule, and detect the biochemical consequence of the interaction with the protein and the target molecule. Assays that can be utilized to determine peptide activity are described, for example, in Ralph, P. J., et al. (1984) J. Immunol. 132:1858 or Saiki et al. (1981) J. Immunol. 127:1044, .Steward, W. E. U (1980) The friterferon Systems. Springer- Verlag, Vienna and New York, Broxmeyer, H. E., et al. (1982) Blood 60:595, "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987, AK Pafra et al., Protein Expr Purif, 18(2): p/ 182-92 (2000), Kodama et al., J. Biochem. 99: 1465-1472 (1986); Stewart et al., Proc. Nat'l Acad. Sci. USA 90: 5209-5213 (1993); (Lombillo et al., J. Cell Biol. 128:107-115 (1995); (Vale et al., Cell 42:39-50 (1985).
EXAMPLES
Viral Source of Coat Protein-Encoding Nucleic Acid In the following examples, the cowpea chlorotic mottle virus (CCMV) has been used as the source of the coat protein for expression of the desired recombinant peptides. CCMV is a member of the bromoviras group of the Bromoviridae. Bromoviruses are 25-28 nm diameter icosahedral viruses with a four-component, positive sense, single-stranded RNA genome. RNAl and RNA2 code for replicase enzymes. RNA3 codes for a protein involved in viral movement within plant hosts. RNA4 (a subgenomic RNA derived from RNA 3), i.e. sgRNA4, codes for the 20 kDa coat protein (CP) (SEQ ID NO: 13) (Table 1). Each CCMV particle contains 180 copies of the CCMV CP. An exemplary DNA sequence encoding the CCMV CP is shown in SEQ ID NO:14 (Table 2).
Table 1 : Wild type CCMV coat protein encoded by sgRNA4 (Seq. ID No. 13)
Met Ser Thr Val Gly Thr Gly Lys Leu Thr Arg Ala Gin Arg Arg Ala Ala Ala Arg Lys Asn Lys Arg Asn Thr Arg Val Val Gin Pro Val He Val Glu Pro He Ala Ser Gly Gin Gly Lys Ala lie Lys Ala Trp Thr Gly Tyr Ser Val Ser Lys Trp Thr Ala Ser Cys Ala Ala Ala Glu Ala Lys Val Thr Ser Ala He Thr He Ser Leu Pro Asn Glu Leu Ser Ser Glu Arg Asn Lys Gin Leu Lys Val Gly Arg Val Leu Leu Trp Leu Gly Leu Leu Pro Ser Val Ser Gly Thr Val Lys Ser Cys Val Thr Glu Thr Gin Thr Thr Ala Ala Ala Ser Phe Gin Val Ala Leu Ala Val Ala Asp Asn Ser Lys Asp Val Val Ala Ala Met Tyr Pro Glu Ala Phe Lys Gly He Thr Leu Glu Gin Leu Thr Ala Asp Leu Thr He Tyr Leu Tyr Ser Ser Ala Ala Leu Thr Glu Gly Asp Val He Val His Leu Glu Val Glu His Val Arg Pro Thr Phe Asp Asp Ser Phe Thr Pro Val Tyr
Table 2: Exemplary DNA Sequence Encoding the CCMV CP (Seq. ID. No. 14) atg tct aca gtc gga aca ggg aag tta act cgt gca caa cga agg get gcg gcc cgt aag aac aag egg aac act cgt gtg gtc caa cct gtt art gta gaa ccc ate get tea ggc caa ggc aag get art aaa gca tgg ace ggt tac age gta teg aag tgg ace gcc tct tgc gcg gcc gcc gaa get aaa gta ace teg get ata act ate tct etc cct aat gag eta teg tec gaa agg aac aag cag etc aag gta ggt aga gtt tta tta tgg ctt ggg ttg ctt ccc agt gtt agt ggc aca gtg aaa tec tgt gtt aca gag acg cag act act get get gcc tec ttt cag gtg gca tta get gtg gcc gac aac teg aaa gat gtt gtc get get atg tac ccc gag gcg ttt aag ggt ata ace ctt gaa caa etc ace gcg gat tta acg ate tac ttg tac age agt gcg get etc act gag ggc gac gtc ate gtg cat ttg gag gtt gag cat gtc aga cct acg ttt gac gac tct ttc act ccg gtg tat tag
The crystal structure of CCMV has been solved. This structure provides a clearer picture of the coat protein interactions that appear to be critical to particle stability and dynamics and has been helpful in guiding rational design of insertion sites. Previous studies have demonstrated that CCMV coat proteins can be genetically modified to carry heterologous peptides without interfering with their ability to form particles. A number of suitable insertion sites have been identified. A total of up to 180 copies of a heterologous peptide unit (whether as individual peptide units or in concatameric units) can be inserted into the CCMV particle at a single insertion site in the CCMV CP. Insertion sites identified within CCMV CP to date can accommodate peptides of various lengths.
Materials and Methods Unless otherwise noted, standard techniques, vectors, control sequence elements, and other expression system elements known in the field of molecular biology are used for nucleic acid manipulation, fransformation, and expression. Such standard techniques, vectors, and elements can be found, for example, in: Ausubel et al. (eds.), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (eds.), Molecular Cloning
(1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology
152: Guide to Molecular Cloning Techniques (1987) (Academic Press); and Bukhari et al. (eds.), DNA Insertion Elements, Plasmids and Episomes (1977) (Cold Spring Harbor Laboratory Press, NY). Unless noted otherwise, PCR reactions were performed using a PTC225 thermocycler (MJ Research, South San Francisco, CA, USA) according to the following protocol:
Table 3. PCR protocol
Figure imgf000045_0001
* (from Invitrogen Corp, Carlsbad, CA, USA, hereinafter "Invitrogen")
Example 1 - Production of Antigenic Peptides in CCMV Virus Particles in Whole Cowpea Plants Inoculated with CCMV RNAl, RNA2, and Chimeric RNA3
Expression of Bacillus anthracis antigenic peptides was performed in whole plants, using cowpea chlorotic mottle virus (CCMV) with capsid proteins (CP) engineered to contain one of four different antigenic peptides. DNA having the nucleotide sequence of CCMV RNA 1 and DNA having the nucleotide sequence of CCMV RNA 2 were each separately subcloned in the cloning vector pUC19 downstream from, and under the confrol of, a T7 promoter and upstream from a unique Xba I site. This produced plasmids pDOW2122 (CCMV RNAl) and pDOW2123 (CCMV RNA2). DNA having the nucleotide sequence of CCMV RNA 3, engineered to contain five
BamH I restriction enzyme cleavage sites, was further engineered for production of the recombinant capsid protein-encoding nucleic acid. Four DNA molecules, each encoding a different one of four exogenous peptides (four different antigenic peptides from Bacillus anthracis Protective Antigen PA) were each synthesized by SOE (splicing-by-overlap-extension) of synthetic oligonucleotides. The resulting nucleic acids contained BamHI recognition site termini. Each PA DNA fragment was restricted with BamHI restriction enzyme and independently inserted into the coat protein at one of the five different engineered restriction enzyme cleavage sites in the CCMV coat protein coding sequence: BamHI at codon 63, BamHI at codon 102, BamHI at codon 114, BamHI at codon 129, and BamHI at codon 160. The four different peptides were PAl (SEQ ID NO:l encoded by SEQ ID NO: 15), PA2 (SEQ ID NO: 2, encoded by SEQ ID NO: 16), PA3 (SEQ ID NO: 3, encoded by SEQ ED NO: 17), and PA4 (SEQ ID NO:4, encoded by SEQ ID NO: 18).
Table 4: Bacillus anthracis antigenic nucleic acid and amino acid sequences.
Figure imgf000046_0001
Each of these was inserted into each of the five plasmids: pDOW2125 (pUC-CCMV RNA3-CP635β»2Hi), pDOW2126 (pUC-CCMV-RNA3-1025αmHi), pDOW2127 (pUC- CCMN-RNA3-CP1145αmH7), pDOW2128 (ρUC-CCMV-RNA3-CP129#amH7/>, and pDOW2129 (pUC-CCMV-RNA3-CPl 60BamHI) which had been digested with BamHI restriction enzyme and then dephoshorylated. This produced a total of 20 different versions of DNA for "chimeric RNA 3." Plasmids pDOW2135 (pUC-CCMV-RNA3-CP635α?«H/-PAl), pDOW2139 (pUC-CCMV-RNA3- CP102Bamffl-~AΪ), pDOW2143 (pUC-CCMV-RNA3-CP1145αmH/-PAl), pDOW2147 (pUC- CCMV-RNA3-CP129£ 7κHT-PAl), and pDOW2151 (pUC-CCMV-RNA3-CP160# mH/-PAl) are examples of chimeric RNA3 having a PAl insert at position 63, 102, 114, 129, and 160. Wild-type CCMV coat protein-encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing BamHI restriction site but no inserts were used as controls. Each modified RNA3 construct was separately sub-cloned in the cloning vector pUC19 downstream from and under the control of a T7 promoter, and upstream from a unique Xba I site. Each of the three classes of plasmids was cloned in E. coli. Plasmids were isolated, linearized by Xba I restriction enzyme digestion, and then one microgram of each was transcribed into RNA in vitro using a mMESSAGE mMACHINE T7 Kit (RNA transcription kit, from Ambion, Inc., Austin, TX, USA). This produced 24 different RNA varieties: one for RNAl, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls. Cocktail mixes of RNAl, RNA2, RNA3 or chimeric RNA3s containing a PA insert were used to infect cowpea plants. Cowpea plants were sprouted from Cowpea California Blackeye #5 seeds (Ferry-Morse Seed Co. KY). Sprouts were transplanted singly into 6 inch pots with Miracle-Gro potting mix (Miracle-Gro Lawn Products OH). Cowpea plants were infected at 2- leaf stage (approximately 7 days post germination). A dusting of Carborundum powder 400grit (Fisher Scientific cat.409-21-2) was applied onto one leaf of each plant. RNA cocktail mixes were applied onto the carborundum layer. Leaves were abraded by gentle rubbing with a gloved finger. Infections were established 7-14 days post inoculation. Unexpectedly, in this whole plant system, even though the native host plant was used, the chimeric coat proteins reverted to the wild type or in some cases, the desired exogenous antigen peptide was partially deleted. This was verified by sequencing the virus progeny. The RNA was extracted and reverse-transcribed into DNA using ThermoScript RT-PCR system (Invitrogen cat.11146-024) and CCMVRNA4.R gene specific primer (SEQ ID NO:19) (5'-CTC GAG CTA ATA CAC CGG AGT GAA AG-3'). cDNAs were further amplified by PCR using primers CCMVRNA4.F (SEQ ED NO:20) (5'-CTG CAG ATG TCT ACA GTC GGA ACA GG-3') and CCMVRNA4.R. The reactions were purified and sequenced with CCMV-CP-F1 primer, (SEQ ED NO: 21) (5'- AAC CCA TCG CTT CAG GCC AA-3'). Sequences were analyzed with Sequencher software version 4.0.5 (Gene Codes Corporation). For example, upon sequencing of RNA3 progeny derived from pDOW2128 containing the PAl insert, the coat protein contained a small, unrecognized nucleotide insert (5 '-CGTATTTCTGATCCTCTC-3 ') that was translated as RISDPL instead of the PAl insert amino acid sequence. The inserted nucleotide sequence kept the rest of the coat protein in frame. It has been determined that the engineered CCMV RNA3 is unstable upon expression in the whole plant, easily undergoes recombinations, and that the whole plant system is not useful for production of epitopes on chimeric CCMV virus particles. Example 2 - Production of Antigenic Peptides in CCMV Virus Particles in Tobacco Suspension Culture Inoculated with CCMV RNAl, RNA2, and Chimeric RNA3
Expression of the same CCMV-peptide-encoding constructs was performed in plant cell suspension culture. Nicotiana tabacum N l cells were transfected by elecfroporation with RNA transcripts of CCMV RNA 3 coding for the chimeric CCMV coat proteins and CCMV RNA 1 and 2 coding for the replicase genes. Wild-type CCMV coat protein-encoding RNA 3 and engineered CCMV coat protein-encoding RNA 3 containing the appropriate BamHI restriction site but no inserts were used as controls. 24 different RNA varieties were obtained by in vitro RNA transcription as described in the Example 1: one for RNAl, one for RNA2, 20 for chimeric RNA3, and two for RNA3 controls. In 22 different groups, two micrograms of each of three resulting RNAs (RNAl, RNA2, and one of the RNA3s) were transformed into tobacco cells by elecfroporation.
The following protocol was used for plant cell fransfection: 1) Media Preparation: NTl media QliterV. 4.33g Murashige & Skoog basal salt (Phyto Technology Laboratories KS cat.M524), lOOmg Myo-Inositol (Sigma cat.I-3011), 1ml of lmg/ml solution of Thiamine HCI (Sigma cat. T-3902), 180mg Potassium Phosphate Monobasic KH2PO4 (Sigma cat. P-8416), 30g Sucrose (Sigma cat.S-5390), and 200μl 2,4-D solution of lOmgml (Sigma cat. D-7299) were mixed in a small amount of water. Purified water was added to the solution to bring volume up to 1 liter. The pH was adjusted to 5.8, and the solution was autoclaved. Mannitol Wash Solution 0.4M: 36.43 Mannitol (Sigma cat. M-1902) was added to small amount of purified water. Purified water was added to bring volume up to 500 ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize. Enzyme solution: 0.4M mannitol, and 0.02M MES were mixed in a small amount of water. Purified water was added to bring volume up to 500ml and the pH was adjusted to 5.5. The solution was autoclaved in order to sterilize, and the solution was stored at 4°C. Prior to use, 1% cellulysin (Calbiochem cat.219466) and 0.3% Macerase Pectinase (Calbiochem cat.441201) was added to solution, and the solution was shaken until cellylysin and Macerase Pectinase were dissolved. Electroporation buffer 0.8% NaCl, 0.02% KC1, 0.02% KH2PO4, and 0.11% Na2HPO4 were added to a small amount of purified water. Purified water was added to bring the solution up to 100 is, and the pH was adjusted to 6.5. The buffer was autoclaved and stored at 4°C.
2) Tobacco cell partial digestion protocol:
Tobacco cell line NTl was partially digested prior to electroporation as following. A robust cell line was maintained by sub-culturing weekly, cells were grown in NTl media at 24°C or 28°C with gentle shaking, and three days before digestion, 5ml of cell suspension was sub-cultured into 50ml of NTl media and incubated at 28°C. Cells were spun down in 50ml tubes for 5 minutes at 800 rpm. The enzyme solution was prepared, and cells were washed in the mannitol wash solution (approx. 40ml). Cells were spun for 5 minutes at 800 rpm, and 3 volumes of enzyme solution were added to the cells. Cells were resuspended by inversion; transfeπed into 10cm petri dishes by pouring, and the dish was shaken very slowly at room temperature while wrapped in aluminum foil for 60-120 minutes. The cells were then fransfeπed back into 50ml plastic tubes; and spun for 5 minutes at 800 rpm. Cells were washed with 40ml mannitol wash solution and spun again, washed with elecfroporation buffer, and spun. Three volumes of electroporation buffer (total volume is usually 20ml) were added to the cells; and the cells were stored at 4°C wrapped in aluminum foil.
3) Electroporation of partially digested cells protocol: lml of digested cells were aliquoted into electroporation cuvettes (4mm gap). 2μg each RNA transcript - CCMV RNAl, RNA2, and Chimeric RNA3 - were added to the cuvettes and placed on ice for 5 minutes. 10ml of NTl plating media were added (NTI+0.4M mannitol) to each Petri dish. The cells were elecfroporated at 500μF, 250V, and the cuvettes were placed back on ice. The cells were then transfeπed into Petri dishes, and incubate at room temperature in darkness with no shaking. The cells were then collected for analysis at 48 hours post transfection.
Results Expression of chimeric coat protein was analyzed by Western blot using anti-CCMV coat protein polyclonal antibody. Also, RNA was extracted from each of the cultures and the chimeric CCMV RNA4 was reverse transcribed into cDNA, which was then amplified by PCR. The PCR products were sequenced as described in Example 1. All samples were positive on the western blot except for the negative control that was transfected with only RNAl and 2. Compared to control CCMV capsid proteins, the chimeric coat proteins had greater size and slower mobility on the gel indicating that the chimeric coat proteins contained PA inserts. This was verified by sequencing of the viral RNA progeny. Results demonstrated that 19 out of 20 chimeric constructs expressed the chimeric CCMV coat protein properly without mutation in the desired antigen peptide. The results indicate that chimeric CCMV RNA3s expressed in suspension cells are stable. Figure 2 shows the expression of CCMV CP in cells transfected with CCMV RNAl, RNA2, and RNA3 transcribed from pDOW2125 (CCMV63BamHI), pDOW2126 (CCMV102BamHI), pDOW2127 (CCMV114BamHI), pDOW2128 (CCMV129BamHI) and pDOW2129 (CCMV160BamHI). The results demonstrate that CCMV CP is expressed from all RNA3s with engineered BamHI site in different positions in the CP. All 4 PA peptides (PAl, PA2, PA3, and PA4) fused to CCMV coat protein at the 63, 102, 114, 129, and 160 BamHI site were successfully produced in tobacco cells. Figure 3 and Figure 4 show the expression of chimeric CCMV CP in cells transfected with CCMV RNAl, RNA2, and chimeric RNA3 containing CP with the four PA peptide inserts in the position 63, 102, 114, 129, and 160. Figure 3 demonstrates that the fusion protein of CCMV CP with PAl, PA2, PA3, or PA4 peptide that has been inserted at the position 63, 102, or 114, is expressed in the tobacco plant cells with the exception of PA2 peptide that has been inserted into the CCMP CP at the position 63. Figure 4 demonstrates that the fusion protein of CCMV CP with PAl, PA2, PA3, or PA4 peptide that has been inserted at the position 129 or 160, is expressed in the tobacco plant cells.
Example 3 - Production of 4 Antigenic Peptides in CCMV Virus-like Particles in Tobacco Suspension Culture Transfected with Plant Expression Plasmids Encoding the Chimeric CCMV CPs
1) Vector construction: Plasmid pIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were Xbal and EcoRI. This plasmid contains the Cassava Vein Mosaic
Virus promoter upstream of the Xbal site and a Nos terminator downstream of the EcoRI site.
The vector was prepared by digestion with Xba and EcoRI and dephosphorylated before litigation with the inserts. 2) Insert construction: CCMV CP-PA fusions were amplified by PCR out of pDOW2147 (pUC-CCMV-RNA3- Pl29BamHI-?Al), pDOW2148 (pUC-CCMV-RNA3-CP1295fl H/-PA2), pDOW2149 (pUC- CCMV-RNA3-CP1295flmH/-PA3), pDOW2150 (pUC-CCMV-RNA3-CP1295 H/-PA4) using primers CCMV-CP-Xbal (SEQ ID NO:22) and CCMV-CP-EcoRI (SEQ ID NO: 23) to create pDOW2160 (pIL-Tab-CCMV1295α?wH7-PAl) (SEQ ID NO: 5), pDOW2161 (pIL-Tab- CCMV129J8β/«H/-PA2) (SEQ ID NO:6), pDOW2162 (pIL-Tab-CCMV1295αmH7-PA3) (SEQ ID NO:7), and pDOW2163 (pIL-Tab-CCMV1295αmHJ-PA4) (SEQ JD NO:8). Plasmid maps for pDOW2160, pDOW 2161, pDOW2162, and pDOW 2163 are shown in Figures 5, 6, 7, and 8. 3) Plant Cell Transfection: Plant cells were transfected with lOμg of plasmid pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Plant cell transfection was performed as in Example 2.
Results All four PA peptides-CCMV CP fusions at 129BamHI site were successfully expressed in tobacco cells. Figure 9 shows the expression of chimeric CCMV CP in cells transfected with pDOW2160, pDOW2161, pDOW2162, and pDOW2163. Compared to the control (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts.
Example 4 -Production of 4 Antigenic Peptides as CCMV CP fusions in Virus-like Particles in Tobacco Suspension Culture Transfected with Plant Expression Plasmids Encoding the Chimeric CCMV CPs and 3 'UTR (CCMVRNA3 3 ' untranslated region) 1) Vector construction. Plasmid ρIL-Tab358 was used as the plant expression vector. Restriction sites chosen for CCMV CP insertion were Xba and EcoRI. This plasmid contains the Cassava Vein Mosaic Virus promoter upstream of the Xbal site and a Nos terminator downstream of the EcoRI site. The vector was prepared by digestion with Xbal and EcoRI and depshophorylated before litigation with the inserts.
2) Insert construction: CCMV CP-PA fusions containing the 3'UTRof RNA3 were amplified by PCR out of pDOW2147, pDOW2148, pDOW2149, and pDOW2150 using primers CCMV-CP-Xbal and CCMV-CP-EcoRI-3'UTR (SEQ ID NO: 24) to create pDOW2169 (pIL-Tab-CP129J?αmH/-
PA1-3'UTR) (SEQ ID NO: 9), pDOW2170 (pIL-Tab-CP1295« H/-PA2-3'UTR) (SEQ ID NO: 10), pDOW2171 (pIL-Tab-CP1295α H7-PA3-3'UTR) (SEQ ID NO:ll), and pDOW2172 (pIL- Tab-CP1295αmHi-PA4-3'UTR) (SEQ ID NO: 12).
3) Plant Cell Transfection: Plant cells were transfected with 10/xg of plasmid pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Plant cell transfection was performed as in Example 2.
Results All four PA peptides-CCMV CP fusions at l29BamHI site containing the 'UTR were successfully expressed in tobacco cells. Figure 10 shows the expression of chimeric CCMV CP in cells transfected with pDOW2169, pDOW2170, pDOW2171, and pDOW2172. Compared to the confrol (CCMV coat protein with no insert), all four chimeric coat proteins showed slower mobility indicative of having PA inserts.
Example 5 - Production of 4 Antigenic Peptides as CCMV CP fusions in Virus-like Particles in Transgenic Tobacco Suspension Cell Culture Transformed with Plant Expression Plasmids Encoding the Chimeric CCMV CPs
Tobacco cell line NTl was maintained by subculruring weekly. Cells were grown in NTl media at 24°C or 28°C with gentle shaking. Three days before transformation, 5ml of cell suspension was subcultured into 50ml of NTl media and incubated at 28°C.
1) Plant cell fransformation by particle bombardment: Plasmids pDOW2160, pDOW2161, pDOW2162, ρDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter (pBBV) were used for NTl tobacco cells transformation by micro-particle bombardment. The plasmid ratio used was 1: 6 pBBV:pDOW2160, pBBV:ρDOW2161, pBBV:pDOW2162, or pBBV:ρDOW2163. Total of 5ug of plasmid DNAs were sufficient for 6 bombardments. Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
2) Plating Bombarded cells were transfeπed on non-selective NTl media agar plates for 4 hours before transferring to NTl media agar plate with 25ug/ml of Glufosinate-ammonium (Sigma cat#45520). 3) Selecting transgenic calli. After 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome. Transgenic calli expressing chimeric CCMV CPs were transferred to liquid NTl media. Cells were grown in NTl media at
24°C or 28°C with gentle shaking and subcultured weekly.
Results Figure 11 shows the expression of chimeric CCMV CP in cells stably transformed with pDOW2160, pDOW2161, pDOW2162, and pDOW2163. The CP fusion was detected by polyclonal antibodies for CCMV. Expression of all four chimeric coat protein fransgenes was detected.
Example 6 — Production of 4 Antigenic Peptides as CCMV CP fusions in CCMV Virus-like Particles in Transgenic Rice Suspension Culture Transformed with Plant Expression Plasmids Encoding the Chimeric CCMV CPs
Rice cell lines were maintained by sub-culturing weekly. Cells were grown in NB media (Li, L et al. Plant Cell Reports. (1993) 12: 250-255) at 28°C with gentle shaking. Three days before transformation, 5ml of cell suspension was sub-cultured into 50ml of NB media and incubated at 28°C.
1) Plant cell transformation by particle bombardment. Plasmids pDOW2160, pDOW2161, pDOW2162, and pDOW2163 and plant expression plasmid pBBV containing plant selectable marker Pat driven by the Cassava Vein Mosaic Virus promoter were used for rice cells fransformation by microparticle bombardment. The plasmid ratio used was 1: 6 pBBV:pDOW2160, pBBV:pDOW2161, pBBV:pDOW2162, or pBBV:pDOW2163. Total of 5ug of plasmid DNAs were sufficient for 6 bombardments. Biorad bombardment protocol as described in Chen, L et al. Plant Cell Reports (1998) 18: 25-31 was used for transformation.
2) Plating. Bombarded cells were transfeπed to NB media agar plates with 25ug/ml of Glufosinate- ammonium (Sigma cat#45520) for selection.
3) Selecting transgenic calli. After 21 days, calli that had white fluffy cell growth were selected for analysis by western blotting to test for the expression of CP fusions and PCR to test for integration of promoter-CP fusion gene-terminator cassette into the plant genome.
Results Figure 12 shows the expression of chimeric CCMV CP in cells stably transformed with ρDOW2160, pDOW2161, pDOW2162, and pDOW2163 as detected by polyclonal antibodies to CCMV. Expression of all four chimeric coat protein transgenes was detected. The following protocol has been used to extract genomic DNA and test for integration of promoter-CP fusion gene-terminator cassette into the plant genome by PCR. Qiagen DNeasy Plant Mini was used to extract genomic DNA following the manufacturer directions. Approximately 50 — 100 mg of fresh rice callus was placed into a 1.5ml tube. The tissue was frozen in liquid N2 for immediate DNA extraction or placed in -80°C freezer for storage. Prior to DNA extraction the tissue was manually disrupted by grinding with a micropestle. The sample was placed on ice and the genomic DNA was extracted as described in Qiagen DNeasy Plant Mini Kit manual. The Access Quick Master Mix 2x (Promega cat#A1720) was used to set up the PCR reaction as follows:
Master mix 25ul CCMV-F (1 OmM) primer, SEQ ID NO: 25 lul
Nos-teπn-R (1 OmM) primer, SEQ ID NO: 26 lul
Genomic DNA lul water 22ul
Total 50ul
The following PCR cycle has been used to amplify the promoter-CP fusion gene- terminator cassette from the genomic DNA:
1 cycle 95°C 2 min
35 cycles of 95°C 30sec 55°C 30sec 70°C 2 min
1 cycle 70°C 5 min 4°C hold 10 ul of PCR reaction was run on 1.2% agarose gel stained with EtBr. Figure 13 shows a PCR products amplified from selected individual rice calli. The samples that contained a PCR product of predicted size were scored as positive for stable transformation and integration of the chimeric CP transgene into the plant genome. Transgenic calli expressing chimeric CCMV CPs were transfeπed to liquid NB media to create a cell suspension culture suitable for scale up fermentation. Cells were grown in NB media at 28 °C with gentle shaking and subcultured weekly.
VLP extraction: Chimeric VLPs were precipitated by lysis of shake-flask culture samples, followed by
PEG (polyethylene glycol)-treatment of the resulting cell lysates and ultrafiltration, according to the following protocol: 50mL aliquots of each shake-flask culture were centrifuged to pellet the cells. Pelleted cells were resuspended in virus buffer (0.2M Sodium Acetate pH 5.2; lOmM EDTA.0) at a 2 volume buffer to 1 volume pellet ratio. Cells were then disrupted by blending for 60 sec multiple times, with 2 minutes resting on ice in between. The resulting homogenate was squeezed through 3 layers of cheese cloth and was then centrifuged for 15 min at 15,000xG at 4°C. The resulting supernatants were removed and their volumes measured. To each supernatant, PEG8000 was added to a final concentration of 10% and the solution was incubated on ice for 1 hr or overnight at 4°C. Then, the solution was centrifuged at 15,000xG for 10 min at 4°C. Precipitated pellets were then resuspended in 1/10 initial supernatant volume of virus buffer and stored at 4°C and analyzed by western blotting with polyclonal anti-CCMV antibodies. Figure 14 shows that the chimeric CCMV VLPs were recovered from cells stably transformed with pDOW2160. Chimeric CP-PAl fusion proteins were detected in the resuspended PEC pellets but not the supernatant indicating the chimeric CP assembled into VLPs. Alternatively, the resuspended samples were centrifuged for 10 min at 15,000xG at 4°C, the supernatant was recovered and subjected to the second round of PEG precipitation. PEG8000 was added to final concentration of 15% and stiπed at 4°C for 2 hours. The solution was then centrifuged at 15,000xG for 10 mins and the pellet was resuspended in small volume of virus buffer. The resuspended VLP solution was loaded on to Centricon Plus-20 with 300K molecular weight cut-off and spun at 4,000xG for 5 mins. The concentrated VLP sample was then analyzed by western blotting with polyclonal anti-CCMV antibodies (see Figure 14). Chimeric CP-PAl fusion proteins were detected in the resuspended and size-filtered second PEG pellets, but not in the supernatant, indicating the chimeric CP assembled into VLPs.

Claims

We Claim: 1) A process for producing a heterologous peptide comprising: a) transforming a plant cell with a non-infectious nucleic acid comprising a nucleic acid sequence encoding a fusion peptide, wherein the fusion peptide is comprised of at least one heterologous peptide of interest and at least one viral capsid protein, and wherein the nucleic acid is integrated into the genome of the plant cell; b) expressing the nucleic acid in the plant cell, wherein the plant cells are grown in a suspension plant cell culture in a fermentation process; c) wherein the expression in the plant cell provides for in vivo assembly of the fusion peptide into a virus like particle; and d) isolating the virus like particle. 2) The process of claim 1 , wherein the nucleic acid encoding the fusion peptide is operably linked to a promoter sequence and a terminator sequence. 3) The process of claim 2, wherein the nucleic acid further comprises a viral 3 'UTR. 4) The process of claim 3, wherein the 3 'UTR comprises an encapsidation signal. 5) The process of claim 2, wherein the nucleic acid further comprises an encapsidation signal. 6) The process of claim 1 , wherein the viral capsid protein is derived from a virus that does not display native trophism for the plant cell host. 7) The process of claim 1 , wherein the viral capsid protein is derived from a virus that displays native trophism for the plant cell host. 8) The process of claim 1, wherein the viral capsid protein is derived from an icosahedral plant virus. 9) The process of claim 8, wherein the icosahedral virus is selected from the group of viruses consisting of Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus. 10) The process of claim 1 , wherein the heterologous peptide is an antigenic peptide. 11) The process of claim 10, wherein the antigenic peptide is a Bacillus anthracis peptide. 12) The process of claim 11, wherein the antigenic peptide is selected from the group consisting of Seq. ID. Nos. 1-4. 13) The process of claim 1, wherein the nucleic acid is selected from the group consisting of Seq. ID. Nos. 5-12. 14) The process of claim 1, wherein the virus like particle is administered to an animal as a vaccine.
15) The process of claim 1, wherein the plant cell is a dicot.
16) The process of claim 15, wherein the plant cell is Nicotiana tabacum.
17) The process of claim 1 , wherein the plant cell is a monocot.
18) The process of claim 17, wherein the plant cell is Oryza sativa.
19) The process of claim 1, wherein the nucleic acid does not contain viral sequences encoding viral proteins other than the capsid protein.
20) A plant cell comprising a non-infectious nucleic acid comprising a nucleic acid sequence encoding a fusion peptide, wherein the fusion peptide is comprised of at least one heterologous peptide of interest and at least one viral capsid protein, and wherein the nucleic acid is integrated into the genome of the plant cell.
21) The plant cell of claim 20, wherein the plant cell expresses the fusion peptide.
22) The plant cell of claim 21, wherein the fusion peptide assembles in vivo into a virus like particle.
23) The plant cell of claim 20, wherein the antigenic peptide is selected from the group consisting of Seq. ID. Nos. 1-4.
24) The plant cell of claim 20, wherein the nucleic acid is selected from the group consisting of Seq. ID. Nos. 5-12.
25) The plant cell of claim 20, wherein the plant cell is Nicotiana tabacum.
26) The plant cell of claim 20, wherein the plant cell is Oryza sativa.
27) The plant cell of claim 20, wherein the nucleic acid further comprises a 3 'UTR
28) The plant cell of claim 20, wherein the nucleic acid further comprises a viral 3 'UTR.
29) The plant cell of claim 28, wherein the 3 'UTR comprises an encapsidation signal.
30) The plant cell of claim 20, wherein the nucleic acid further comprises an encapsidation signal.
31) The plant cell of claim 20, wherein the viral capsid protein is derived from a virus that does not display native trophism for the plant cell host.
32) The plant cell of claim 20, wherein the viral capsid protein is derived from a virus that displays native trophism for the plant cell host.
33) The plant cell of claim 20, wherein the viral capsid protein is derived from an icosahedral plant virus. 34) The plant cell of claim 33, wherein the icosahedral virus is selected from the group of viruses consisting of Cowpea Mosaic Virus, Cowpea Chlorotic Mottle Virus, and Alfalfa Mosaic Virus.
35) A nucleic acid construct comprising the sequences selected from the group consisting of Seq. ID. Nos. 5-12.
PCT/US2005/006342 2004-02-27 2005-02-28 High efficiency peptide production in plant cells WO2005086667A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005220734A AU2005220734A1 (en) 2004-02-27 2005-02-28 High efficiency peptide production in plant cells
EP05756363A EP1720990A4 (en) 2004-02-27 2005-02-28 High efficiency peptide production in plant cells
EP18173991.3A EP3388521A1 (en) 2004-02-27 2005-02-28 High efficiency peptide production in plant cells
JP2007500784A JP2007528727A (en) 2004-02-27 2005-02-28 Highly efficient peptide production in plant cells
CA002557668A CA2557668A1 (en) 2004-02-27 2005-02-28 High efficiency peptide production in plant cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54874404P 2004-02-27 2004-02-27
US60/548,744 2004-02-27

Publications (2)

Publication Number Publication Date
WO2005086667A2 true WO2005086667A2 (en) 2005-09-22
WO2005086667A3 WO2005086667A3 (en) 2006-09-14

Family

ID=34976075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006342 WO2005086667A2 (en) 2004-02-27 2005-02-28 High efficiency peptide production in plant cells

Country Status (7)

Country Link
US (1) US7928290B2 (en)
EP (2) EP1720990A4 (en)
JP (1) JP2007528727A (en)
CN (1) CN1926238A (en)
AU (1) AU2005220734A1 (en)
CA (1) CA2557668A1 (en)
WO (1) WO2005086667A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085147A2 (en) * 2005-12-02 2008-07-17 Dow Global Technologies Inc. Novel plant virus particles and methods of inactivation thereof
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2010047839A1 (en) * 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
JP2010533001A (en) * 2007-07-13 2010-10-21 メディカゴ インコーポレイテッド Influenza virus-like particles (VLPs) containing hemagglutinin produced in plants
JP2014064573A (en) * 2006-06-09 2014-04-17 Biomay Ag Vaccine carrier
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US10117947B2 (en) 2013-09-18 2018-11-06 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US11207339B2 (en) 2015-10-30 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215179A1 (en) * 2001-07-20 2009-08-27 Transalgae Transgenically preventing establishment and spread of transgenic algae in natural ecosystems
EP1909829A4 (en) * 2005-07-19 2009-11-11 Dow Global Technologies Inc Recombinant flu vaccines
WO2009019693A2 (en) * 2007-08-07 2009-02-12 Sepal Pharma Sa Analgesic effect of jasmonate derivatives
US8367392B2 (en) * 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
WO2010027516A2 (en) * 2008-09-05 2010-03-11 Jonathan Gressel Transgenically preventing establishment and spread of transgenic algae in natural ecosystems
ES2752323T3 (en) * 2009-09-18 2020-04-06 Fraunhofer Usa Inc Virus-like particles comprising target proteins fused to plant virus coat proteins
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
CA2777030C (en) * 2009-10-16 2022-06-07 Dow Agrosciences Llc Use of dendrimer nanotechnology for delivery of biomolecules into plant cells
CN107164376B (en) 2011-12-21 2021-03-30 阿普斯有限责任公司 Methods of using VLPs having capsids resistant to hydrolases
US20140287507A1 (en) 2012-10-24 2014-09-25 Qian Wang Incorporation of Plant Virus Particles and Polymers as 2D and 3D Scaffolds to Manipulate Cellular Behaviors
BR112015029559A2 (en) * 2013-06-19 2017-12-12 Apse Llc virus-like particle, nucleic acid, and methods for producing double-stranded rna and sirna, shrna, sshrna, 1shrna, and mirna
WO2016061149A1 (en) * 2014-10-14 2016-04-21 Medgenics Medical Israel Ltd. Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof
KR101830792B1 (en) * 2016-01-27 2018-02-21 건국대학교 산학협력단 Method for producing antimicrobial peptide using insoluble fusion protein containing antimicrobial peptide
WO2020014013A1 (en) * 2018-07-09 2020-01-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Viral-vectored vaccine for malaria
KR20220122815A (en) * 2021-02-25 2022-09-05 주식회사 바이오앱 Method for manufacturing alfalfa mosaic virus-like particles using plant expression system and application thereof

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US206A (en) 1837-05-30 Machine fob
US507A (en) 1837-12-07 John crabtree
US5693A (en) 1848-08-01 Window-catch
US6515A (en) 1849-06-05 Boom-derrick
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5057422A (en) 1988-03-23 1991-10-15 Mogen International N.V. Recombinant dna: transformed microorganisms, plant cells and plants: a process for introducing an inducible property in plants, and a process for producing a polypeptide or protein by means of plants or plant cells
WO1992018618A1 (en) 1991-04-19 1992-10-29 Agricultural Genetics Company Limited Modified plant viruses as vectors
US5591605A (en) 1983-04-15 1997-01-07 Mycogen Plant Science, Inc. Plant structural gene expression
US5641876A (en) 1990-01-05 1997-06-24 Cornell Research Foundation, Inc. Rice actin gene and promoter
WO1997048819A1 (en) 1996-06-20 1997-12-24 The Scripps Research Institute Cassava vein mosaic virus promoters and uses thereof
US5834250A (en) 1988-10-28 1998-11-10 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1998056921A1 (en) 1997-06-12 1998-12-17 Dow Agrosciences Llc Regulatory sequences for transgenic plants
WO1999010513A1 (en) 1997-08-07 1999-03-04 Auburn University Universal chloroplast integration and expression vectors, transformed plants and products thereof
WO2000012681A1 (en) 1998-08-27 2000-03-09 Rutgers, The State University Of New Jersey Compositions and methods for producing high-level seed-specific gene expression in corn
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
WO2001021782A2 (en) 1999-09-24 2001-03-29 Calgene Llc Enhancer elements for increased translation in plant plastids
WO2001020974A1 (en) 1999-09-22 2001-03-29 The Penn State Research Foundation Quantitative transient protein expression in plant tissue culture
US6218145B1 (en) 1998-04-02 2001-04-17 Monsanto Company Bacterial expression systems based on plastic or mitochondrial promoter combinations
US6232099B1 (en) 1994-10-18 2001-05-15 Scottish Crop Research Institute Method of producing a chimeric protein
WO2001070939A1 (en) 2000-03-22 2001-09-27 Icon Genetics, Inc. Methods for transforming plant plastids and making transplastomic plants
WO2002055651A2 (en) 2001-01-12 2002-07-18 Icon Genetics Ag Processes and vectors for plastid transformation
WO2002057466A2 (en) 2001-01-19 2002-07-25 Icon Genetics Ag Processes and vectors for plastid transformation of higher plants
US6472586B1 (en) 1995-08-10 2002-10-29 Rutgers, The State University Of New Jersey Nuclear-encoded transcription system in plastids of higher plants
US6660911B2 (en) 1999-12-16 2003-12-09 Monsanto Technology Llc Plant expression constructs
US6825006B2 (en) 1996-11-27 2004-11-30 Monsanto Technology Llc Nucleic acid and polypeptide compositions encoding lepidopteran-toxic polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660500B2 (en) * 1988-02-26 2003-12-09 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
CA2114636C (en) * 1991-08-01 2006-11-28 Jon Donson Recombinant plant viral nucleic acids
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6515206B1 (en) 1998-12-23 2003-02-04 Calgene Llc Plastid transformation of Brassica
US20020061309A1 (en) 2000-03-08 2002-05-23 Garger Stephen J. Production of peptides in plants as N-terminal viral coat protein fusions
US6730306B1 (en) * 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
IT1317046B1 (en) 2000-06-16 2003-05-26 Ist Superiore Sanita MELTING PROTEIN, VIRAL PARTICLES THAT EXPOSE IT ON SUCH CAPS, PLANTS INFECTED WITH SUCH PARTICLES, THEIR USES AND COMPOSITIONS
US20030018557A1 (en) * 2001-07-18 2003-01-23 Gilbert James A. Financial processing gateway structure
AU2002358292B2 (en) * 2001-12-26 2008-12-18 University Of Central Florida Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines
AU2002306484A1 (en) 2002-02-13 2003-09-04 Dow Global Technologies Inc. Over-expression of extremozyme genes in pseudomonads and closely related bacteria
EP1501935B1 (en) 2002-04-22 2009-09-23 Dow Global Technologies Inc. Low-cost production of peptides
EP1539794B1 (en) 2002-07-03 2008-12-31 Dow Global Technologies Inc. Benzoate- and anthranilate-inducible promoters
CA2497798A1 (en) 2002-09-03 2004-04-22 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
CN1894277A (en) 2003-02-24 2007-01-10 陶氏环球技术公司 Periodic antimicrobial peptides
JP2007512842A (en) * 2003-12-01 2007-05-24 ダウ グローバル テクノロジーズ インコーポレイティド Production of recombinant icosahedral virus-like particles in Pseudomonas

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US507A (en) 1837-12-07 John crabtree
US5693A (en) 1848-08-01 Window-catch
US6515A (en) 1849-06-05 Boom-derrick
US206A (en) 1837-05-30 Machine fob
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5591605A (en) 1983-04-15 1997-01-07 Mycogen Plant Science, Inc. Plant structural gene expression
US5057422A (en) 1988-03-23 1991-10-15 Mogen International N.V. Recombinant dna: transformed microorganisms, plant cells and plants: a process for introducing an inducible property in plants, and a process for producing a polypeptide or protein by means of plants or plant cells
US5834250A (en) 1988-10-28 1998-11-10 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5641876A (en) 1990-01-05 1997-06-24 Cornell Research Foundation, Inc. Rice actin gene and promoter
US5874087A (en) 1991-04-19 1999-02-23 Axis Genetics Plc Modified plant viruses as vectors
WO1992018618A1 (en) 1991-04-19 1992-10-29 Agricultural Genetics Company Limited Modified plant viruses as vectors
US6232099B1 (en) 1994-10-18 2001-05-15 Scottish Crop Research Institute Method of producing a chimeric protein
US6472586B1 (en) 1995-08-10 2002-10-29 Rutgers, The State University Of New Jersey Nuclear-encoded transcription system in plastids of higher plants
WO1997048819A1 (en) 1996-06-20 1997-12-24 The Scripps Research Institute Cassava vein mosaic virus promoters and uses thereof
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6825006B2 (en) 1996-11-27 2004-11-30 Monsanto Technology Llc Nucleic acid and polypeptide compositions encoding lepidopteran-toxic polypeptides
WO1998056921A1 (en) 1997-06-12 1998-12-17 Dow Agrosciences Llc Regulatory sequences for transgenic plants
WO1999010513A1 (en) 1997-08-07 1999-03-04 Auburn University Universal chloroplast integration and expression vectors, transformed plants and products thereof
US6218145B1 (en) 1998-04-02 2001-04-17 Monsanto Company Bacterial expression systems based on plastic or mitochondrial promoter combinations
WO2000012681A1 (en) 1998-08-27 2000-03-09 Rutgers, The State University Of New Jersey Compositions and methods for producing high-level seed-specific gene expression in corn
WO2001020974A1 (en) 1999-09-22 2001-03-29 The Penn State Research Foundation Quantitative transient protein expression in plant tissue culture
WO2001021782A2 (en) 1999-09-24 2001-03-29 Calgene Llc Enhancer elements for increased translation in plant plastids
US6660911B2 (en) 1999-12-16 2003-12-09 Monsanto Technology Llc Plant expression constructs
WO2001070939A1 (en) 2000-03-22 2001-09-27 Icon Genetics, Inc. Methods for transforming plant plastids and making transplastomic plants
WO2002055651A2 (en) 2001-01-12 2002-07-18 Icon Genetics Ag Processes and vectors for plastid transformation
WO2002057466A2 (en) 2001-01-19 2002-07-25 Icon Genetics Ag Processes and vectors for plastid transformation of higher plants

Non-Patent Citations (74)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Virology", 1999, ACADEMIC PRESS
"Methods in Enzymology : Guide to Molecular Cloning Techniques", 1987, ACADEMIC PRESS
"Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"Practical Approach Series", 2001, OXFORD PRESS, article "A Practical Approach"
"Principles and Practice", 1982, SPRINGER- VERLAG, article "R. Scopes, Protein Purification"
"Principles of Molecular Virology", 2001, ACADEMIC PRESS
"Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses", 2000, ACADEMIC PRESS/ELSEVIER
A. DESHAYES ET AL., EMBO J., vol. 4, 1985, pages 2731 - 2737
AH CHRISTENSEN; PH QUAIL: "Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants", TRANSGENIC RES, vol. 5, no. 3, 1996, pages 213 - 18, XP002725067, DOI: doi:10.1007/BF01969712
AK PATRA ET AL., PROTEIN EXPR PURIF, vol. 18, no. 2, 2000, pages 182 - 92
AP GLEAVE AP: "A versatile binary vector system with a T-DNA organisational structure conducive to efficient integration of cloned DNA into the plant genome", PLANT MOL. BIOL., vol. 20, no. 6, 1992, pages 1203 - 07, XP002051379, DOI: doi:10.1007/BF00028910
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS
BERGER; KIMMEL: "Methods in Enzymology 152: Guide to Molecular Cloning Techniques", 1987, ACADEMIC PRESS
BROXMEYER, H. E. ET AL., BLOOD, vol. 60, 1982, pages 595
BRUMFIELD ET AL., J. GEN. VIROL., vol. 85, 2004, pages 1049 - 1053
BUKHARI ET AL.: "DNA Insertion Elements, Plasmids and Episofnes", 1977, COLD SPRING HARBOR LABORATORY PRESS
BUSTOS ET AL., PLANT CELL, vol. 1, 1989, pages 839
C MARUSIC ET AL., J VIROL, vol. 75, no. 18, September 2001 (2001-09-01), pages 8434 - 39
C PORTA ET AL., INTERVIROLOGY, vol. 39, no. 1-2, 1996, pages 79 - 84
CALLIS ET AL., PLANT PHYSIOL, vol. 88, 1988, pages 965
CHEN, L ET AL., PLANT CELL REPORTS, vol. 18, 1998, pages 25 - 31
CK SHEWMAKER MOL. GEN., GENETICS, vol. 202, 1986, pages 179 - 185
COLIGAN ET AL.: "Current Protocols in Protein Science", 1996, WILEY/GREENE
COLIGAN ET AL.: "Current Protocols in Protein Science", 1996, WILEY/GREENE, article "Current Protocols in Protein Science Wiley /Greene, NY, S. Roe"
CROWE ET AL.: "QIAexpress: The High Level Expression & Protein Purification System", 1992, QUIAGEN, INC.
D. BOLLAG ET AL.: "Protein Methods", 1996, WILEY-LISA, INC.
DAWSON ET AL.: "Assessment of recombinants that arise from the use of a TMV-based transient expression vector", VIROL, vol. 284, no. 2, 2001, pages 182 - 189, XP008114927, DOI: doi:10.1006/viro.2001.0910
DEUTSCHER: "Guide to Protein Purification", 1990, ACADEMIC PRESS
DEUTSCHER: "Guide to Protein Purification", METHODS IN ENZYMOLOGY, vol. 182, 1990
DLD CASPAR, BIOPHYS. J., vol. 32, 1980, pages 103
DLD CASPAR; A KLUG, COLD SPRING HARBOR SYMP. QUANT. BIOL., vol. 27, 1962, pages 1
DOLJA ET AL.: "Spontaneous mutagenesis of a plant potyvirus genome after insertion of a foreign gene", J. VIROL, vol. 67, no. 10, 1993, pages 5968 - 5975
FR BRENNAN ET AL., VACCINE, vol. 17, no. 15-16, 9 April 1999 (1999-04-09), pages 1846 - 57
HELLWIG ET AL.: "Plant cell cultures for the production of recombinant proteins", NATURE BIOTECH, vol. 22, no. 11, 2004, pages 1415 - 1422, XP002420852, DOI: doi:10.1038/nbt1027
HOCHULI, CHEMISCHE INDUSTRIE, vol. 12, 1989, pages 69 - 70
HOCHULI: "Genetic Engineering, Principle and Methods", vol. 12, 1990, PLENUM PRESS, article "Purification of Recombinant Proteins with Metal Chelate Absorbent", pages: 87 - 98
I. POTRYKUS ET AL., MOL. GEN. GENETICS, vol. 197, pages 183 - 188
IJ GODERIS IJ ET AL.: "A set of modular plant transformation vectors allowing flexible insertion of up to six expression units", PLANT MOL. BIOL., vol. 50, no. 1, 2002, pages 17 - 27, XP002412980, DOI: doi:10.1023/A:1016052416053
J GRIMES ET AL., NATURE, vol. 395, 1988, pages 470
J JOHNSON; J SPEIR, J. MOL. BIOL., vol. 269, 1997, pages 665
JD JONES ET AL.: "Effective vectors for transformation, expression of heterologous genes, and assaying transposon excision in transgenic plants", TRANSGENIC RES, vol. 1, no. 6, 1992, pages 285 - 97, XP009094273, DOI: doi:10.1007/BF02525170
JD WATSON ET AL.: "Recombinant DNA", 1992, SCIENTIFIC AMERICAN BOOKS, W. H. FREEMAN AND CO., pages: 273 - 92
JE JOHNSON, PROC. NAT'L ACAD. SCI. USA, vol. 93, 1996, pages 27
KODAMA ET AL., J. BIOCHEM., vol. 99, 1986, pages 1465 - 1472
KUHLEMEIER ET AL., PLANT CELL, vol. 1, 1989, pages 471
LEATHERS ET AL.: "A phylogenetically conserved sequence within viral 3' untranslated RNA pseudolmots regulates translation", MOL. CELL BIOL., vol. 13, no. 9, 1993, pages 5331 - 5347, XP002296534
LI, L ET AL., PLANT CELL REPORTS, vol. 12, 1993, pages 250 - 255
LOMBILLO ET AL., J. CELL BIOL., vol. 128, 1995, pages 107 - 115
MARCOTTE ET AL., PLANT CELL, vol. 1, 1989, pages 969
MC CHUPEAU ET AL., BIO/TECHNOLOGY, vol. 7, 1989, pages 503
MH LEE ET AL., PROTEIN EXPR. PURIF., vol. 25, no. 1, 2002, pages 166 - 73
MITSUHARA ET AL.: "Efficient promoter cassettes for enhanced expression of foreign genes in dicotyledonous and monocotyledonous plants", PLANT CELL PHYSIOL, vol. 37, no. 1, 1996, pages 49 - 59, XP002927004
P. J. ET AL., J. IMMUNOL., vol. 132, 1984, pages 1858
PORTA & LOMONOSSOFF: "Viruses as vectors for the expression of foreign sequences in plants", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, vol. 19, 2002, pages 245 - 291
PORTA; LOMONOSSOFF: "Use of viral replicons for the expression of genes in plants", MOLECULAR BIOTECHNOLOGY, vol. 5, 1996, pages 209 - 221, XP001096010, DOI: doi:10.1007/BF02900359
R GRIESBACH, BIOTECHNOLOGY, vol. 3, pages 348 - 350
R. MUKHIJA ET AL., GENE, vol. 165, no. 2, 1995, pages 303 - 6
ROSHAL ET AL., EMBO J., vol. 6, 1987, pages 1155
S. ROE: "Protein Purification Techniques: A Practical Approach (Practical Approach Series", 2001, OXFORD PRESS
SAIKI ET AL., J. IMMUNOL., vol. 127, 1981, pages 1044
SAJC ET AL.: "Bioreactors for plant engineering: an outlook for further research", BIOCHEM ENGIN. J., vol. 4, 2000, pages 89 - 99
SAMBROOK; FRITSCH; MANIATIS: "Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS
SCHAFFNER; SHEEN, PLANT CELL, vol. 3, 1991, pages 997
SCHERNTHANER ET AL., EMBO J., vol. 7, 1988, pages 1249
See also references of EP1720990A4
SHAHMURADOV ET AL.: "PlantProm: a database of plant promoter sequences", NUCLEIC ACID RES, vol. 31, no. 1, 2003, pages 114 - 117, XP002993034, DOI: doi:10.1093/nar/gkg041
SIEBERTZ ET AL., PLANT CELL, vol. 1, 1989, pages 961
SIMPSON ET AL., EMBO J., vol. 4, 1985, pages 2723
STAUB, J. M.; MALIGA, P: "Long regions of homologous DNA are incorporated into the tobacco plastid genome by transformation", PLANT CELL, vol. 4, 1992, pages 39 - 45, XP002090407, DOI: doi:10.1105/tpc.4.1.39
STEWARD, W. E. II: "The Interferon Systems", 1980, SPRINGER-VERLAG
STEWART ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 90, 1993, pages 5209 - 5213
V. VASIL ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 743
VALE ET AL., CELL, vol. 42, 1985, pages 39 - 50
W. K. CHO ET AL., J. BIOTECHNOLOGY, vol. 77, no. 2-3, 2000, pages 169 - 78

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085147A3 (en) * 2005-12-02 2008-12-18 Dow Global Technologies Inc Novel plant virus particles and methods of inactivation thereof
WO2008085147A2 (en) * 2005-12-02 2008-07-17 Dow Global Technologies Inc. Novel plant virus particles and methods of inactivation thereof
JP2014064573A (en) * 2006-06-09 2014-04-17 Biomay Ag Vaccine carrier
JP2014087341A (en) * 2006-06-09 2014-05-15 Biomay Ag Vaccine carrier
WO2009014782A2 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2009014782A3 (en) * 2007-04-27 2009-07-23 Dow Global Technologies Inc Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
JP2010533001A (en) * 2007-07-13 2010-10-21 メディカゴ インコーポレイテッド Influenza virus-like particles (VLPs) containing hemagglutinin produced in plants
WO2010047839A1 (en) * 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
US10179168B2 (en) 2009-04-13 2019-01-15 INSERM (Institut National de la Santé et de la Recherche Médicale HPV particles and uses thereof
US10688172B2 (en) 2009-04-13 2020-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US9855347B2 (en) 2012-02-07 2018-01-02 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US10300150B2 (en) 2012-02-07 2019-05-28 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US10596275B2 (en) 2012-02-07 2020-03-24 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
US10117947B2 (en) 2013-09-18 2018-11-06 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US10588984B2 (en) 2013-09-18 2020-03-17 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US11110181B2 (en) 2013-09-18 2021-09-07 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US11806406B2 (en) 2013-09-18 2023-11-07 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
US11207339B2 (en) 2015-10-30 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy

Also Published As

Publication number Publication date
EP1720990A4 (en) 2008-04-30
EP3388521A1 (en) 2018-10-17
EP1720990A2 (en) 2006-11-15
CN1926238A (en) 2007-03-07
WO2005086667A3 (en) 2006-09-14
AU2005220734A1 (en) 2005-09-22
JP2007528727A (en) 2007-10-18
CA2557668A1 (en) 2005-09-22
US7928290B2 (en) 2011-04-19
US20050260758A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
US7928290B2 (en) Viral capsid fusion peptide expressing plant cells
Mason et al. Transgenic plants as vaccine production systems
Porta et al. Cowpea mosaic virus-based chimaeras: Effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses
KR101956910B1 (en) RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES(VLPs) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
DK2610345T3 (en) RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ
CN103031310B (en) Protein is expressed in plant
AU747647B2 (en) A process for isolating and purifying viruses, soluble proteins and peptides from plant sources
KR101541330B1 (en) INFLUENZA VIRUS-LIKE PARTICLES(VLPs) COMPRISING HEMAGGLUTININ PRODUCED WITHIN A PLANT
Chebolu et al. Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality
US20070041999A1 (en) Production of multivalent virus like particles
EP1996711B1 (en) Novel plant virus particles and methods of inactivation thereof
CN101151272A (en) Recombinant icosahedral virus like particle production in pseudomonads
KR20150134423A (en) Influenza virus-like particle production in plants
AU702802B2 (en) Method of producing a chimeric protein
AU2008279584A1 (en) Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
EP1522585A1 (en) Chimeric carrier molecules for the production of mucosal vaccines
US20030092624A1 (en) Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
JP4769977B2 (en) Vaccine gene introduction rice
AU785020B2 (en) Plant Virus particles with exogenous internal eitopes
Yusibov et al. Plant viral expression vectors: history and new developments
Ahmad Molecular Farming: Production of Pharmaceuticals in Transgenic Tobacco
Capuano Chimeric oil bodies as an alternative delivery system for peptide vaccines
Elkins Transient expression of ova antigen: RTB fusions in plants for production of improved subunit vaccines
Varshney Recombinant expression and immunological and biophysical characterization of the major mountain cedar allergen, Jun a 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005220734

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4520/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005756363

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2557668

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005220734

Country of ref document: AU

Date of ref document: 20050228

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005220734

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007500784

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580006309.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005756363

Country of ref document: EP